What changed in this filing

/stocks — the workspaceLOADING

Item 9A. Controls and Procedures

2022-03-24 compared with 2021-03-24 · 1904 added, 1917 removed, 460 unchanged (89% of the section changed)

1 unchanged sentence

of Disclosure Controls and Procedures

13a-15(e) under the Exchange Act defines the term “disclosure controls and procedures”

as those controls and procedures

designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange

Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such

information is accumulated and communicated to the company’s management, including its principal executive and principal

financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

13a-15(e) under the Exchange Act defines the term “disclosure controls and procedures” as those controls and procedures designed

to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded,

processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated

and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing

similar functions, as appropriate to allow timely decisions regarding required disclosure.

upon an evaluation of the effectiveness of our disclosure controls and procedures performed by our management, with the participation

of our Chief Executive Officer, and Chief Financial Officer (Principal Financial and Accounting Officer), as of the end of the

period covered by this annual report, our management concluded that our disclosure controls and procedures are effective at a

reasonable assurance level in ensuring that information required to be disclosed by us in our reports is recorded, processed,

summarized and reported within the required time periods.

The foregoing conclusion is based, in part, on the fact that we are

a small public company in the early stage of our business, with limited revenues and employees.

Management’s

of our Chief Executive Officer, and Chief Financial Officer (Principal Financial and Accounting Officer), as of the end of the period

covered by this annual report, our management concluded that our disclosure controls and procedures are effective at a reasonable assurance

level in ensuring that information required to be disclosed by us in our reports is recorded, processed, summarized and reported within

the required time periods.

The foregoing conclusion is based, in part, on the fact that we are a small public company with limited revenues and employees.

Report on Internal Control Over Financial Reporting

is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in

Exchange Act Rule 13a-15(f) under the Exchange Act.

Our management, with the participation of our Chief Executive Officer, and

Chief Financial Officer, conducted an evaluation of the effectiveness of our control over financial reporting based on the framework

in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.

on management’s evaluation under the framework, management has concluded that our internal control over financial reporting

was effective as of December 31, 2020.

continuously seek to improve and strengthen our control processes to ensure that all of our controls and procedures are adequate

and effective.

Any failure to implement and maintain improvements in the controls over our financial reporting could cause us

to fail to meet our reporting obligations under the SEC’s rules and regulations.

Any failure to improve our internal controls

to address the weakness we have identified could also cause investors to lose confidence in our reported financial information,

which could have a negative impact on the trading price of our common stock.

annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal

control over financial reporting.

Management’s report was not subject to attestation by our registered public accounting

firm pursuant to SEC rules applicable to smaller reporting companies that permit us to provide only management’s

report in this annual report.

is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange

Act Rule 13a-15(f) under the Exchange Act.

Our management, with the participation of our Chief Executive Officer, and Chief Financial

Officer, conducted an evaluation of the effectiveness of our control over financial reporting based on the framework in Internal Control-Integrated

Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.

Based on management’s evaluation under

the framework, management has concluded that our internal control over financial reporting was effective as of December 31, 2021.

continuously seek to improve and strengthen our control processes to ensure that all of our controls and procedures are adequate and

Any failure to implement and maintain improvements in the controls over our financial reporting could cause us to fail to

meet our reporting obligations under the SEC’s rules and regulations.

Any failure to improve our internal controls to address the

weakness we have identified could also cause investors to lose confidence in our reported financial information, which could have a negative

impact on the trading price of our common stock.

This report does not include an

attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting.

report was not subject to attestation by our registered public accounting firm pursuant to SEC rules applicable to smaller reporting companies.

in Internal Control Over Financial Reporting

have been no changes in our internal control over financial reporting during the fourth quarter of the year ended December 31,

were no changes in our internal control over financial reporting during the fourth quarter of the year ended December 31, 2021

that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

OTHER INFORMATION

REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not Applicable.

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

following table sets forth the name, age and position of each of our executive officers as of March 23, 2022:

and Chief Executive Officer

Executive Officer

Financial Officer, Treasurer and Corporate Secretary

1 unchanged sentence

Technology Officer

Ruport served as Executive Chairman from December 3, 2019 until April 30, 2020 and became our President and

Chief Executive Officer on April 30, 2020.

Additional information regarding Mr.

Ruport is set forth below under “Board

of Directors and Corporate Governance.”

Orzechowski has served as our Chief Financial Officer, Treasurer, principal accounting officer, principal financial officer,

and Corporate Secretary since July 1, 2019.

and Chief Operating Officer

Mark Ruport served as

Executive Chairman from December 3, 2019 until April 30, 2020 and became our President and Chief Executive Officer on April 30, 2020.

On February 16, 2022, Mr.

Ruport resigned as President but continues to be our Chief Executive Officer.

Additional information

regarding Mr.

Ruport is set forth below under “Board of Directors and Corporate Governance.”

Orzechowski has served as our Chief Financial Officer, Treasurer, principal accounting officer, principal financial officer, and

Corporate Secretary since July 1, 2019.

Prior to joining the Company, Mr.

Orzechowski served as the Chief Financial Officer

of StormHarbour Partners LP, an independent global markets and financial advisory firm since September 2013.

From May 2013 to

August 2013, Mr.

Orzechowski served as a contract CFO for Etouches Inc., a cloud-based event management software company, to assist

with financial matters in connection with that company’s planned equity financing.

Prior to that, he served as President

and Owner/Operator of Four-O Technologies Inc.

from August 2009 to December 2012, where he successfully launched and guided operations

for two Cartridge World franchise units in Connecticut.

Orzechowski served as the Chief Financial Officer of StormHarbour

Partners LP, an independent global markets and financial advisory firm since September 2013.

From May 2013 to August 2013, Mr.

served as a contract CFO for Etouches Inc., a cloud-based event management software company, to assist with financial matters in connection

with that company’s planned equity financing.

Prior to that, he served as President and Owner/Operator of Four-O Technologies Inc.

from August 2009 to December 2012, where he successfully launched and guided operations for two Cartridge World franchise units in Connecticut.

From February 2006 to July 2009, Mr.

Orzechowski served as President and

Chief Financial Officer of Nikko Americas Holding Company Inc., where he was responsible for managing all of the support and infrastructure

for that company’s U.S.

business, as well as investment manager selection and due diligence functions for its World Series

Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984 and received

his Bachelor of Science in Business Administration with a major in Accounting from Georgetown University in 1982.

Beckett served as our Engineering Manager beginning on September 25, 2017, was appointed as our Vice President of Engineering

on June 29, 2018, and had his title changed to Chief Technology Officer of the Company on October 18, 2018.

Beckett has over

20 years of experience in the semiconductor industry, including since 1997 with Intel Corporation at which he held various technical

and managerial positions, including process engineer of ion implant charged particle systems, chemical vapor deposition systems,

and, since 2008, engineering manager of multiple engineering groups such as rapid thermal anneal, defect metrology equipment and

fab environment micro contamination.

Beckett’s expertise is in process engineering for advanced manufacturing technology,

including statistical process control for fabrication of semiconductor devices.

Beckett serves as an independent director

and board member of M&T Foundation, San Diego, California.

Orzechowski served as President and Chief Financial Officer of Nikko Americas Holding Company Inc.,

where he was responsible for managing all of the support and infrastructure for that company’s U.S.

business, as well as investment

manager selection and due diligence functions for its World Series Platform.

Orzechowski began his career at Coopers & Lybrand

in 1982, received his CPA certification in 1984 and received his Bachelor of Science in Business Administration with a major in Accounting

from Georgetown University in 1982.

Beckett served as our Engineering Manager beginning on September 25, 2017, was appointed as our Vice President of Engineering on

June 29, 2018, and had his title changed to Chief Technology Officer of the Company on October 18, 2018.

Beckett has over 20 years

of experience in the semiconductor industry, including since 1997 with Intel Corporation at which he held various technical and managerial

positions, including process engineer of ion implant charged particle systems, chemical vapor deposition systems, and, since 2008, engineering

manager of multiple engineering groups such as rapid thermal anneal, defect metrology equipment and fab environment micro contamination.

Beckett’s expertise is in process engineering for advanced manufacturing technology, including statistical process control

for fabrication of semiconductor devices.

Beckett serves as an independent director and board member of M&T Foundation, San Diego,

Beckett earned a B.

in Mechanical Engineering from University

of Limerick, Ireland.

Fisher was appointed as Vice President of Business Development of Sigma on August 10, 2015 and leads the PrintRite3D®

Operating Division.

in Mechanical Engineering from University of Limerick, Ireland.

Fisher was appointed as Vice President of Business Development of Sigma on August 10, 2015 and leads the PrintRite3D® Operating

Fisher is a Mechanical Engineer with hands-on experience in quality, manufacturing, and product development.

He has an MBA and has distinguished himself as a lead sales and marketing officer as well as a Chief Operating Officer.

a Program Manager at Swagelok from 1988-2004, and Vice President and General Manager, Aftermarket and Geometry Systems, at Micropoise

Measurement Systems from 2004 until 2013, and a Partner and COO of Laszeray Technology, LLC from 2013 until 2014.

a bachelor’s degree in Mechanical Engineering Technology from the University of Akron as well as an MBA from Kent

State University.

MBA and has distinguished himself as a lead sales and marketing officer as well as a Chief Operating Officer.

He was a Program Manager

at Swagelok from 1988-2004, and Vice President and General Manager, Aftermarket and Geometry Systems, at Micropoise Measurement Systems

from 2004 until 2013, and a Partner and COO of Laszeray Technology, LLC from 2013 until 2014.

Fisher holds a bachelor’s degree

in Mechanical Engineering Technology from the University of Akron as well as an MBA from Kent State University.

Brunsberg was appointed Senior Vice-President of Product Management and Strategic Relationships on September 20, 2021, and

on February 16, 2022, he was named President and Chief Operating Officer.

Prior to joining the Company, Mr.

Brunsberg was a P&L

leader for General Electric’s Binder Jet Technology unit, with management responsibility for strategy, development, commercialization,

and overall business performance.

From 2017 to 2019 he served as Sr.

Managing Director of the Central Region, tasked with helping establish

the US sales infrastructure for post-acquisition integration of several additive manufacturing technology companies including Concept

Laser, Arcam and GEonX into the newly formed GE Additive business entity.

Prior to GE, Mr.

Brunsberg worked for the American Roller Company

in sales leadership and product marketing positions, responsible for the development and oversight of growth strategies, focused on advanced

welding, cladding, thermal spray, and powder metallurgy technologies across a number of industrial markets.

Brunsberg holds a Bachelor

of Science degree in Material Science and Engineering from the University of Wisconsin-Madison.

OF DIRECTORS AND CORPORATE GOVERNANCE

1 unchanged sentence

of the Board and Director

and Chief Executive Officer

Chief Executive Officer

Battinelli(1)

Duitch(1)(2)(3)

Summers(1)(2)(3)

Member of our Audit Committee

Member of our Compensation Committee

Member of our Nominating and Corporate Governance Committee

Rice was appointed to our Board of Directors on February 15, 2017, was appointed as Chairman of our Board on April 19, 2017,

was appointed as our interim Chief Executive Officer on July 24, 2017, became our Chief Executive Officer on July 14, 2017

and was appointed as our President on October 10, 2018.

Member of our Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.

Rice was appointed to our Board of Directors on February 15, 2017, was appointed as Chairman of our Board on April 19, 2017, was

appointed as our interim Chief Executive Officer on July 24, 2017, became our Chief Executive Officer on July 14, 2017 and was appointed

as our President on October 10, 2018.

Effective April 30, 2020, Mr.

Rice resigned from his position as President

and Chief Executive Officer.

Rice remains a director on the Board of Directors and continues to serve as Chairman of the Board.

Rice has extensive experience in business operations.

Rice founded ASiQ, LLC, a firm specializing in operations

management services ranging from launching successful startups and executing business turnarounds to financings, crisis management

and the repositioning of enterprises for sale at optimum market prices.

Rice presently serves as ASiQ’s CEO and President.

He also served as CEO of Coca-Cola Bottling Company of Santa Fe, a client of ASiQ’s, from 2009 to 2015.

From 2010 to 2012,

Rice served as Director and Contracts Officer of Detector Networks International.

Rice frequently lectures on breakout

growth strategies, crisis management, corporate turnarounds, venture capital, and financial structuring and strategies.

also served on a number of boards.

Rice resigned from his position as President and Chief Executive

Rice has extensive

experience in business operations.

Rice founded ASiQ, LLC, a firm specializing in operations management services ranging

from launching successful startups and executing business turnarounds to financings, crisis management and the repositioning of enterprises

for sale at optimum market prices.

Rice presently serves as ASiQ’s CEO and President.

He also served as CEO of Coca-Cola Bottling

Company of Santa Fe, a client of ASiQ’s, from 2009 to 2015.

From 2010 to 2012, Mr.

Rice served as Director and Contracts Officer

of Detector Networks International.

Rice frequently lectures on breakout growth strategies, crisis management, corporate turnarounds,

venture capital, and financial structuring and strategies.

He has also served on a number of boards.

Since 2005, Mr.

Rice has served as Director of New Mexico Angels, Inc., a New Mexico based

group of accredited individual angel investors.

Rice has served

as Director of New Mexico Angels, Inc., a New Mexico based group of accredited individual angel investors.

Since 2016, Mr.

Rice has served as Director of Akal Security, Inc.

a Director of Detector Networks International from 2010-2012, where he successfully negotiated the principal component of a business

turnaround for the company.

Rice has served

as Director of Akal Security, Inc.

He was also a Director of Detector Networks International from 2010-2012, where he successfully negotiated

the principal component of a business turnaround for the company.

Rice is an honors graduate of Harvard College.

Board of Directors believes that Mr.

Rice is qualified to serve as a member of the board because of his broad and deep experience

in improving business operations, engineering financial structures that support ongoing needs of operating companies, and building

investor and shareholder values.

Rice is qualified to serve as a member of the board because of his broad and deep experience in

improving business operations, engineering financial structures that support ongoing needs of operating companies, and building investor

and shareholder values.

Battinelli was appointed to our Board of Directors on August 16, 2017.

Battinelli is currently the President and Chief

Executive Officer of Bello e Preciso Co., a manufacturer and wholesaler of Italian-made fashion watches and has served in those

roles since early 2017.

Battinelli is currently the President and Chief Executive

Officer of Bello e Preciso Co., a manufacturer and wholesaler of Italian-made fashion watches and has served in those roles since early

Prior to joining Bello e Preciso Co., from 2011 to 2013, Mr.

Battinelli served as Vice-President of Development

and Long-Term Strategy of North American Management Corporation, a wealth management firm based in Boston, Massachusetts with

over $2 billion in assets under management.

Battinelli served as Vice-President of Development and Long-Term Strategy

of North American Management Corporation, a wealth management firm based in Boston, Massachusetts with over $2 billion in assets under

From 1987 to 2011, Mr.

Battinelli served as Executive Vice-President and acting Chief

Executive Officer and Chief Operating Officer of Faneuil Hall Associates, Inc., a concierge boutique family office devoted to

five interrelated ultra-high net-worth families.

Battinelli’s primary responsibilities while at Faneuil Hall Associates

included providing planning and investment advice, the management of approximately 30 asset portfolios and more than 65 individual

business entities;

and assisting the families in their various business ventures worldwide while working closely with law, accounting

and banking functions.

During his tenure at Faneuil Hall Associates, Mr.

Battinelli served as an executive officer or director

for certain of the family-owned entities and successfully managed several portfolio company IPOs, as well as serving as

CEO and COO for Designhouse International, a Scandinavian furniture company operating out of Atlanta, Georgia, which was previously

listed on NASDAQ in 1983.

Battinelli served as Executive Vice-President and acting Chief Executive Officer and Chief Operating

Officer of Faneuil Hall Associates, Inc., a concierge boutique family office devoted to five interrelated ultra-high net-worth families.

Battinelli’s primary responsibilities while at Faneuil Hall Associates included providing planning and investment advice, the

management of approximately 30 asset portfolios and more than 65 individual business entities;

and assisting the families in their various

business ventures worldwide while working closely with law, accounting and banking functions.

During his tenure at Faneuil Hall Associates,

Battinelli served as an executive officer or director for certain of the family-owned entities and successfully managed several portfolio

company IPOs, as well as serving as CEO and COO for Designhouse International, a Scandinavian furniture company operating out of Atlanta,

Georgia, which was previously listed on NASDAQ in 1983.

1970 to 1974, Mr.

Battinelli served as Audit Manager for Deloitte & Touche (formally Touche Ross), where he specialized in

management information systems.

Battinelli served as Audit Manager for Deloitte & Touche (formally Touche Ross), where he specialized in management

information systems.

From 2002 to 2011, Mr.

Battinelli also served as the Chairman of the Board of Directors of HealthLink

Europe, BV, a logistics and services company that serves the healthcare industry.

Battinelli is a Certified Public Accountant

and received a BS in accounting and an MBA with an emphasis in international economics and accounting, both from Babson College.

Battinelli also served as the Chairman of the Board of Directors of HealthLink Europe, BV,

a logistics and services company that serves the healthcare industry.

Battinelli is a Certified Public Accountant and received a

BS in accounting and an MBA with an emphasis in international economics and accounting, both from Babson College.

board of directors believes that Mr.

3 unchanged sentences

Effective April 30, 2020, Mr.

became our President and Chief Executive Officer.

Ruport remains a director on the Board of Directors but no longer serves

as Executive Chairman.

Ruport brings more than 30 years of public and private company experience in the software sector to

his position at Sigma Labs.

Ruport became

our President and Chief Executive Officer and, as of February 16, 2022, no longer serves as President.

Ruport remains a director

on the Board of Directors but no longer serves as Executive Chairman.

Ruport brings more than 30 years of public and private company

experience in the software sector to his position at Sigma Labs.

Prior to joining Sigma Labs, Mr.

Ruport served since 2010 as the President of Step Function Consulting,

LLC, a consulting firm that provides strategic consulting services to early and mid-stage portfolio software companies.

also served from 2014 to 2017 as the Executive Chairman of the Board of Directors of Content Analyst Company, a leading developer

of advanced analytics software for searching and analyzing unstructured text, and before that served as its Vice Chairman from

2012 to 2013.

Ruport served since 2010 as the President

of Step Function Consulting, LLC, a consulting firm that provides strategic consulting services to early and mid-stage portfolio software

Ruport also served from 2014 to 2017 as the Executive Chairman of the Board of Directors of Content Analyst Company, a

leading developer of advanced analytics software for searching and analyzing unstructured text, and before that served as its Vice Chairman

from 2012 to 2013.

From 2005 to 2009, Mr.

1 unchanged sentence

Enterprise Systems Management company, where he orchestrated an OEM agreement which later led to its acquisition by EMC Corp.

Prior to Configuresoft, Mr.

Ruport served from 2004 to 2005 as the Executive Vice President of Worldwide Operations at Stellent,

Inc., which was subsequently acquired by Oracle, Inc., and from 1995 to 2005 as the President, Chief Executive Officer and Chairman

of the Board of Directors of Optika, Inc., a venture-backed Enterprise Content Management Company that he led through its initial

public offering and merger with Stellent, Inc.

Configuresoft, Mr.

Ruport served from 2004 to 2005 as the Executive Vice President of Worldwide Operations at Stellent, Inc., which was

subsequently acquired by Oracle, Inc., and from 1995 to 2005 as the President, Chief Executive Officer and Chairman of the Board of Directors

of Optika, Inc., a venture-backed Enterprise Content Management Company that he led through its initial public offering and merger with

Stellent, Inc.

From 1990 to 1994, Mr.

Ruport served as the President and Chief Executive Officer

of Interleaf, Inc., a public software company.

He also held various senior executive positions from 1985 to 1989 at Informix,

Inc., a relational database management system company later acquired by IBM, and from 1985 to 1989 at Cullinet, Inc., a mainframe

database management system and enterprise resource planning company later acquired by Computer Associates, Inc.

Ruport received

his Bachelor of Science degree and MBA from Bowling Green State University.Mr.

Ruport received a Bachelor of Science in Business

and an MBA from Bowling Green State University.

Ruport served as the President and Chief Executive Officer of Interleaf, Inc., a public software

He also held various senior executive positions from 1985 to 1989 at Informix, Inc., a relational database management system

company later acquired by IBM, and from 1985 to 1989 at Cullinet, Inc., a mainframe database management system and enterprise resource

planning company later acquired by Computer Associates, Inc.

Ruport received his Bachelor of Science degree and MBA from Bowling

Green State University.Mr.

Ruport received a Bachelor of Science in Business and an MBA from Bowling Green State University.

Board of Directors believes that Mr.

Ruport is qualified to serve as a member of the board because of his extensive experience

in management and leadership in the technology industry.

Ruport is qualified to serve as a member of the board because of his extensive experience in management

and leadership in the technology industry.

Duitch was appointed to our Board of Directors on August 8, 2017.

1 unchanged sentence

Group, a private consulting company, since 2003.

Prior to that time, he practiced public accounting, business management, mediation

and consultancy nationally, with expertise in strategic and operations management, finance, accounting, strategic planning and

business operations for a wide spectrum of companies, including technology, manufacturing and distribution, marketing, real estate,

entertainment, and professional practices.

He has served in executive officer roles and as a director of public and private companies,

not-for-profit organizations, including as Vice-Chairman for Accountants Global Network, and as a top-level advisor for public

companies, closely held businesses, families and high-wealth individuals for over thirty years.

Duitch began his career with the international CPA firm Grant Thornton in its Chicago, San Francisco and Beverly Hills offices

before founding Duitch & Franklin LLP, which evolved to become one of Southern California’s largest independent CPA/Business

Management/Consultancy practices, and which was acquired by a public company in 1998.

He subsequently served as President for

a consumer products company with direct responsibility for marketing, retail, and fulfillment operations, until forming Duitch

Consulting Group in 2003 to serve clients in advisory, C-level, and board of director roles.

Duitch is a Certified Family Business and Estate Advisor, and mediator for matters including partner/shareholder agreements and

disputes, business and marital property dissolution, and dysfunctional executive teams and boards of directors.

He has lectured

extensively in management, financial and accounting areas for the California CPA Foundation, business and professional groups,

has instructed at several colleges and universities, and has authored technical articles in management and taxation for regional

and national publications.

Duitch earned a B.B.A degree in Accounting from the University of Iowa and a Master of Business Administration in Finance from

Northwestern University.

Prior to that time, he practiced public accounting, business management, mediation and

consultancy nationally, with expertise in strategic and operations management, finance, accounting, strategic planning and business operations

for a wide spectrum of companies, including technology, manufacturing and distribution, marketing, real estate, entertainment, and professional

He has served in executive officer roles and as a director of public and private companies, not-for-profit organizations,

including as Vice-Chairman for Accountants Global Network, and as a top-level advisor for public companies, closely held businesses,

families and high-wealth individuals for over thirty years.

Duitch began his career with the international CPA firm Grant Thornton in its Chicago, San Francisco and Beverly Hills offices before

founding Duitch & Franklin LLP, which evolved to become one of Southern California’s largest independent CPA/Business Management/Consultancy

practices, and which was acquired by a public company in 1998.

He subsequently served as President for a consumer products company with

direct responsibility for marketing, retail, and fulfillment operations, until forming Duitch Consulting Group in 2003 to serve clients

in advisory, C-level, and board of director roles.

Duitch is a Certified Family Business and Estate Advisor, and mediator for matters including partner/shareholder agreements and disputes,

business and marital property dissolution, and dysfunctional executive teams and boards of directors.

He has lectured extensively in

management, financial and accounting areas for the California CPA Foundation, business and professional groups, has instructed at several

colleges and universities, and has authored technical articles in management and taxation for regional and national publications.

Duitch earned a B.B.A degree in Accounting from the University of Iowa and a Master of Business Administration in Finance from Northwestern

Board of Directors believes that Mr.

Duitch is qualified to serve as a member of the board because of his extensive public accounting

experience, which will assist the Board and the Audit Committee in addressing the numerous accounting-related issues, regulations

and SEC reporting requirements to which we are subject, as well as his expertise in business management, finance and strategic

experience, which will assist the Board and the Audit Committee in addressing the numerous accounting-related issues, regulations and

SEC reporting requirements to which we are subject, as well as his expertise in business management, finance and strategic planning.

Summers was appointed to our Board of Directors on January 18, 2018.

Summers was also appointed to serve as a member of

the Company’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.

Summers currently divides his time among a number of independent activities which focus on early-stage technology company formation

and development strategies, and sales planning and execution needs for emerging- and mid-market technology companies located primarily

in the Boston metropolitan area, including:

Summers was also appointed to serve as a member of the Company’s

Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.

Summers currently divides his time among a number of independent activities which focus on early-stage technology company formation and

development strategies, and sales planning and execution needs for emerging- and mid-market technology companies located primarily in

the Boston metropolitan area, including:

management consultant to private and family-owned businesses;

volunteer Mentor and

Instructor with the Massachusetts Institute of Technology Venture Mentoring Services program;

regular lectures on enterprise,

business-to-business sales to company founders and students enrolled at the Massachusetts Institute of Technology Sloan School

of Management, the Harvard MBA Program, the Wharton School at the University of Pennsylvania, and a number of domestic and international

entrepreneurship support organizations;

volunteer Mentor and Instructor

with the Massachusetts Institute of Technology Venture Mentoring Services program;

regular lectures on enterprise, business-to-business

sales to company founders and students enrolled at the Massachusetts Institute of Technology Sloan School of Management, the Harvard

MBA Program, the Wharton School at the University of Pennsylvania, and a number of domestic and international entrepreneurship support

organizations;

and consultant to Fellows enrolled in the Harvard Advanced Leadership Initiative.

Summers has served in those roles at various times from 2003 to the present.

Summers has served in those roles

at various times from 2003 to the present.

From 2009 to the present, Mr.

Summers has served

as the non-executive Chairman of CADNexus, Inc., and from 2017 to the present, director and Chairman of the Compensation Committee

with iQ3 Connect, Inc.

Summers also currently serves as Chairman, Board of Managers, Massachusetts Materials Technologies

Summers has served as the non-executive Chairman of CADNexus,

Inc., and from 2017 to the present, as a director and Chairman of the Compensation Committee with iQ3 Connect, Inc.

also currently serves as Chairman, Board of Managers, Massachusetts Materials Technologies LLC.

2005 to 2017, Mr.

Summers served as Managing Partner at Practical Computer Applications, Inc., a Boston-based database consulting

and engineering services firm, where he was responsible for sales planning and execution activities.

Prior to Practical Computer

Applications, from 2001 to 2005, Mr.

Summers provided independent merger & acquisition advisory services to support the sale

of privately-owned companies.

Summers served as Managing Partner at Practical Computer Applications, Inc., a Boston-based database consulting and

engineering services firm, where he was responsible for sales planning and execution activities.

Prior to Practical Computer Applications,

from 2001 to 2005, Mr.

Summers provided independent merger & acquisition advisory services to support the sale of privately-owned

Over a prior 14-year period, Mr.

Summers served in leadership roles at several software and internet

start-ups, including:

Summers served in leadership roles at several software and internet start-ups, including:

Chairman and CEO of Collego Corporation (acquired by MRO Software), founder and CEO of MyHelpDesk, Inc.

(acquired by Support.com), founder of PCMovingVan.com (acquired by a PE firm), and Vice President of Marketing at Electronic Book

Technologies, Inc.

(acquired by INSO Corporation, formerly listed on Nasdaq).

(acquired by Support.com), founder

of PCMovingVan.com (acquired by a PE firm), and Vice President of Marketing at Electronic Book Technologies, Inc.

(acquired by INSO Corporation,

formerly listed on Nasdaq).

to the software industry, Mr.

Summers served as Technology Analyst at Electronic Joint Venture Partners LLC and Associate Program

Trader on the Options Trading Desk at Bear Stearns & Co.

Summers received a BA in English from the University

Summers served as Technology Analyst at Electronic Joint Venture Partners LLC and Associate Program Trader

on the Options Trading Desk at Bear Stearns & Co.

Summers received a BA in English from the University of Houston.

Board of Directors believes that Mr.

Summers is qualified to serve as a member of our Board on the basis of his deep understanding

of early-stage business growth strategies, enterprise sales, business acquisitions, as well as his background and extensive company

management and leadership experience.

Summers is qualified to serve as a member of our Board on the basis of his deep understanding of

early-stage business growth strategies, enterprise sales, business acquisitions, as well as his background and extensive company management

and leadership experience.

Board of Directors currently consists of five members.

As a result of his previous role as Chief Executive Officer, Mr.

Rice is not considered an independent director.

As a result of his April 30, 2020 appointment as Chief Executive

Ruport is also not considered an independent director.

Our Board of Directors has determined that our other

directors, Salvatore Battinelli, Dennis Duitch and Kent Summers, constituting a majority of our directors, are “independent”

as that term is defined under Rule 5605(a)(2) of the NASDAQ marketplace rules.

Pursuant to NASDAQ rules, our board must consist

of a majority of independent directors.

NASDAQ independence definition includes a series of objective tests, including that the director is not, and has not been for

at least three years, one of our employees and that neither the director nor any of his family members has engaged in various

types of business dealings with us.

In addition, as required by NASDAQ rules, our Board of Directors has made a subjective determination

as to Messrs.

Battinelli, Duitch and Summers, our independent directors, that no relationships exists, which, in the opinion of

our Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

In making these determinations, our Board of Directors reviewed and discussed information provided by the directors and us with

regard to each director’s business and personal activities and relationships as they may relate to us and our management.

There are no family relationships among any of our directors or executive officers.

Rice is not considered

an independent director.

As a result of his April 30, 2020 appointment as Chief Executive Officer, Mr.

Ruport is also not considered

an independent director.

Our Board of Directors has determined that our other directors, Salvatore Battinelli, Dennis Duitch and Kent

Summers, constituting a majority of our directors, are “independent” as that term is defined under Rule 5605(a)(2) of the

NASDAQ marketplace rules.

Pursuant to NASDAQ rules, our board must consist of a majority of independent directors.

NASDAQ independence definition includes a series of objective tests, including that the director is not, and has not been for at least

three years, one of our employees and that neither the director nor any of his family members has engaged in various types of business

dealings with us.

In addition, as required by NASDAQ rules, our Board of Directors has made a subjective determination as to Messrs.

Battinelli, Duitch and Summers, our independent directors, that no relationships exist, which, in the opinion of our Board of Directors,

would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

In making these determinations,

our Board of Directors reviewed and discussed information provided by the directors and us with regard to each director’s business

and personal activities and relationships as they may relate to us and our management.

There are no family relationships among any of

our directors or executive officers.

Board of Directors

accordance with our amended and restated bylaws, our Board of Directors is divided into three classes with staggered, three-year

At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from

the time of election and qualification until the third annual meeting following election.

accordance with our amended and restated bylaws, our Board of Directors is divided into three classes with staggered, three-year terms.

At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of

election and qualification until the third annual meeting following election.

Our directors are classified as follows:

3 unchanged sentences

amended and restated bylaws provide that the authorized number of directors may be changed by resolution of the Board of Directors.

Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes

so that, as nearly as possible, each class will consist of one-third of the directors.

The division of our Board of Directors

into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our

additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as

nearly as possible, each class will consist of one-third of the directors.

The division of our Board of Directors into three classes

with staggered three-year terms may delay or prevent a change of our management or a change in control of our company.

Structure of the Board

directors may be removed with or without cause at any meeting of stockholders by the affirmative vote of the holders of at least

two-thirds of our outstanding voting stock entitled to vote in the election of directors.

Our amended and restated bylaws provide

our Board of Directors with flexibility in its discretion to combine or separate the positions of Chairman of the Board and Chief

Executive Officer, if we elect to appoint a Chairman of the Board.

Our Board of Directors believes it is important to select the

Company’s Chairman and Chief Executive Officer in the manner it considers in the best interests of the Company at any given

Our Board of Directors believes that the Chairman and Chief Executive Officer positions may be filled by one individual

or by two different individuals, as determined by our Board of Directors based on circumstances then in existence.

directors may be removed with or without cause at any meeting of stockholders by the affirmative vote of the holders of at least two-thirds

of our outstanding voting stock entitled to vote in the election of directors.

Our amended and restated bylaws provide our Board of Directors

with flexibility in its discretion to combine or separate the positions of Chairman of the Board and Chief Executive Officer, if we elect

to appoint a Chairman of the Board.

Our Board of Directors believes it is important to select the Company’s Chairman and Chief

Executive Officer in the manner it considers in the best interests of the Company at any given time.

Our Board of Directors believes

that the Chairman and Chief Executive Officer positions may be filled by one individual or by two different individuals, as determined

by our Board of Directors based on circumstances then in existence.

August 19, 2017, our Board of Directors appointed Mr.

Rice as Chairman of the Board.

The Chairman of the Board presides

at all meetings of our Board of Directors and exercises and performs such other powers and duties as may be assigned

to him from time to time by the Board or prescribed by our amended and restated bylaws.

The Chairman of the Board is appointed

by our Board of Directors on an annual basis.

Board of Directors has no established policy on whether it should be led by a Chairman who is also the Chief Executive Officer,

and has in the past combined the roles of Chairman and Chief Executive Officer.

Our Board currently is committed

to the separated roles given the circumstances of our Company.

However, our Board of Directors continually evaluates

our leadership structure and could, in the future, decide to combine the Chairman and Chief Executive Officer positions

if it believes that doing so would serve the best interests of our Company and our stockholders.

The Chairman of the Board presides at all meetings

of our Board of Directors and exercises and performs such other powers and duties as may be assigned to him from time to time by the

Board or prescribed by our amended and restated bylaws.

The Chairman of the Board is appointed by our Board of Directors on an annual

Board of Directors has no established policy on whether it should be led by a Chairman who is also the Chief Executive Officer, and has

in the past combined the roles of Chairman and Chief Executive Officer.

Our Board currently is committed to the separated roles given

the circumstances of our Company.

However, our Board of Directors continually evaluates our leadership structure and could, in the future,

decide to combine the Chairman and Chief Executive Officer positions if it believes that doing so would serve the best interests of our

Company and our stockholders.

Meetings and Committees

our fiscal year ended December 31, 2020, the Board of Directors held five meetings, and each director attended at least 75% of

the aggregate of (i) the total number of meetings of our Board of Directors held during the period for which he has been a director

and (ii) the total number of meetings held by all committees of our Board of Directors on which he served during the periods that

we do not have a formal policy regarding attendance by members of our Board of Directors at annual meetings of stockholders, we

encourage, but do not require, our directors to attend.

Each of our then current directors attended our 2020 Annual Meeting of

Stockholders.

our fiscal year ended December 31, 2021, the Board of Directors held eight meetings, and each director attended at least 75% of the aggregate

of (i) the total number of meetings of our Board of Directors held during the period for which he has been a director and (ii) the total

number of meetings held by all committees of our Board of Directors on which he served during the periods that he served.

we do not have a formal policy regarding attendance by members of our Board of Directors at annual meetings of stockholders, we encourage,

but do not require, our directors to attend.

Each of our then current directors attended our 2021 Annual Meeting of Stockholders.

Board has established three standing committees-audit, compensation, and nominating and corporate governance-each of which operates

under a written charter that has been approved by our board.

Until February 15, 2017, when our common stock became listed on The

Nasdaq Capital Market, we were not required to establish or maintain an audit, nominating or compensation committee.

committee charter has been posted on the Investors section of our website at www.sigmalabsinc.com.

The reference to our website

address does not constitute incorporation by reference of the information contained at or available through our website, and you

should not consider it to be a part of this Annual Report.

Audit Committee’s responsibilities include:

Until February 15, 2017, when our common stock became listed on The Nasdaq

Capital Market, we were not required to establish or maintain an audit, nominating or compensation committee.

Each committee charter

has been posted on the Investors section of our website at www.sigmalabsinc.com.

The reference to our website address does not constitute

incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part

of this Annual Report.

Audit Committee’s responsibilities include:

approving the compensation of, and assessing the independence of our registered public accounting firm;

the work of our registered public accounting firm, including through the receipt and consideration of reports from such firm;

and discussing with management and the registered public accounting firm our annual and quarterly financial statements and

related disclosures;

and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related

our internal control over financial reporting, disclosure controls and procedures;

7 unchanged sentences

Our Board of Directors has determined that each of Messrs.

Duitch, Battinelli and Summers is an independent director under the

applicable Nasdaq rules and under SEC Rule 10A-3.

All members of our Audit Committee meet the requirements for financial literacy

under the applicable rules and regulations of the SEC and Nasdaq.

Our Board of Directors has determined that each member

of our Audit Committee is an “audit committee financial expert”

as defined by applicable SEC rules and has the requisite

financial sophistication as defined under the applicable Nasdaq rules and regulations.

The Audit Committee met four times

Compensation Committee’s responsibilities include:

Duitch, Battinelli and Summers is an independent director under the applicable

Nasdaq rules and under SEC Rule 10A-3.

All members of our Audit Committee meet the requirements for financial literacy under the applicable

rules and regulations of the SEC and Nasdaq.

Our Board of Directors has determined that each member of our Audit Committee is an “audit

committee financial expert” as defined by applicable SEC rules and has the requisite financial sophistication as defined under

the applicable Nasdaq rules and regulations.

The Audit Committee met four times during 2021.

Compensation Committee’s responsibilities include:

reviewing and approving corporate goals and objectives applicable to CEO compensation;

our CEO’s compensation;

and approving, or making recommendations to our board with respect to, the compensation of our other executive officers;

2 unchanged sentences

and making recommendations to our board with respect to director compensation;

and discussing annually with management our “Compensation Discussion and Analysis”

when it is required by SEC

rules to be included in our Proxy Statements.

and discussing annually with management our “Compensation Discussion and Analysis” when it is required by SEC rules to

be included in our Proxy Statements.

members of our Compensation Committee are Messrs.

Duitch, Battinelli and Summers, and Mr.

Battinelli serves as the chairperson

of the committee.

Battinelli serves as the chairperson of the

Our board has determined that each of Messrs.

Duitch, Battinelli and Summers is independent under the applicable

Nasdaq rules and regulations and is a “non-employee director”

as defined in Rule 16b-3 promulgated under the

Securities Exchange Act of 1934, as amended (the “Exchange Act”).

The Compensation Committee was established effective

February 15, 2017 (i.e., when our common stock became listed on The Nasdaq Capital Market).

Duitch, Battinelli and Summers is independent under the applicable Nasdaq rules

and regulations and is a “non-employee director” as defined in Rule 16b-3 promulgated under the Securities Exchange Act of

1934, as amended (the “Exchange Act”).

and Corporate Governance Committee

Nominating and Corporate Governance Committee’s responsibilities include:

individuals qualified to become board members;

to our board the persons to be nominated for election as directors and to each of the board’s committees;

an annual evaluation of the board.

members of our Nominating and Corporate Governance Committee are Messrs.

The members of our Nominating

and Corporate Governance Committee are Messrs.

Duitch, Battinelli and Summers, and Mr.

Duitch serves

as the interim chairperson of the committee.

Duitch serves as the chairperson of the committee.

Our board has determined that each of Messrs.

Duitch, Battinelli and Summers is independent

under the applicable NASDAQ rules and regulations.

The Nominating and Corporate Governance Committee was established effective

February 15, 2017 (i.e., when our common stock became listed on The NASDAQ Capital Market).

Duitch, Battinelli and Summers is independent under the applicable NASDAQ rules and regulations.

of Ethics and Business Conduct

Company has a code of ethics that applies to all employees, including the Company’s principal executive officer, principal

financial officer, and principal accounting officer, as well as to the members of the Board of Directors.

The code is available

at www.sigmalabsinc.com.

The Company intends to disclose any changes in, or waivers from, this code by posting such information

on the same website or by filing a Form 8-K, in each case to the extent such disclosure is required by rules of the SEC or Nasdaq.

The reference to our website address does not constitute incorporation by reference of the information contained at or available

through our website, and you should not consider it to be a part of this Annual Report.

The Company has a code of ethics

that applies to all employees, including the Company’s principal executive officer, principal financial officer, and principal

accounting officer, as well as to the members of the Board of Directors.

The code is available at www.sigmalabsinc.com.

The Company intends

to disclose any changes in, or waivers from, this code by posting such information on the same website or by filing a Form 8-K, in each

case to the extent such disclosure is required by rules of the SEC or Nasdaq.

The reference to our website address does not constitute

incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part

of this report.

Considerations

1 unchanged sentence

Nominating and Corporate Governance Committee uses a variety of methods for identifying and evaluating director nominees.

evaluation of director candidates, our Nominating and Corporate Governance Committee will consider the current size and composition

of our Board of Directors and the needs of our Board of Directors and the respective committees of our Board of Directors.

of the qualifications that our Nominating and Corporate Governance Committee considers include, without limitation, issues of

character, integrity, judgment, diversity of experience, independence, area of expertise, corporate experience, length of service,

potential conflicts of interest and other commitments.

Nominees must also have the ability to offer advice and guidance to our

Chief Executive Officer based on past experience in positions with a high degree of responsibility and be leaders in the companies

or institutions with which they are affiliated.

Director candidates must have sufficient time available in the judgment of our

Nominating and Corporate Governance Committee to perform all board of director and committee responsibilities.

Members of our

Board of Directors are expected to prepare for, attend, and participate in all board of director and applicable committee meetings.

Other than the foregoing, there are no stated minimum criteria for director nominees, although our Nominating and Corporate Governance

Committee may also consider such other factors as it may deem, from time to time, are in our and our stockholders’

our Board of Directors does not maintain a specific policy with respect to board diversity, our Board of Directors believes that

our Board of Directors should be a diverse body, and our Nominating and Corporate Governance Committee considers a broad range

of backgrounds and experiences.

In making determinations regarding nominations of directors, our Nominating and Corporate Governance

Committee may take into account the benefits of diverse viewpoints.

Our Nominating and Corporate Governance Committee also will

consider these and other factors as it oversees the annual board of director and committee evaluations.

After completing its review

and evaluation of director candidates, our Nominating and Corporate Governance Committee recommends to our full Board of Directors

the director nominees for selection.

In its evaluation

of director candidates, our Nominating and Corporate Governance Committee will consider the current size and composition of our Board

of Directors and the needs of our Board of Directors and the respective committees of our Board of Directors.

Some of the qualifications

that our Nominating and Corporate Governance Committee considers include, without limitation, issues of character, integrity, judgment,

diversity of experience, independence, area of expertise, corporate experience, length of service, potential conflicts of interest and

other commitments.

Nominees must also have the ability to offer advice and guidance to our Chief Executive Officer based on past experience

in positions with a high degree of responsibility and be leaders in the companies or institutions with which they are affiliated.

candidates must have sufficient time available in the judgment of our Nominating and Corporate Governance Committee to perform all board

of director and committee responsibilities.

Members of our Board of Directors are expected to prepare for, attend, and participate in

all board of director and applicable committee meetings.

Other than the foregoing, there are no stated minimum criteria for director

nominees, although our Nominating and Corporate Governance Committee may also consider such other factors as it may deem, from time to

time, are in our and our stockholders’ best interests.

our Board of Directors does not maintain a specific policy with respect to board diversity, our Board of Directors believes that our

Board of Directors should be a diverse body, and our Nominating and Corporate Governance Committee considers a broad range of backgrounds

and experiences.

In making determinations regarding nominations of directors, our Nominating and Corporate Governance Committee may take

into account the benefits of diverse viewpoints.

Our Nominating and Corporate Governance Committee also will consider these and other

factors as it oversees the annual board of director and committee evaluations.

After completing its review and evaluation of director

candidates, our Nominating and Corporate Governance Committee recommends to our full Board of Directors the director nominees for selection.

Recommendations for Nominations to the Board of Directors

Nominating and Corporate Governance Committee will consider candidates for director recommended by stockholders so long as such

recommending stockholder was a stockholder of record both at the time of giving notice and at the time of the annual meeting,

and such recommendations comply with our amended and restated articles of incorporation and amended and restated bylaws and applicable

laws, rules and regulations, including those promulgated by the SEC.

The Nominating and Corporate Governance Committee will evaluate

such recommendations in accordance with its charter, our amended and restated bylaws, our policies and procedures for director

candidates, as well as the regular director nominee criteria described above.

This process is designed to ensure that our Board

of Directors includes members with diverse backgrounds, skills and experience, including appropriate financial and other expertise

relevant to our business.

Eligible stockholders wishing to recommend a candidate for nomination should contact the Secretary in

Our Nominating and Corporate Governance Committee has discretion to decide which individuals to recommend for nomination

as directors.

Nominating and Corporate Governance Committee will consider candidates for director recommended by stockholders so long as such recommending

stockholder was a stockholder of record both at the time of giving notice and at the time of the annual meeting, and such recommendations

comply with our amended and restated articles of incorporation and amended and restated bylaws and applicable laws, rules and regulations,

including those promulgated by the SEC.

The Nominating and Corporate Governance Committee will evaluate such recommendations in accordance

with its charter, our amended and restated bylaws, our policies and procedures for director candidates, as well as the regular director

nominee criteria described above.

This process is designed to ensure that our Board of Directors includes members with diverse backgrounds,

skills and experience, including appropriate financial and other expertise relevant to our business.

Eligible stockholders wishing to

recommend a candidate for nomination should contact the Secretary in writing.

Our Nominating and Corporate Governance Committee has discretion

to decide which individuals to recommend for nomination as directors.

of Board in Risk Oversight Process

2 unchanged sentences

to promote a culture that incorporates risk management into our corporate strategy and day-to-day business operations.

discusses strategic and operational risks at regular management meetings and conducts specific strategic planning and review sessions

during the year that include a focused discussion and analysis of the risks we face.

Throughout the year, senior management reviews

these risks with the Board of Directors at regular board meetings as part of management presentations that focus on particular

business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks.

Our Board of Directors does not have a standing risk management committee, but rather administers this oversight function directly

through the Board of Directors as a whole, as well as through standing committees of the Board of Directors that will address

risks inherent in their respective areas of oversight.

In particular, our Audit Committee is responsible for overseeing our major

financial risk exposures and the steps our management has taken to monitor and control these exposures.

The Audit Committee also

monitors compliance with legal and regulatory requirements and considers and approves or disapproves any related-person transactions.

Our Nominating and Governance Committee monitors the effectiveness of our corporate governance guidelines that we may adopt or

amend from time to time.

Our Compensation Committee assesses and monitors whether any of our compensation policies and programs

has the potential to encourage excessive risk-taking by our management.

Management discusses

strategic and operational risks at regular management meetings and conducts specific strategic planning and review sessions during the

year that include a focused discussion and analysis of the risks we face.

Throughout the year, senior management reviews these risks

with the Board of Directors at regular board meetings as part of management presentations that focus on particular business functions,

operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks.

Our Board of Directors does

not have a standing risk management committee, but rather administers this oversight function directly through the Board of Directors

as a whole, as well as through standing committees of the Board of Directors that will address risks inherent in their respective areas

of oversight.

In particular, our Audit Committee is responsible for overseeing our major financial risk exposures and the steps our management

has taken to monitor and control these exposures.

The Audit Committee also monitors compliance with legal and regulatory requirements

and considers and approves or disapproves any related-person transactions.

Our Nominating and Governance Committee monitors the effectiveness

of our corporate governance guidelines that we may adopt or amend from time to time.

Our Compensation Committee assesses and monitors

whether any of our compensation policies and programs has the potential to encourage excessive risk-taking by our management.

Section 16(a) Reports

16(a) of the Securities Exchange Act of 1934 requires the Company’s executive officers and directors, and persons who own

more than 10% of a registered class of the Company’s equity securities, to file reports of ownership and changes in ownership

with the Securities and Exchange Commission (“SEC”).

Executive officers, directors and greater than 10% stockholders

are required by SEC regulations to furnish the Company with copies of all Section 16(a) forms they file.

Company believes that during its most recent fiscal year ended December 31, 2020, its executive officers, directors and greater

than 10% stockholders complied with the filing requirements under Section 16(a), except that each of Salvatore Battinelli and

Mark Ruport filed a Form 4 late in connection with their respective purchase of shares of the Company’s Series E Preferred

Stock and warrants to purchase shares of common stock.

16(a) of the Securities Exchange Act of 1934 requires the Company’s executive officers and directors, and persons who own more

than 10% of a registered class of the Company’s equity securities, to file reports of ownership and changes in ownership with the

Securities and Exchange Commission (“SEC”).

Executive officers, directors and greater than 10% stockholders are required

by SEC regulations to furnish the Company with copies of all Section 16(a) forms they file.

Company believes that during the fiscal year ended December 31, 2021, its executive officers, directors and greater than 10% stockholders

complied with the filing requirements under Section 16(a).

EXECUTIVE COMPENSATION

and Procedures for Compensation Decisions

Compensation Committee is responsible for the executive compensation programs for our executive officers and reports to our board

of directors on its discussions, decisions and other actions.

Typically, our Chief Executive Officer makes recommendations to

our Compensation Committee and is involved in the determination of compensation for the respective executive officers that report

Our Chief Executive Officer does not determine his own compensation.

Our Chief Executive Officer makes recommendations

to our Compensation Committee regarding short- and long-term compensation for all executive officers based on our results, an

individual executive officer’s contribution toward these results and performance toward individual goal achievement.

Compensation Committee then reviews the recommendations and other data and makes decisions (or makes recommendations to the Board)

as to total compensation for each executive officer as well as each individual compensation component.

Compensation Committee is responsible for the executive compensation programs for our executive officers and reports to our board of

directors on its discussions, decisions and other actions.

Typically, our Chief Executive Officer makes recommendations to our Compensation

Committee and is involved in the determination of compensation for the respective executive officers that report to him.

Our Chief Executive

Officer does not determine his own compensation.

Our Chief Executive Officer makes recommendations to our Compensation Committee regarding

short- and long-term compensation for all executive officers based on our results, an individual executive officer’s contribution

toward these results and performance toward individual goal achievement.

Our Compensation Committee then reviews the recommendations

and other data and makes decisions (or makes recommendations to the Board) as to total compensation for each executive officer as well

as each individual compensation component.

following table sets forth compensation for services rendered in all capacities to the Company:

(i) for each person who served

as the Company’s Chief Executive Officer at any time during the past fiscal year, and (ii) for our two most highly compensated

executive officers, other than our Chief Executive Officer, who were employed with the Company on December 31, 2020 (the foregoing

executives are herein collectively referred to as the “named executive officers”).

(i) for each person who served as the

Company’s Chief Executive Officer at any time during the past fiscal year, and (ii) for our two most highly compensated executive

officers, other than our Chief Executive Officer, who were employed with the Company on December 31, 2021 (the foregoing executives are

herein collectively referred to as the “named executive officers”).

Compensation Table

3 unchanged sentences

Other Compensation ($)

Rice - Former President & Chief

Officer (1) and Director

of the Board)

Ruport - President & Chief

Ruport - Chief

Officer and Director

Fisher - Vice President

Beckett - Chief Technology Officer

Rice served as President and Chief Executive Officer from January 1, 2020 through April 30, 2020.

Ruport has served as President and Chief Executive Officer since April 30, 2020.

Orzechowski - Chief Financial Officer

amounts paid or accrued.

January 24, 2022, the Compensation Committee granted Messrs.

Ruport, Beckett, and Orzechowski performance bonuses of $208,333, $25,800,

and $26,500 respectively, for the fiscal year ended December 31, 2021 in accordance with the provisions of their incentive compensation

February 25, 2021, the Compensation Committee granted Mr.

Ruport a $50,000 performance bonus for the fiscal year ended December 31,

In October 2020, we granted Mr.

Beckett a performance

bonus of $10,000, and in December 2020, Mr.

Beckett was granted an additional performance bonus of $8,000.

In October 2020, the Compensation Committee granted Mr.

Beckett a performance bonus of $10,000.

In December 2020, Mr.

was granted an additional performance bonus of $8,000, and Mr.

Orzechowski was granted a performance bonus of $15,500.

April 10, 2020 Messrs.

Ruport, Fisher, and Beckett were granted 969, 1,125, and 1,125 shares of our common stock, respectively,

at the closing price of $2.05 on the date of the grant.

Ruport, Beckett and Orzechowski were granted 969, 1,125, and 969 shares of our common stock, respectively,

valued at the closing price of $2.05 on the date of the grant.

The shares fully vested on December 31, 2020.

1 unchanged sentence

On June 23, 2020, we adopted the 2020 Stock Appreciation Rights Plan.

The Plan only provides for incentive awards that are only made in the form of stock appreciation rights (“SARs”)

payable in cash.

No shares of common stock were reserved in connection with the adoption of the Plan since no shares will

be issued pursuant to the Plan.

The Fair Value of option

and SARs awards are calculated in accordance with FASB ASC Topic 718.

The amount recognized for all awards is

calculated using the Black Scholes pricing model.

May 1, 2020, we granted Mr.

Rice an option to purchase up to 16,044 shares of our common stock under our 2013 Equity Incentive

Plan in connection with his employment arrangement.

The option has an exercise price of $2.28, is fully vested, and

had an aggregate grant date fair value of $29,583.

each of the first day of each month commencing January 1, 2019 and ending on August 1, 2019, we granted Mr.

Rice an option

to purchase up to 2,292 shares of our common stock, under our 2013 Equity Incentive Plan in connection with his employment

The options are fully vested and have the following exercise prices:

$15.00, $19.30, $20.40, $14.70, $15.00,

$12.00, $14.00, and $7.40.

The options had an aggregate grant date fair value of $26,630, $34,254, $36,418, $26,161, $26,642,

$21,291, $25,405, and $13,546, respectively

only provides for incentive awards that are only made in the form of stock appreciation rights (“SARs”) payable in cash.

No shares of common stock were reserved in connection with the adoption of the Plan since no shares will be issued pursuant to the

The Fair Value of option and SARs awards are calculated in accordance with FASB ASC Topic 718.

The amount recognized for all

awards is calculated using the Black Scholes pricing model.

August 11, 2021, we granted Mr.

Ruport an option to purchase 51,832 shares of our common stock under our 2013 Equity Incentive Plan

in connection with his employment arrangement.

The option has an exercise price of $3.42 and vests as follows:

25%, or 12,958 shares

vested and became exercisable on August 11, 2021, and the remaining 38,874 shares will vest in equal monthly installments over the

next three years.

As of December 31, 2021, 17,278 shares were vested and exercisable.

The option had a grant date fair value of $147,464.

On August 11, 2021, pursuant to our 2020 Stock Appreciation Rights Plan, we granted Mr.

Ruport 77,748 Stock Appreciation Rights (“SAR’s).

The SAR’s have an exercise price of $3.42 and will vest and become exercisable in three equal installments on each of the first,

second, and third anniversaries of the grant date.

The SAR’s had an aggregate grant date fair value of $221,196.

May 28, 2020, we granted Mr.

Ruport an option to purchase 116,654 shares of our common stock under our 2013 Equity Incentive

Plan in connection with his employment arrangement.

Ruport an option to purchase 116,654 shares of our common stock under our 2013 Equity Incentive Plan

in connection with his employment arrangement.

The option has an exercise price of $2.50 and vests as follows:

29,164 shares vested and became exercisable on June 15, 2020, and the remaining 87,490 shares will vest in equal monthly

installments over the next three years.

25%, or 29,164 shares

vested and became exercisable on June 15, 2020, and the remaining 87,490 shares will vest in equal monthly installments over the

next three years.

As of December 31, 2021, 72,904 shares were vested and exercisable.

had an aggregate grant date fair value of $254,474.

The option had an aggregate grant date fair

value of $254,474.

On November 24, 2020, we granted Mr.

Ruport and option to purchase 114,915

shares of our common stock under our 2013 Equity Incentive Plan in connection with his employment arrangement.

option has an exercise price of $2.55 and vests over three years in equal monthly installments beginning one month from the

Ruport and option to purchase 114,915 shares of our common stock under our

2013 Equity Incentive Plan in connection with his employment arrangement.

The option has an exercise price of $2.55 and vests over

three years in equal monthly installments beginning one month from the grant date.

As of December 31, 2021, 41,496 shares were fully

vested and exercisable.

The option had an aggregate grant date fair value of $236,519.

On June 23, 2020, pursuant to our 2020 Stock

Appreciation Rights Plan, we granted Mr.

Ruport 60,094 Stock Appreciation Rights (“SAR’s).

The SAR’s have an exercise

price of $2.63 and will vest and become exercisable in three equal installments on each of the first, second, and third anniversaries

of the grant date.

As of December 31, 2021, 20,031 SARs were vested and exercisable.

The SAR’s had an aggregate grant date

fair value of $127,987.

August 11, 2021, we granted Mr.

Beckett an option to purchase 50,869 shares of our common stock under our 2013 Equity Incentive Plan

in connection with his employment arrangement.

The option has an exercise price of $3.42 and vests as follows:

25%, or 12,718 shares

vested and became exercisable on August 11, 2021, and the remaining 38,151 shares will vest in equal monthly installments over the

next three years.

As of December 31, 2021, 16,957 shares were vested and exercisable.

The option had a grant date fair value of $144,724.

On August 11, 2021, pursuant to our 2020 Stock Appreciation Rights Plan, we granted Mr.

Beckett 76,304 Stock Appreciation Rights

The SAR’s have an exercise price of $3.42 and will vest and become exercisable in three equal installments

on each of the first, second, and third anniversaries of the grant date.

The SAR’s had an aggregate grant date fair value of

May 28, 2020, we granted Mr.

Beckett an option to purchase 46,661 shares of our common stock under our 2013 Equity Incentive Plan

in connection with his employment arrangement.

The option has an exercise price equal to $2.50 per share and vests as follows:

or 11,665 shares vested and became exercisable on June 15, 2020, and the remaining 34,996 shares will vest in equal monthly installments

over the next three years.

As of December 31, 2021, 29,161 shares were fully vested and exercisable.

The option had an aggregate grant

date fair value of $236,519.

The option had an aggregate

grant date fair value of $101,788.

On June 23, 2020, pursuant to our 2020 Stock Appreciation Rights Plan, we granted Mr.

60,094 Stock Appreciation Rights (“SAR’s).

The SAR’s have an exercise price of $2.63 and will vest and become

exercisable in three equal installments on each of the first, second, and third anniversaries of the grant date.

The SAR’s

had an aggregate grant date fair value of $127,987.

December 3, 2019, we granted Mr.

Ruport (i) an option to purchase up to 10,000 shares of our common stock with an exercise

price of $11.20, which fully vested and became exercisable on January 3, 2020;

and (ii) an option to purchase up to 40,000

shares of our common stock with an exercise price of $11.20, which will vest and become exercisable in equal monthly installments

over three years from the grant date.

As of December 31, 2020, 14,053 shares were fully vested and exercisable.

had aggregate grant date fair values of $90,366 and $361,457, respectively.

May 28, 2020, we granted Mr.

Fisher an option to purchase 23,331 shares of our common stock under our 2013 Equity Incentive

24,038 Stock Appreciation Rights (“SAR’s).

The SAR’s have an exercise price of $2.63 and will vest and become exercisable

in three equal installments on each of the first, second, and third anniversaries of the grant date.

As of December 31, 2021, 8,013

SARs were vested and exercisable.

The SAR’s had an aggregate grant date fair value of $51,196.

August 11, 2021, we granted Mr.

Orzechowski an option to purchase 48,580 shares of our common stock under our 2013 Equity Incentive

Plan in connection with his employment arrangement.

The option has an exercise price of $3.42 and vests as follows:

5,833 shares vested and became exercisable on June 15, 2020, and the remaining 17,498 shares will vest in equal monthly installments

25%, or 12,145

shares vested and became exercisable on August 11, 2021, and the remaining 36,435 shares will vest in equal monthly installments

over the next three years.

As of December 31, 2020, 8,749 shares were fully vested and exercisable.

The option had

an aggregate grant date fair value of $50,895.

On June 23, 2020, pursuant to our 2020 Stock Appreciation Rights Plan, we

Fisher 12,019 Stock Appreciation Rights (“SAR’s).

The SAR’s have an exercise price of $2.63

and will vest and become exercisable in three equal installments on each of the first, second, and third anniversaries of

the grant date.

The SAR’s had an aggregate grant date fair value of $25,598.

January 10, 2019, we granted Mr.

Fisher an option to purchase 1,184 shares of our common stock.

The option has an exercise

price equal to $20.20 per share and is fully vested.

On November 1, 2019, we granted Mr.

Fisher an option to purchase

100 shares of our common stock.

The option has an exercise price equal to $5.20 per share and is fully vested.

26, 2019, we granted Mr.

Fisher an option to purchase 100 shares of our common stock.

The option has an exercise price equal

to $8.20 per share and is fully vested.

On December 3, 2019, we granted Mr.

Fisher an option to purchase 500

shares of our common stock.

The option has an exercise price equal to $11.20 per share and is fully vested.

had aggregate grant date fair value of $18,271, $420, $661, and $4,518, respectively.

As of December 31, 2021, 16,193 shares were vested and exercisable.

The option had a grant date fair value

On August 11, 2021, pursuant to our 2020 Stock Appreciation Rights Plan, we granted Mr.

Orzechowski 48,580 Stock Appreciation

Rights (“SAR’s).

The SAR’s have an exercise price of $3.42 and will vest and become exercisable in three equal

installments on each of the first, second, and third anniversaries of the grant date.

The SAR’s had an aggregate grant date

fair value of $138,212.

May 28, 2020, we granted Mr.

Beckett an option to purchase 46,661 shares of our common stock under our 2013 Equity Incentive

Plan in connection with his employment arrangement.

The option has an exercise price equal to $2.50 per share

and vests as follows:

25%, or 11,665 shares vested and became exercisable on June 15, 2020, and the remaining 34,996 shares

will vest in equal monthly installments over the next three years.

As of December 31, 2020, 17,497 shares were fully

vested and exercisable.

The option had an aggregate grant date fair value of $101,788.

On June 23, 2020, pursuant to our

2020 Stock Appreciation Rights Plan, we granted Mr.

Beckett 24,038 Stock Appreciation Rights (“SAR’s).

The SAR’s

have an exercise price of $2.63 and will vest and become exercisable in three equal installments on each of the first, second,

and third anniversaries of the grant date.

The SAR’s had an aggregate grant date fair value of $51,196.

January 1, 2019, we granted Mr.

Beckett an option to purchase up to 375 shares of our common stock under our 2013 Equity Incentive

Orzechowski an option to purchase 34,996 shares of our common stock under our 2013 Equity Incentive

Plan in connection with his employment arrangement.

The option has an exercise price per share equal to $15.00.

vests as follows:

94 shares vested and became exercisable on January 1, 2020;

the remaining 281 shares will vest and become

exercisable in equal installments on the second through the fourth anniversaries of the date of grant.

As of December 31,

2020, 94 shares were fully vested and exercisable.

On July 18, 2019, we granted Mr.

Beckett an option to purchase up to 500

shares of our common stock under our 2013 Equity Incentive Plan in connection with his employment arrangement.

has an exercise price per share equal to $12.40.

The option vests and will become exercisable in equal installments on the

first through the fourth anniversaries of the date of grant.

The option has an exercise price equal to $2.50 per share and vests as follows:

25%, or 8,749 shares vested and became exercisable on June 15, 2020, and the remaining 26,247 shares will vest in equal monthly installments

over the next three years.

As of December 31, 2021, 21,871 shares were fully vested and exercisable.

On October 11, 2019, we granted Mr.

Beckett an option to purchase up to 5,000 shares of our common stock under our 2013 Equity

Incentive Plan in connection with his employment arrangement.

The option has an exercise price per share equal to $6.70.

option is fully vested and exercisable.

The options had aggregate grant date fair values of $4,358, $4,885,

and $26,857, respectively.

The option had an aggregate

grant date fair value of $76,342.

On June 23, 2020, pursuant to our 2020 Stock Appreciation Rights Plan, we granted Mr.

18,028 Stock Appreciation Rights (“SAR’s).

The SAR’s have an exercise price of $2.63 and will vest and become exercisable

in three equal installments on each of the first, second, and third anniversaries of the grant date.

As of December 31, 2021, 6,009

SARs were vested and exercisable.

The SAR’s had an aggregate grant date fair value of $38,396.

Executive Officer Employment Agreements

to April 30, 2020, Mr.

Rice served as President, Chief

Executive Officer, and principal executive officer of the Company at an annual base salary of $155,000.

On April 30, 2020,

he resigned from such positions.

Rice has remained a director on the Board of Directors and has continued to serve as

Chairman of the Board.

Rice was compensated as a non-employee director (on a pro-rata basis for 2020 based on the partial

year during which Mr.

Rice served as a non-employee director) under the Company’s director compensation program,

as may be adjusted from to time for all non-employee directors.

On May 1, 2020, we entered into a consulting agreement with Mr.

Rice, pursuant to which Mr.

Rice was engaged to provide, among other services to be determined by the Company, advice regarding

the structure of certain financial and other strategic transactions involving the Company, on an as-needed basis.

The consulting

agreement expired on December 31, 2020.

December 3, 2019, we entered into an “at-will’

employment letter agreement with Mark Ruport, effective as of December

3, 2019 (the “effective date”), pursuant to which Mr.

Ruport agreed to serve as our Executive Chairman on an

“at-will”

December 3, 2019, we entered into an “at-will’ employment letter agreement with Mark Ruport, effective as of December 3,

2019 (the “effective date”), pursuant to which Mr.

Ruport agreed to serve as our Executive Chairman on an “at-will”

Additionally, Mr.

Ruport was appointed to serve as a member of our Board of Directors, effective

as of December 3, 2019, with a term expiring at the 2021 annual meeting of stockholders.

Ruport was appointed to serve as a member of our Board of Directors, effective as of December 3, 2019, with

a term expiring at the 2021 annual meeting of stockholders.

As of April 30, 2020, Mr.

appointed as President, Chief Executive Officer, and principal executive officer of the Company, and no longer serves as Executive

Ruport was appointed as President, Chief Executive

Officer, and principal executive officer of the Company, and no longer serves as Executive Chairman.

On February 16, 2022, Mr.

resigned as President, and continues to serve as Chief Executive Officer and as a member of the Board of Directors.

the employment letter agreement, Mr.

Ruport is entitled to (i) an annual base salary of $155,000 (such base salary is not subject

to decrease, but may be increased in the discretion of the Company’s Compensation Committee of the Board of Directors based

on annual or special case assessments of Mr.

Ruport’s performance and other factors), and (ii) all benefits that

we elect in our sole discretion to provide from time to time to our other executive officers, and received a grant of (1)

a five-year stock option to purchase up to 10,000 shares of common stock of the Company, which has an exercise price

equal to the closing price of the Company’s common stock on the effective date, and vested and became exercisable

in full on the first month’s anniversary of the effective date, and (2) a five-year stock option to purchase up to

40,000 shares of common stock of the Company, which has an exercise price equal to the closing price of the Company’s

common stock on the effective date, and will vest and become exercisable in equal (as closely as possible) monthly installments

over three years from the effective date, provided, in each case, that Mr.

Ruport remains an employee of the Company through

such vesting date.

options are on such other terms and provisions as are contained in the Company’s standard form nonqualified stock

option agreement;

provided, however, that (x) upon the occurrence of a Change of Control (as defined in the employment letter

agreement), any unvested portion of the options as of the date of such Change of Control will immediately and automatically vest;

provided, however, that, the options may be assumed or, in the discretion of the Board of Directors, an equivalent option may

be substituted by an applicable successor corporation or any subsidiary of the successor corporation in connection with a Change

of Control), and (y) in the event that the Board of Directors determines that Mr.

Ruport is unable to perform his duties due to

an accident, illness or other event or condition which physically or mentally incapacitates him for a period of 45 consecutive

days (“Disability”), if he ceases to be employed by the Company as a result of a Disability, the options will continue

to vest and remain exercisable for the 5-year term of the options in accordance with the terms of the option agreements.

Ruport is entitled to (i) an annual base salary of $155,000, which was increased to $250,000 effective

January 1, 2021, and in connection with his resignation as President was decreased to $200,000 effective February 16, 2022 (such base

salary is not subject to decrease, but may be increased in the discretion of the Company’s Compensation Committee of the Board

of Directors based on annual or special case assessments of Mr.

Ruport’s performance and other factors), and (ii) all benefits

that we elect in our sole discretion to provide from time to time to our other executive officers, and received a grant of (1) a five-year

stock option to purchase up to 10,000 shares of common stock of the Company, which has an exercise price equal to the closing price of

the Company’s common stock on the effective date, and vested and became exercisable in full on the first month’s anniversary

of the effective date, and (2) a five-year stock option to purchase up to 40,000 shares of common stock of the Company, which has an

exercise price equal to the closing price of the Company’s common stock on the effective date, and will vest and become exercisable

in equal (as closely as possible) monthly installments over three years from the effective date, provided, in each case, that Mr.

remains an employee of the Company through such vesting date.

options are on such other terms and provisions as are contained in the Company’s standard form nonqualified stock option agreement;

provided, however, that (x) upon the occurrence of a Change of Control (as defined in the employment letter agreement), any unvested

portion of the options as of the date of such Change of Control will immediately and automatically vest;

provided, however, that, the

options may be assumed or, in the discretion of the Board of Directors, an equivalent option may be substituted by an applicable successor

corporation or any subsidiary of the successor corporation in connection with a Change of Control), and (y) in the event that the Board

of Directors determines that Mr.

Ruport is unable to perform his duties due to an accident, illness or other event or condition which

physically or mentally incapacitates him for a period of 45 consecutive days (“Disability”), if he ceases to be employed

by the Company as a result of a Disability, the options will continue to vest and remain exercisable for the 5-year term of the options

in accordance with the terms of the option agreements.

Additionally,

during the term of his employment, Mr.

Ruport is eligible to receive one or more bonuses relating to each fiscal year in

recognition of his achievement of individual and Company goals established by the Board of Directors from time to time.

the decision to provide any such bonuses and the amount and terms of any such bonuses is in the sole discretion of the

Board of Directors.

On February 25, 2021, Mr.

Ruport received a performance bonus of $50,000 for 2020.

Beckett has served as an employee of the Company since September 25, 2017, pursuant to an “at will”

employment agreement

Ruport is eligible to receive one or more bonuses relating to each fiscal year in recognition

of his achievement of individual and Company goals established by the Board of Directors from time to time.

However, the decision to

provide any such bonuses and the amount and terms of any such bonuses is in the sole discretion of the Board of Directors.

24, 2022, Mr.

Ruport was awarded a performance bonus of $208,333 for 2021.

Beckett has served as an employee of the Company since September 25, 2017, pursuant to an “at will” employment agreement

with the Company, under which he was engaged to serve as our Engineering Manager.

On October 18, 2018, his title was changed from Vice President of Engineering to Chief Technology

Officer of the Company.

On October 18, 2018, the Company also increased the annual base salary of Mr.

Beckett from $135,000 to

$180,000, effective retroactive to September 16, 2018, and granted Mr.

Beckett an option to purchase 2,000 shares of common stock

under the 2013 Plan at an exercise price of $12.10 per share.

The option has a term of five years and vests in equal annual installments

over four years from the date of grant subject, in each case, to Mr.

Beckett being in the continuous employ of the Company

on the applicable vesting date.

On October 18, 2018, his title was changed from Vice

President of Engineering to Chief Technology Officer of the Company.

On October 18, 2018, the Company also increased the annual base

salary of Mr.

Beckett from $135,000 to $180,000, effective retroactive to September 16, 2018, and granted Mr.

Beckett an option to purchase

2,000 shares of common stock under the 2013 Plan at an exercise price of $12.10 per share.

The option has a term of five years and vests

in equal annual installments over four years from the date of grant subject, in each case, to Mr.

Beckett being in the continuous employ

of the Company on the applicable vesting date.

Under the agreement, Mr.

Beckett is eligible to receive medical and dental benefits, life insurance,

short and long-term disability coverage, and to participate in the Company’s Section 125 cafeteria plan, vision plan and

Beckett is eligible to receive medical and dental benefits, life

insurance, short and long-term disability coverage, and to participate in the Company’s Section 125 cafeteria plan, vision plan

and 401K plan.

On October 13, 2017, in connection with his employment, Mr.

Beckett was granted an option to purchase up to

1,500 shares of our common stock with an exercise price equal to $19.20 per share.

Such option is vested and exercisable as to

675 shares at December 31, 2020, and the remaining 825 shares will vest on October 23, 2021 provided Mr.

Beckett is an employee

of the Company on that date.

have entered into an “at will”

employment agreement, effective as of August 10, 2015, with Mr.

Fisher under which

he was engaged to serve as our Vice President of Business Development.

Fisher is entitled to receive an annual base salary

Pursuant to the employment agreement, Mr.

Fisher also was granted, as a signing bonus, (i) a stock option

to purchase up to 2,375 shares of common stock of the Company, at an exercise price equal to $118.00 per share, which was the

closing market price of the Company’s common stock on August 10, 2015 (i.e., the date of grant), under the 2013 Equity Incentive

Such option is fully vested and exercisable.

The option has a ten - year term and is on such other terms

set forth in the Company’s standard form of non-qualified stock option agreement, and (ii) 125 shares of common stock

of the Company with a value equal to the closing price of our common stock on the date of grant and is on such other terms and

provisions as are contained in Sigma Labs’

standard form of restricted stock letter agreement under the Plan.

are fully vested.

Additionally, the Company granted Mr.

Fisher under the 2013 Plan, effective as of August 11, 2016, a stock

option to purchase up to 500 shares of common stock of the Company.

Such option has an exercise price equal to the closing price

of our common stock on the date of grant and is fully vested and exercisable.

Fisher is eligible to

participate in the Company’s 2013 Equity Incentive Plan and is eligible to receive medical and dental benefits, life insurance,

short and long-term disability coverage, and to participate in the Company’s Section 125 cafeteria plan, vision plan and

September 18, 2017, we and Mr.

Fisher entered into Amendment No.

Fisher’s employment agreement, effective August

10, 2015, pursuant to which, effective as of February 11, 2017, item 2, entitled “Performance Bonuses,”

Fisher’s employment agreement was deleted in its entirety and replaced with the new item 2 that was set forth in

the amendment to employment agreement.

Such amendment provided that Mr.

Fisher would become entitled to receive performance-based

stock and cash bonuses if certain milestones were satisfied by February 11, 2018, so long as Mr.

Fisher remained an employee of

the Company as of the date the applicable milestone was satisfied.

On February 21, 2018, the Company and Mr.

Fisher entered into

Amendment No.

Fisher’s employment agreement, pursuant to which the foregoing February 11, 2018 date was extended

to December 31, 2018.

On January 10, 2019, the Company granted Mr.

Fisher an option to purchase up to 1,184 shares of common stock

in exchange for the cancellation of his accrued but unpaid vacation balance at December 31, 2018.

On March 7, 2019, the Company

issued 150 shares of common stock under the 2013 Plan to Mr.

Fisher connected with the satisfaction of a performance milestone.

Beckett was granted an option to purchase up to 1,500 shares

of our common stock with an exercise price equal to $19.20 per share.

Such option is fully vested and exercisable at December 31, 2021.

July 1, 2019, we entered into an “at will” employment agreement, with Frank Orzechowski under which he was engaged to serve

as our Chief Financial Officer, Treasurer, Principal Accounting Officer and Corporate Secretary of the Company.

Orzechowski’s

employment agreement, he was entitled to receive an annual base salary of $135,000, which was increased to $155,000 effective March 1,

2020, which was increased to $180,000 on January 1, 2021, and which was increased to $200,000 on October 1, 2021.

Pursuant to the employment

agreement, Mr.

Orzechowski was granted (1) a stock option to purchase up to 250 shares of common stock of the Company, at an exercise

price equal to $14.00 per share, which was the closing market price of the Company’s common stock on July 1, 2019 (i.e., the Effective

Date), and (2) to purchase up to 6,000 shares of common stock of the Company, with an exercise price of $14.00, and will vest and become

exercisable as follows:

387 shares vested and became exercisable on the one-year anniversary of the Effective Date, 900 shares vested

and became exercisable on the second-year anniversary of the Effective Date, 1,413 shares will vest and become exercisable on the third-year

anniversary of the Effective Date, and 3,300 shares will vest and become exercisable on the fourth-year anniversary of the Effective

Date, provided, in each case, that Mr.

Orzechowski remains an employee of the Company through such vesting dates.

is eligible to participate in the Company’s 2013 Equity Incentive Plan, and is eligible to receive medical and dental benefits,

life insurance, short and long-term disability coverage, and to participate in the Company’s Section 125 cafeteria plan, vision

plan and 401K plan.

Equity Awards at 2021 Fiscal Year-End

following tables set forth outstanding equity awards issued under our 2013 Equity Incentive Plan and 2020 Stock Appreciation

Rights Plan as of December 31, 2020 that are held by our named executive officers.

following table sets forth outstanding equity awards issued under or outside of our 2013 Equity Incentive Plan and 2020

Stock Appreciation Rights Plan as of December 31, 2021 that are held by our named executive officers.

of securities underlying unexercised options (#) exercisable

of securities underlying unexercised options (#) unexercisable

Orzechowski (4)

On June 23, 2020, we adopted the 2020 Stock Appreciation Rights Plan.

The Plan only provides for incentive awards that are only

made in the form of stock appreciation rights (“SARs”) payable in cash.

No shares of common stock were reserved in

connection with the adoption of the Plan since no shares will be issued pursuant to the Plan.

On April 19, 2018, we granted Mr.

Rice three options (the “Options”)

to purchase up to 2,000 shares of our common stock under our 2013 Equity Incentive Plan in connection with his employment arrangement.

The Options have an exercise price per share equal to $18.80, $15.40 and $14.80, respectively, and each is fully vested.

also granted Mr.

Rice an option to purchase up to 2,000 shares on each of April 30, 2018, May 31, 2018, June 30, 2018 and July

Such options have an exercise price per share equal to $11.00 $14.70, $11.90 and $8.70, respectively, and each is fully

On November 1, 2018 the Company granted Mr.

Rice a fully vested option to purchase up to 6,875 shares at an exercise price

On December 1, 2018 the Company granted Mr.

Rice a fully vested option to purchase up to 2,292 shares at an exercise

price of $15.70.

On each of the first day of each month commencing January 1, 2019 and ending on August 1, 2019, we granted Mr.

Rice an option to purchase up to 2,292 shares of our common stock, under our 2013 Equity Incentive Plan in connection with his

employment arrangement.

The options are fully vested and have the following exercise prices:

$15.00, $19.30, $20.40, $14.70, $15.00,

$12.00, $14.00, and $7.40.

On May 1, 2020, we granted Mr.

Rice an option to purchase up to 16,044 shares of our common stock under

our 2013 Equity Incentive Plan in connection with his employment arrangement.

The option has an exercise price of $2.28

and is fully vested and exercisable.

On December 3, 2019, in conjunction with the hiring of Mark

Ruport, the Company’s President and Chief Executive Officer, the Company granted to Mr.

Ruport (i) an option to purchase

10,000 shares of our common stock with an exercise price of $11.20, which fully vested and became exercisable on January 3,2020;

and (ii) an option to purchase up to 40,000 shares of our common stock, with an exercise price of $11.20, which will vest and

become exercisable in equal monthly installments over three years from the date of grant.

The Plan only provides for incentive awards that are only made

in the form of stock appreciation rights (“SARs”) payable in cash.

No shares of common stock were reserved in connection

with the adoption of the Plan since no shares will be issued pursuant to the Plan.

Awards issued under the Plan are included in the

On December 3, 2019, in conjunction with the hiring of Mark K.

Ruport, the Company’s Chief Executive Officer, the Company granted

Ruport (i) an option to purchase 10,000 shares of our common stock with an exercise price of $11.20, which fully vested and became

exercisable on January 3,2020;

and (ii) an option to purchase up to 40,000 shares of our common stock, with an exercise price of $11.20,

which will vest and become exercisable in equal monthly installments over three years from the date of grant.

As of December 31, 2021,

a total of 27,025 shares were vested and exercisable.

On May 28, 2020, we granted Mr.

an option to purchase 116,654 shares of our common stock under our 2013 Equity Incentive Plan in connection with his employment

Ruport an option to purchase 116,654 shares of

our common stock under our 2013 Equity Incentive Plan in connection with his employment arrangement.

The option has an exercise price

of $2.50 and vests as follows:

29,164 shares vested and became exercisable on June 15, 2020, and the remaining 87,490 shares will vest

in equal monthly installments over the next three years.

As of December 31, 2021, a total of 72,904 shares were vested and exercisable.

On November 24, 2020, we granted Mr.

Ruport an option to purchase up to 114,915 shares of our common stock.

The option has an exercise

price of $2.55 and vests over three years in equal monthly installments beginning one month from the grant date.

As of December 31, 2021,

41,496 shares were vested and exercisable.

On June 23, 2020, pursuant to our 2020 Stock Appreciation Rights Plan, we granted Mr.

The SARs have an exercise price of $2.63 and will vest and become exercisable in three equal installments on each of the

first, second, and third anniversaries of the grant date.

As of December 31, 2021, 20,031 SARs were vested and exercisable.

11, 2021, we granted Mr.

Ruport an option to purchase 51,832 shares of our common stock under our 2013 Equity Incentive Plan in connection

with his employment arrangement.

The option has an exercise price of $3.42 and vests as follows:

29,164 shares vested and became exercisable on June

15, 2020, and the remaining 87,490 shares will vest in equal monthly installments over the next three years.

12,958 shares vested and became exercisable

on August 11, 2021, and the remaining 38,874 shares will vest in equal monthly installments over the next three years.

As of December

31, 2021, a total of 17,278 shares were vested and exercisable.

On November 24, 2020, we granted Mr.

Ruport an option to purchase

up to 114,915 shares of our common stock.

The option has an exercise price of $2.55 and vests over three years in equal monthly

installments beginning one month from the grant date.

As of December 31, 2020, 3,192 shares were vested and exercisable.

June 23, 2020, pursuant to our 2020 Stock Appreciation Rights Plan, we granted Mr.

On August 11, 2021, pursuant to our 2020 Stock Appreciation Rights Plan,

we granted Mr.

Ruport 77,748 SARs.

The SARs have an exercise

price of $2.63 and will vest and become exercisable in three equal installments on each of the first, second, and third anniversaries

of the grant date.

In August 2015, in conjunction with the hiring of Ronald Fisher,

the Company’s Vice President of Business Development, the Company granted to Mr.

Fisher a stock option (the “Option”)

to purchase up to 2,375 shares of common stock of the Company, at an exercise price equal to $118.00 per share, which was the

closing market price of the Company’s common stock on August 10, 2015 (i.e., the date of grant), under the 2013 Plan.

Option is fully vested.

The Option has a ten-year term and is on such other terms set forth in the Company’s standard form

of non-qualified stock option agreement.

The Company granted Mr.

Fisher under the 2013 Equity Incentive Plan, effective as of

August 11, 2016, a stock option to purchase up to 500 shares of common stock of the Company.

Such option has an exercise price

equal to the closing price of our common stock on the date of grant and is fully vested and exercisable.

On April 19, 2018, we

granted to Mr.

Fisher an option to purchase 2,875 shares of our common stock.

Such option has a five-year term with an exercise

price equal to the closing price of our common stock on the date of the grant.

The option is vested as to 691 shares and the remaining

shares vest as follows:

683 shares will vest on April 19, 2021, and the remaining 1,501 shares will vest on April 19, 2022.

January 10, 2019, we granted Mr.

Fisher an option to purchase 1,183 shares of our common stock.

The option has an exercise price

per share equal to $20.20 and is fully vested.

On November 1, 2019, we granted Mr.

Fisher an option to purchase 100 shares of

our common stock.

The option has an exercise price per share equal to $5.20 and is fully vested.

On November 26, 2019, we granted

Fisher an option to purchase 100 shares of our common stock.

The option has an exercise price per share equal to $8.20 and

is fully vested.

On December 3, 2019, we granted Mr.

Fisher an option to purchase 500 shares of our common stock.

The option has

an exercise price per share equal to $11.20 and is fully vested.

On May 28, 2020, we granted Mr.

Fisher an option to purchase

23,331 shares of our common stock.

The option has an exercise price per share equal to $2.50 and vests as follows:

vested and became exercisable on June 15, 2020, and the remaining 17,498 shares will vest in equal monthly installments over the

next three years.

As of December 31, 2020, a total of 8,749 shares were vested and exercisable.

On June 23, 2020, pursuant

to our 2020 Stock Appreciation Rights Plan, we granted Mr.

Fisher 12,019 SARs.

The SARs have an exercise price of $2.63 and will

vest and become exercisable in three equal installments on each of the first, second, and third anniversaries of the grant date.

The SARs have an exercise price of $3.42 and will vest and become exercisable in three equal installments

on each of the first, second, and third anniversaries of the grant date.

On February 26, 2018 we granted Mr.

Beckett an option to purchase

up to 1,500 shares of our common stock under our 2013 Equity Incentive Plan in connection with his employment arrangement.

option has an exercise price per share equal to $15.60 and is vested as to 300 shares.

The remaining shares will vest as follows:

375 shares will vest and become exercisable on February 26, 2021;

and 825 shares will vest and become exercisable on February

Beckett an option to purchase up to 1,500 shares of our common stock under our 2013 Equity Incentive

Plan in connection with his employment arrangement.

The option has an exercise price per share equal to $15.60 and is vested as to 675

The remaining 825 shares will vest and become exercisable on February 26, 2022.

On October 18, 2018, we granted Mr.

Beckett an option to purchase up to 2,000 shares of our common stock.

option has an exercise price per share equal to $12.10 and is vested as to 400 shares.

The remaining shares vest as follows:

shares will vest and become exercisable on September 16, 2021, and 1,100 shares will vest and become exercisable on September

option to purchase up to 2,000 shares of our common stock.

The option has an exercise price per share equal to $12.10 and is vested as

to 900 shares.

The 1,100 remaining shares will vest and become exercisable on September 16, 2022.

On October 13, 2017, we granted Mr.

Beckett an option to purchase up to 1,500 shares of our common stock under our 2013

Equity Incentive Plan in connection with his employment arrangement.

Beckett an option to purchase up to 1,500 shares of our common stock under our 2013 Equity Incentive Plan in connection with his employment

The option has an exercise price per share equal to $19.20.

The option is vested as to 675 shares and the remaining 825 shares will vest and become exercisable on October 13, 2021.

The option is fully vested and exercisable.

On January 1, 2019,

we granted Mr.

Beckett an option to purchase up to 375 shares of our common stock under our 2013 Equity Incentive Plan

in connection with his employment arrangement.

The option has an exercise price per share equal to $15.00.

The option vests as

94 shares vested and became exercisable on January 1, 2020;

the remaining 281 shares will vest and become exercisable

in equal installments on the second through the fourth anniversaries of the date of grant.

On July 18, 2019, we granted Mr.

an option to purchase up to 500 shares of our common stock under our 2013 Equity Incentive Plan in connection with his employment

Beckett an option to purchase up to 375 shares of our common stock under our 2013 Equity Incentive Plan in connection

with his employment arrangement.

The option has an exercise price per share equal to $15.00, and vests in equal installments on the first

through the fourth anniversaries of the grant.

As of December 31, 2021, 188 shares are vested and exercisable.

On July 18, 2019, we granted

Beckett an option to purchase up to 500 shares of our common stock under our 2013 Equity Incentive Plan in connection with his employment

The option has an exercise price per share equal to $12.40.

The option vests and will become exercisable in equal

installments on the first through the fourth anniversaries of the date of grant.

As of December 31, 2020, the option was vested

as to 125 shares.

The option vests and will become exercisable in equal installments

on the first through the fourth anniversaries of the date of grant.

As of December 31, 2021, the option was vested as to 250 shares.

On October 11, 2019, we granted Mr.

Beckett an option to purchase up to 5,000 shares of our common stock under

our 2013 Equity Incentive Plan in connection with his employment arrangement.

The option has an exercise price per share equal

to $6.70 and is fully vested and exercisable.

Beckett an option to purchase up to 5,000 shares of our common stock under our 2013 Equity Incentive

Plan in connection with his employment arrangement.

The option has an exercise price per share equal to $6.70 and is fully vested and

On May 28, 2020, we granted Mr.

Beckett an option to purchase 46,661

shares of our common stock.

The option has an exercise price per share equal to $2.50 and vests as follows:

11,665 shares vested

and became exercisable on June 15, 2020, and the remaining 34,996 shares will vest in equal monthly installments over the next

As of December 31, 2020, a total of 17,497 shares were vested and exercisable.

On June 23, 2020, pursuant to our

2020 Stock Appreciation Rights Plan, we granted Mr.

Beckett an option to purchase 46,661 shares of our common stock.

The option has an exercise

price per share equal to $2.50 and vests as follows:

11,665 shares vested and became exercisable on June 15, 2020, and the remaining

34,996 shares will vest in equal monthly installments over the next three years.

As of December 31, 2021, a total of 29,161 shares were

vested and exercisable.

On June 23, 2020, pursuant to our 2020 Stock Appreciation Rights Plan, we granted Mr.

Beckett 24,038 SARs.

The SARs have an exercise price of $2.63 and will vest

and become exercisable in three equal installments on each of the first, second, and third anniversaries of the grant date.

offer stock options, stock appreciation rights, and stock awards to certain of our employees, including our executive officers,

as the long-term incentive component of our compensation program.

We generally grant equity awards to new hires upon their commencing

employment with us.

Our stock options allow employees to purchase shares of our common stock at a price per share equal to the

fair market value of our common stock on the date of grant and may or may not be intended to qualify as “incentive stock

options”

SARs have an exercise price of $2.63 and will vest and become exercisable in three equal installments on each of the first, second, and

third anniversaries of the grant date.

As of December 31, 2021, 8,013 SARs were vested and exercisable.

On August 11, 2021, we granted

Beckett an option to purchase 50,869 shares of our common stock under our 2013 Equity Incentive Plan in connection with his employment

The option has an exercise price of $3.42 and vests as follows:

12,718 shares vested and became exercisable on August 11,

2021, and the remaining 38,151 shares will vest in equal monthly installments over the next three years.

As of December 31, 2021, a total

of 16,957 shares were vested and exercisable.

On August 11, 2021, pursuant to our 2020 Stock Appreciation Rights Plan, we granted Mr.

Beckett 76,304 SARs.

The SARs have an exercise price of $3.42 and will vest and become exercisable in three equal installments on each

of the first, second, and third anniversaries of the grant date.

On July 1, 2019, in conjunction with the hiring of Frank Orzechowski, the Financial Officer, the Company granted to Mr.

Orzechowski (i)

an option to purchase 250 shares of our common stock with an exercise price of $14.00, which fully vested and became exercisable on July

and (ii) an option to purchase up to 6,000 shares of our common stock, with an exercise price of $14.00, which will vest and

become exercisable as follows:

387 shares became vested and exercisable on July 1, 2020;

900 shares became vested and exercisable on

July 1, 2021;

1,413 shares will vest and become exercisable on July 1, 2022, and the remaining 3,300 shares will vest and become exercisable

on July 1, 2023.

As of December 31, 2021, a total of 1,287 shares were vested and exercisable.

On May 28, 2020, we granted Mr.

an option to purchase 34,996 shares of our common stock under our 2013 Equity Incentive Plan in connection with his employment arrangement.

The option has an exercise price of $2.50 and vests as follows:

8,749 shares vested and became exercisable on June 15, 2020, and the

remaining 26,247 shares will vest in equal monthly installments over the next three years.

As of December 31, 2021, a total of 21,871

shares were vested and exercisable.

On June 23, 2020, pursuant to our 2020 Stock Appreciation Rights Plan, we granted Mr.

The SARs have an exercise price of $2.63 and will vest and become exercisable in three equal installments on each of the

first, second, and third anniversaries of the grant date.

As of December 31, 2021, 6,009 SARs were vested and exercisable.

11, 2021, we granted Mr.

Orzechowski an option to purchase 48,580 shares of our common stock under our 2013 Equity Incentive Plan in

connection with his employment arrangement.

The option has an exercise price of $3.42 and vests as follows:

12,145 shares vested and

became exercisable on August 11, 2021, and the remaining 36,435 shares will vest in equal monthly installments over the next three years.

As of December 31, 2021, a total of 16,193 shares were vested and exercisable.

On August 11, 2021, pursuant to our 2020 Stock Appreciation

Rights Plan, we granted Mr.

Orzechowski 48,580 SARs.

The SARs have an exercise price of $3.42 and will vest and become exercisable in

three equal installments on each of the first, second, and third anniversaries of the grant date.

offer stock options, stock appreciation rights, and stock awards to certain of our employees, including our executive officers, as the

long-term incentive component of our compensation program.

We generally grant equity awards to new hires upon their commencing employment

Our stock options allow employees to purchase shares of our common stock at a price per share equal to the fair market value

of our common stock on the date of grant and may or may not be intended to qualify as “incentive stock options” for U.S.

federal income tax purposes.

Our stock appreciation rights allow employees to receive a cash payment for

the difference between the market price of our common stock on the date of exercise and the strike price.

We sometimes also offer

stock options, stock appreciation rights and stock awards to our consultants in lieu of cash.

Our stock options allow consultants

to purchase shares of our common stock at a price per share equal to the fair market value of our common stock on the date of

grant and are not intended to qualify as “incentive stock options”

Our stock appreciation rights allow employees to receive a cash payment for the difference between the market

price of our common stock on the date of exercise and the strike price.

We sometimes also offer stock options, stock appreciation rights

and stock awards to our consultants in lieu of cash.

Our stock options allow consultants to purchase shares of our common stock at a

price per share equal to the fair market value of our common stock on the date of grant and are not intended to qualify as “incentive

stock options” for U.S.

federal income tax purposes.

appreciation rights allow consultants to receive a cash payment for the difference between the market price of our common

stock on the date of exercise and the strike price.

Stock options, stock appreciation rights, and stock awards granted to our

executive officers may be subject to accelerated vesting in certain circumstances.

Our stock appreciation rights allow consultants to receive a cash payment

for the difference between the market price of our common stock on the date of exercise and the strike price.

Stock options, stock appreciation

rights, and stock awards granted to our executive officers may be subject to accelerated vesting in certain circumstances.

maintain a qualified 401(k) plan, in which all eligible employees may participate.

We make safe harbor contributions to

match 100% of each participant’s contribution up to 3% of salary, and 50% of the next 2% of salary contributed.

harbor contributions are 100% vested.

We may also elect, on an annual basis, to make a discretionary contribution to the plan,

but have not done so to date.

Our elective matches and elective contributions vest to participant accounts as follows:

20% after two years of service, and 20% per year thereafter until the participant reaches 6 years of service, at which time, employer

contributions vest 100%.

As a tax-qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions

are not taxable to the employees until distributed from the 401(k) plan.

We make safe harbor contributions to match 100% of

each participant’s contribution up to 3% of salary, and 50% of the next 2% of salary contributed.

Safe harbor contributions are

We may also elect, on an annual basis, to make a discretionary contribution to the plan, but have not done so to date.

elective matches and elective contributions vest to participant accounts as follows:

20% after two years of service, and 20% per year

thereafter until the participant reaches 6 years of service, at which time, employer contributions vest 100%.

As a tax-qualified retirement

plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the

Tax Gross-Ups

do not make gross-up payments to cover our executive officers’

personal income taxes that may pertain to any of the compensation

do not make gross-up payments to cover our executive officers’ personal income taxes that may pertain to any of the compensation

paid or provided by our company.

Equity Incentive Plan

Board of Directors adopted the 2013 Plan to (1) encourage selected employees, officers, directors, consultants and advisers to

improve our operations and increase our profitability, (2) encourage selected employees, officers, directors, consultants and

advisers to accept or continue employment or association with us, and (3) increase the interest of selected employees, officers,

directors, consultants and advisers in our welfare through participation in the growth in value of our common stock.

current employees, directors and consultants are eligible to participate in the 2013 Plan.

Board of Directors adopted the 2013 Plan to (1) encourage selected employees, officers, directors, consultants and advisers to improve

our operations and increase our profitability, (2) encourage selected employees, officers, directors, consultants and advisers to accept

or continue employment or association with us, and (3) increase the interest of selected employees, officers, directors, consultants

and advisers in our welfare through participation in the growth in value of our common stock.

All of our current employees, directors

and consultants are eligible to participate in the 2013 Plan.

Administration

2013 Plan is to be administered by the Board or by a committee to which administration of the Plan, or of part of thereof, is

delegated by the Board.

The 2013 Plan is currently administered by our Compensation Committee, which we refer to below as the

“Administrator.”

The Administrator is responsible for selecting the officers, employees, directors, consultants and

advisers who will receive Options, Stock Appreciation Rights and Stock Awards.

Subject to the requirements imposed by the 2013

Plan, the Administrator is also responsible for determining the terms and conditions of each Option and Stock Appreciation Right

award, including the number of shares subject to the Option, the exercise price, expiration date and vesting period of the Option

and whether the option is an Incentive Option or a Non-Qualified Option.

Subject to the requirements imposed by the 2013 Plan,

the Administrator is also responsible for determining the terms and conditions of each Stock Award, including the number of shares

granted, the purchase price (if any), and the vesting, transfer and other restrictions imposed on the stock.

The Administrator

has the power, authority and discretion to make all other determinations deemed necessary or advisable for the administration

of the 2013 Plan or of any award under the 2013 Plan.

the Board nor any committee of the Board to which administration of the 2013 Plan is delegated will provide advice to participants

about whether or not to accept or exercise their awards.

Each participant must make his or her own decision about whether or not

to accept or exercise an award.

2013 Plan is not subject to the Employee Retirement Income Security Act of 1974 and is not a qualified pension, profit sharing

or bonus plan under Section 401(a) of the Internal Revenue Code

2013 Plan is to be administered by the Board or by a committee to which administration of the Plan, or of part of thereof, is delegated

by the Board.

The 2013 Plan is currently administered by our Compensation Committee, which we refer to below as the “Administrator.”

The Administrator is responsible for selecting the officers, employees, directors, consultants and advisers who will receive Options,

Stock Appreciation Rights and Stock Awards.

Subject to the requirements imposed by the 2013 Plan, the Administrator is also responsible

for determining the terms and conditions of each Option and Stock Appreciation Right award, including the number of shares subject to

the Option, the exercise price, expiration date and vesting period of the Option and whether the option is an Incentive Option or a Non-Qualified

Subject to the requirements imposed by the 2013 Plan, the Administrator is also responsible for determining the terms and conditions

of each Stock Award, including the number of shares granted, the purchase price (if any), and the vesting, transfer and other restrictions

imposed on the stock.

The Administrator has the power, authority and discretion to make all other determinations deemed necessary or

advisable for the administration of the 2013 Plan or of any award under the 2013 Plan.

the Board nor any committee of the Board to which administration of the 2013 Plan is delegated will provide advice to participants about

whether or not to accept or exercise their awards.

Each participant must make his or her own decision about whether or not to accept

or exercise an award.

2013 Plan is not subject to the Employee Retirement Income Security Act of 1974 and is not a qualified pension, profit sharing or bonus

plan under Section 401(a) of the Internal Revenue Code

Subject to the 2013 Plan

to the provisions of the 2013 Plan relating to adjustments upon changes in common stock, an aggregate of 890,000 shares

of common stock are currently subject to outstanding awards under the 2013 Plan or future awards under the 2013 Plan.

awards granted under the 2013 Plan expire or otherwise terminate or are cancelled without being exercised in full, the shares

of common stock not acquired pursuant to such awards will again become available for issuance under the 2013 Plan.

common stock issued pursuant to awards under the 2013 Plan are forfeited to or repurchased by us, the forfeited or repurchased

stock will again become available for issuance under the 2013 Plan.

shares of common stock subject to an award are not delivered to a participant because such shares are withheld for payment of

taxes incurred in connection with the exercise of an Option, or the issuance of shares under a Stock Award, or the award is exercised

through a reduction of shares subject to the award (“net exercised”), then the number of shares that are not delivered

will not again be available for issuance under the 2013 Plan.

In addition, if the exercise price of any award is satisfied by

the tender of shares of common stock to us (whether by actual delivery or attestation), the shares tendered will not again be

available for issuance under the 2013 Plan.

directors, employees, consultants and advisors of the Company and its subsidiaries are eligible to receive awards under the 2013

Incentive Options may only be granted under the 2013 Plan to a person who is a full-time officer or employee of the Company

or a subsidiary.

The Administrator will determine from time-to-time which directors, employees, consultants and advisers

will be granted awards under the 2013 Plan.

As of March 23, 2022, there

were 1,473,297 shares previously issued or subject to outstanding awards under the 2013 Plan and 262,262 shares were available for future issuance

under the 2013 Plan.

awards granted under the 2013 Plan expire or otherwise terminate or are cancelled without being exercised in full, the shares of common

stock not acquired pursuant to such awards will again become available for issuance under the 2013 Plan.

If shares of common stock issued

pursuant to awards under the 2013 Plan are forfeited to or repurchased by us, the forfeited or repurchased stock will again become available

for issuance under the 2013 Plan.

shares of common stock subject to an award are not delivered to a participant because such shares are withheld for payment of taxes incurred

in connection with the exercise of an Option, or the issuance of shares under a Stock Award, or the award is exercised through a reduction

of shares subject to the award (“net exercised”), then the number of shares that are not delivered will not again be available

for issuance under the 2013 Plan.

In addition, if the exercise price of any award is satisfied by the tender of shares of common stock

to us (whether by actual delivery or attestation), the shares tendered will not again be available for issuance under the 2013 Plan.

directors, employees, consultants and advisors of the Company and its subsidiaries are eligible to receive awards under the 2013 Plan.

Incentive Options may only be granted under the 2013 Plan to a person who is a full-time officer or employee of the Company or a subsidiary.

The Administrator will determine from time-to-time which directors, employees, consultants and advisers will be granted awards under

the 2013 Plan.

award under the 2013 Plan will be evidenced by an agreement in a form approved by the Administrator.

exercise price for a Non-Qualified Option or an Incentive Option may not be less than 100% of the fair market value of the Common

Stock on the date of the grant of the Non-Qualified Option or Incentive Option.

With respect to an Option holder who owns stock

possessing more than 10% of the total voting power of all classes of our stock, the exercise price for an Incentive Option may

not be less than 110% of the fair market value of the Common Stock on the date of the grant of the Incentive Option.

value of a Stock Appreciation Right shall also be no less than 100% of the Common Stock on the date of the grant of the Stock

Appreciation Right.

The 2013 Plan does not specify a minimum exercise price for Stock Awards.

Option, Stock Appreciation Right or Stock Award will become exercisable or non-forfeitable (that is, “vest”) under

conditions specified by the Administrator at the time of grant.

Vesting typically is based upon continued service as a director

or employee but may be based upon any performance criteria and other contingencies that are determined by the Administrator.

subject to Stock Awards may be subject to specified restrictions concerning transferability, repurchase by the Company and forfeiture

of the shares issued, together with such other restrictions as may be determined by the Administrator.

Option or Stock Appreciation Right must be exercised by a date specified in the award agreement, which may not be more than ten

years after the grant date.

Except as otherwise provided in the relevant agreement, an Option or Stock Appreciation Right ceases

to be exercisable ninety days after the termination of the holder’s employment with us.

exercise price for a Non-Qualified Option or an Incentive Option may not be less than 100% of the fair market value of the Common Stock

on the date of the grant of the Non-Qualified Option or Incentive Option.

With respect to an Option holder who owns stock possessing

more than 10% of the total voting power of all classes of our stock, the exercise price for an Incentive Option may not be less than

110% of the fair market value of the Common Stock on the date of the grant of the Incentive Option.

The base value of a Stock Appreciation

Right shall also be no less than 100% of the Common Stock on the date of the grant of the Stock Appreciation Right.

The 2013 Plan does

not specify a minimum exercise price for Stock Awards.

Option, Stock Appreciation Right or Stock Award will become exercisable or non-forfeitable (that is, “vest”) under conditions

specified by the Administrator at the time of grant.

Vesting typically is based upon continued service as a director or employee but

may be based upon any performance criteria and other contingencies that are determined by the Administrator.

Shares subject to Stock

Awards may be subject to specified restrictions concerning transferability, repurchase by the Company and forfeiture of the shares issued,

together with such other restrictions as may be determined by the Administrator.

Option or Stock Appreciation Right must be exercised by a date specified in the award agreement, which may not be more than ten years

after the grant date.

Except as otherwise provided in the relevant agreement, an Option or Stock Appreciation Right ceases to be exercisable

ninety days after the termination of the holder’s employment with us.

otherwise determined by the Administrator, Options are not transferable except by will or the laws of descent and distribution.

2 unchanged sentences

or check at the time of an Option exercise or acquisition of a Stock Award.

The Company does not charge participants any fees

or commissions in connection with their acquisition of Common Stock under the 2013 Plan.

The Administrator also has discretion

to accept the following types of payment from participants:

secured or unsecured promissory note, provided that this method of payment is not available to a participant who is a director

or an executive officer;

of our Common Stock already owned by the Option or Stock Award holder as long as the surrendered shares have a fair market

value that is equal to the acquired stock and have been owned by the participant for at least six months;

The Company does not charge participants any fees or commissions

in connection with their acquisition of common stock under the 2013 Plan.

The Administrator also has discretion to accept the

following types of payment from participants:

secured or unsecured promissory note, provided that this method of payment is not available to a participant who is a director or

an executive officer;

of our Common Stock already owned by the Option or Stock Award holder as long as the surrendered shares have a fair market value

that is equal to the acquired stock and have been owned by the participant for at least six months;

surrender of shares of Common Stock then issuable upon exercise of an Option;

“cashless”

option exercise in accordance with applicable regulations of the SEC and the Federal Reserve Board.

the time of his or her exercise of an Option or Stock Appreciation Right, an employee is responsible for paying all applicable

federal and state withholding taxes.

A holder of Stock Awards is responsible for paying all applicable federal and state withholding

taxes once the shares covered by the award cease to be forfeitable or at any other time required by applicable law.

“cashless” option exercise in accordance with applicable regulations of the SEC and the Federal Reserve Board.

the time of his or her exercise of an Option or Stock Appreciation Right, an employee is responsible for paying all applicable federal

and state withholding taxes.

A holder of Stock Awards is responsible for paying all applicable federal and state withholding taxes once

the shares covered by the award cease to be forfeitable or at any other time required by applicable law.

Law Compliance

of common stock will not be issued pursuant to the exercise of an Option or the receipt of a Stock Award unless the Administrator

determines that the exercise of the Option or receipt of the Stock Award and the issuance and delivery of such shares will comply

with all relevant provisions of law, including, without limitation, the Securities Act of 1933 (the “Securities Act”),

applicable state and foreign securities laws and the requirements of any stock exchange on which our Common Stock is traded.

determines that the exercise of the Option or receipt of the Stock Award and the issuance and delivery of such shares will comply with

all relevant provisions of law, including, without limitation, the Securities Act of 1933 (the “Securities Act”), applicable

state and foreign securities laws and the requirements of any stock exchange on which our Common Stock is traded.

of Certain Corporate Transactions

as otherwise determined by the Administrator, in the event of a “corporate transaction,”

all previously unexercised

Options and Stock Appreciation Rights will terminate immediately prior to the consummation of the corporate transaction and all

unvested Restricted Stock awards will be forfeited immediately prior to the consummation of the corporate transaction.

The Administrator,

in its discretion, may permit exercise of any Options or Stock Appreciation Rights prior to their termination, even if those awards

would not otherwise have been exercisable, or provide that outstanding awards will be assumed or an equivalent Option or Stock

Appreciation Right substituted by a successor corporation.

The Administrator, in its discretion, may remove any restrictions as

to any Restricted Stock awards or provide that all outstanding Restricted Stock awards will participate in the corporate transaction

with an equivalent stock substituted by the successor corporation subject to the restrictions.

In general, a “corporate

transaction”

as otherwise determined by the Administrator, in the event of a “corporate transaction,” all previously unexercised Options

and Stock Appreciation Rights will terminate immediately prior to the consummation of the corporate transaction and all unvested Restricted

Stock awards will be forfeited immediately prior to the consummation of the corporate transaction.

The Administrator, in its discretion,

may permit exercise of any Options or Stock Appreciation Rights prior to their termination, even if those awards would not otherwise

have been exercisable, or provide that outstanding awards will be assumed or an equivalent Option or Stock Appreciation Right substituted

by a successor corporation.

The Administrator, in its discretion, may remove any restrictions as to any Restricted Stock awards or provide

that all outstanding Restricted Stock awards will participate in the corporate transaction with an equivalent stock substituted by the

successor corporation subject to the restrictions.

In general, a “corporate transaction” means:

liquidation or dissolution;

1 unchanged sentence

sale of all or substantially all of our assets;

purchase or other acquisition of more than 50% of our outstanding stock by one person, or by more than one person acting in

purchase or other acquisition of more than 50% of our outstanding stock by one person, or by more than one person acting in concert.

Adjustment Provisions

the stock of the Company is changed by reason of a stock split, reverse stock split, stock dividend, recapitalization, combination

or reclassification, appropriate adjustments shall be made by the Administrator, in its discretion, in (1) the number and class

of shares of stock subject to the 2013 Plan and each Option and grant of Stock Awards outstanding under the 2013 Plan, and (2)

the purchase price of each outstanding Option and (if applicable) Stock Award.

For example, if an Option is for 1,000 shares for

$20.00 per share and there is a 2-for-1 stock split, the Option would be adjusted to be exercisable for 2,000 shares at $10.00

the stock of the Company is changed by reason of a stock split, reverse stock split, stock dividend, recapitalization, combination or

reclassification, appropriate adjustments shall be made by the Administrator, in its discretion, in (1) the number and class of shares

of stock subject to the 2013 Plan and each Option and grant of Stock Awards outstanding under the 2013 Plan, and (2) the purchase price

of each outstanding Option and (if applicable) Stock Award.

or Termination of the Plan

1 unchanged sentence

With specified exceptions, no amendment, suspension

or termination of the Plan may adversely affect outstanding Options or Stock Appreciation Rights or the terms that are applicable

to outstanding Stock Awards.

No amendment, suspension or termination of the Plan requires stockholder approval unless such approval

is required under applicable law or under the rules of any stock exchange on which our Common Stock is traded.

Unless terminated

earlier by the Board of Directors, the 2013 Plan will terminate automatically on March 15, 2023, which is the tenth anniversary

of the date of the 2013 Plan’s adoption by the Board.

of March 24, 2021, there were 880,319 shares previously issued or subject to outstanding awards under the 2013 Plan

and 9,681 shares were available for future issuance under the 2013 Plan.

or termination of the Plan may adversely affect outstanding Options or Stock Appreciation Rights or the terms that are applicable to

outstanding Stock Awards.

No amendment, suspension or termination of the Plan requires stockholder approval unless such approval is required

under applicable law or under the rules of any stock exchange on which our Common Stock is traded.

Unless terminated earlier by the Board

of Directors, the 2013 Plan will terminate automatically on March 15, 2023, which is the tenth anniversary of the date of the 2013 Plan’s

adoption by the Board.

Stock Appreciation Rights Plan

June 23, 2020, our Board of Directors adopted the Sigma Labs, Inc.

2020 Stock Appreciation Rights Plan (the “Plan”).

The purposes of the Plan are to:

(i) enable the Company to attract and retain the types of employees, consultants, and

directors (collectively, “Service Providers”) who will contribute to the Company’s long-range success;

(ii) provide incentives that align the interests of Service Providers with those of the shareholders of the Company;

promote the success of the Company’s business.

The Plan only provides for incentive awards that are only made in the form

of stock appreciation rights payable in cash (“SARs”).

No shares of common stock were reserved in connection with

the adoption of the Plan since no shares will be issued pursuant to the Plan.

Plan will be administered by the Compensation Committee of the Board or, in the Board’s sole discretion, by the Board.

Compensation Committee will have the authority to, among other things, (i) construe and interpret the Plan and apply its provisions;

(ii) promulgate, amend, and rescind rules and regulations relating to the administration of the Plan;

(iii) delegate its authority

to one or more persons who is an officer of the Company within the meaning of Section 16 of the Securities Exchange Act of 1934,

as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder with respect to SARs that do

not involve “insiders”

within the meaning of Section 16 of the Exchange Act;

(iv) determine when SARs are to be granted

under the Plan and the applicable grant date;

(v) prescribe the terms and conditions of each SAR, including, without limitation,

the exercise price and medium of payment and vesting provisions, and to specify the provisions of the SAR Agreement relating to

(vi) amend any outstanding SARs, subject, in certain cases, to the participant’s consent;

and (vii) make all

other determinations which may be necessary or advisable for the administration of the Plan.

may be granted only to persons who are Service Providers, and those persons whom the Committee determines are reasonably expected

to become Service Providers following the grant date.

The Committee may from time to time designate those Service Providers, if

any, to be granted SARs under the Plan, the number of SARs which will be granted to each such person, and any other terms or conditions

relating to SARs as it may deem appropriate to the extent consistent with the provisions of the Plan.

A participant who has been

granted a SAR may, if otherwise eligible, be granted additional incentive awards at any time.

2020 Stock Appreciation Rights Plan (the “Plan”).

purposes of the Plan are to:

(i) enable the Company to attract and retain the types of employees, consultants, and directors (collectively,

“Service Providers”) who will contribute to the Company’s long-range success;

(ii) provide incentives that align the

interests of Service Providers with those of the shareholders of the Company;

and (iii) promote the success of the Company’s business.

The Plan only provides for incentive awards that are only made in the form of stock appreciation rights payable in cash (“SARs”).

No shares of common stock were reserved in connection with the adoption of the Plan since no shares will be issued pursuant to the Plan.

Plan will be administered by the Compensation Committee of the Board or, in the Board’s sole discretion, by the Board.

The Compensation

Committee will have the authority to, among other things, (i) construe and interpret the Plan and apply its provisions;

(ii) promulgate,

amend, and rescind rules and regulations relating to the administration of the Plan;

(iii) delegate its authority to one or more persons

who is an officer of the Company within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), and the rules and regulations promulgated thereunder with respect to SARs that do not involve “insiders” within

the meaning of Section 16 of the Exchange Act;

(iv) determine when SARs are to be granted under the Plan and the applicable grant date;

(v) prescribe the terms and conditions of each SAR, including, without limitation, the exercise price and medium of payment and vesting

provisions, and to specify the provisions of the SAR Agreement relating to such grant;

(vi) amend any outstanding SARs, subject, in certain

cases, to the participant’s consent;

and (vii) make all other determinations which may be necessary or advisable for the administration

may be granted only to persons who are Service Providers, and those persons whom the Committee determines are reasonably expected to

become Service Providers following the grant date.

The Committee may from time to time designate those Service Providers, if any, to

be granted SARs under the Plan, the number of SARs which will be granted to each such person, and any other terms or conditions relating

to SARs as it may deem appropriate to the extent consistent with the provisions of the Plan.

A participant who has been granted a SAR

may, if otherwise eligible, be granted additional incentive awards at any time.

The Committee may grant SARs to any Service Provider.

A SAR is the right to receive an amount equal to the Spread with respect

to a share of the Company’s common stock upon the exercise of the SAR.

The “Spread”

is the difference between

the exercise price per share specified in a SAR agreement on the date of grant and the fair market value per share on the date

of exercise of the SAR.

A SAR is the right to receive an amount equal to the Spread with respect to a share

of the Company’s common stock upon the exercise of the SAR.

The “Spread” is the difference between the exercise price

per share specified in a SAR agreement on the date of grant and the fair market value per share on the date of exercise of the SAR.

The terms and conditions of each SAR will be evidenced by a SAR agreement.

The exercise price per share will not

be less than 100% of the fair market value of a Share on the date of grant of the SAR.

The term of the SAR will be determined

by the Committee but may not be greater than ten years from the date of grant.

The exercise price per share will not be less

than 100% of the fair market value of a Share on the date of grant of the SAR.

The term of the SAR will be determined by the Committee

but may not be greater than ten years from the date of grant.

SARs are exercisable subject to such terms and conditions as the Committee may specify in the SAR agreement for the SAR.

may be exercised by the delivery of a signed written notice of exercise to the Company, which must be received and accepted by

the Company as of a date set by the Company in advance of the effective date of the proposed exercise.

The notice must set forth

the number of SARs being exercised, together with any additional documents the Company may require.

exercised by the delivery of a signed written notice of exercise to the Company, which must be received and accepted by the Company as

of a date set by the Company in advance of the effective date of the proposed exercise.

The notice must set forth the number of SARs

being exercised, together with any additional documents the Company may require.

Upon exercise of a SAR, the Grantee will receive an amount equal to the Spread.

The Spread, less applicable withholdings, will

be payable only in cash.

The Spread, less applicable withholdings, will be payable

only in cash.

In no event may any SAR be settled in any manner other than by delivery of a cash payment from the Company.

of SAR Agreement

participant to whom a SAR is granted will be required to enter into a SAR agreement with the Company, in such a form as is provided

by the Committee.

The SAR agreement will contain specific terms as determined by the Committee, in its discretion, with respect

to the participant’s particular SAR.

participant to whom a SAR is granted will be required to enter into a SAR agreement with the Company, in such a form as is provided by

the Committee.

The SAR agreement will contain specific terms as determined by the Committee, in its discretion, with respect to the participant’s

particular SAR.

Such terms need not be uniform among all participants or any similarly situated participants.

The SAR agreement may include, without limitation, vesting, forfeiture and other provisions particular to the particular participant’s

SAR, as well as, for example, provisions to the effect that the participant must abide by all the terms and conditions of the

Plan and such other terms and conditions as may be imposed by the Committee.

A SAR will include such terms and conditions as are

determined by the Committee, in its discretion, to be appropriate with respect to any participant.

Committee may specify in a SAR agreement that the participant’s rights, payments, and benefits with respect to a SAR will

be subject to forfeiture upon the occurrence of certain specified events, in addition to any otherwise applicable vesting or performance

conditions of the incentive award.

Such events may include, but are not limited to, termination with cause or other conduct by

the participant that is detrimental to the business or reputation of the Company.

The SAR agreement may include,

without limitation, vesting, forfeiture and other provisions particular to the particular participant’s SAR, as well as, for example,

provisions to the effect that the participant must abide by all the terms and conditions of the Plan and such other terms and conditions

as may be imposed by the Committee.

A SAR will include such terms and conditions as are determined by the Committee, in its discretion,

to be appropriate with respect to any participant.

Committee may specify in a SAR agreement that the participant’s rights, payments, and benefits with respect to a SAR will be subject

to forfeiture upon the occurrence of certain specified events, in addition to any otherwise applicable vesting or performance conditions

of the incentive award.

Such events may include, but are not limited to, termination with cause or other conduct by the participant that

is detrimental to the business or reputation of the Company.

of Employment

otherwise expressly provided in the participant’s SAR agreement, if the participant’s employment is terminated for

any reason other than due to cause, death or disability, any non-vested portion of any outstanding SAR at the time of such termination

will automatically expire and terminate and no further vesting will occur after the termination date.

In such event, except as

otherwise expressly provided in the SAR agreement, the participant will be entitled to exercise such participant’s rights

only with respect to the portion of the SAR that was vested as of the termination date for a period that will end on the earlier

of (i) the expiration date set forth in the SAR agreement or (ii) ninety days after the date of termination.

otherwise expressly provided in the participant’s SAR agreement, in the event of the termination of a participant’s

employment for cause, all vested and non-vested SARs granted to such participant will immediately expire, and will not be exercisable

to any extent.

otherwise expressly provided in the participant’s SAR agreement, upon termination of employment as a result of the participant’s

disability or death, (i) any non-vested portion of any outstanding SAR will immediately terminate upon termination and no further

vesting will occur, and (ii) any vested SAR will expire on the earlier of either (A) the expiration date set forth in the SAR

agreement or (B) 12 months following the participant’s termination of employment.

to the conditions and limitations of the Plan and applicable law, in the event that a participant ceases to be an employee, outside

director or consultant, as applicable, for whatever reason, the Committee and participant may mutually agree with respect to any

outstanding SAR then held by the participant (i) for an acceleration or other adjustment in any vesting schedule applicable to

the SAR award;

(ii) for a continuation of the exercise period following termination for a longer period than is otherwise provided

under such SAR;

or (iii) to any other change in the terms and conditions of the SAR.

In the event of any such change to an outstanding

SAR, a written amendment to the participant’s SAR agreement will be required.

No amendment to a participant’s SAR

will be made to the extent compensation payable pursuant thereto as a result of such amendment would be considered deferred compensation

that is not excepted from taxation or penalties under Code Section 409A, unless otherwise determined by the Committee.

granted under the Plan are not transferable other than to a designated beneficiary upon the Participant’s death or by will

or the laws of descent and distribution.

otherwise provided in a SAR Agreement, notwithstanding any contrary provision in the Plan, in the event of a Change in Control

(as defined in the Plan), all outstanding SARs will become 100% vested and immediately and fully exercisable.

otherwise expressly provided in the participant’s SAR agreement, if the participant’s employment is terminated for any reason

other than due to cause, death or disability, any non-vested portion of any outstanding SAR at the time of such termination will automatically

expire and terminate and no further vesting will occur after the termination date.

In such event, except as otherwise expressly provided

in the SAR agreement, the participant will be entitled to exercise such participant’s rights only with respect to the portion of

the SAR that was vested as of the termination date for a period that will end on the earlier of (i) the expiration date set forth in

the SAR agreement or (ii) ninety days after the date of termination.

otherwise expressly provided in the participant’s SAR agreement, in the event of the termination of a participant’s employment

for cause, all vested and non-vested SARs granted to such participant will immediately expire, and will not be exercisable to any extent.

otherwise expressly provided in the participant’s SAR agreement, upon termination of employment as a result of the participant’s

disability or death, (i) any non-vested portion of any outstanding SAR will immediately terminate upon termination and no further vesting

will occur, and (ii) any vested SAR will expire on the earlier of either (A) the expiration date set forth in the SAR agreement or (B)

12 months following the participant’s termination of employment.

to the conditions and limitations of the Plan and applicable law, in the event that a participant ceases to be an employee, outside director

or consultant, as applicable, for whatever reason, the Committee and participant may mutually agree with respect to any outstanding SAR

then held by the participant (i) for an acceleration or other adjustment in any vesting schedule applicable to the SAR award;

a continuation of the exercise period following termination for a longer period than is otherwise provided under such SAR;

any other change in the terms and conditions of the SAR.

In the event of any such change to an outstanding SAR, a written amendment to

the participant’s SAR agreement will be required.

No amendment to a participant’s SAR will be made to the extent compensation

payable pursuant thereto as a result of such amendment would be considered deferred compensation that is not excepted from taxation or

penalties under Code Section 409A, unless otherwise determined by the Committee.

granted under the Plan are not transferable other than to a designated beneficiary upon the Participant’s death or by will or the

laws of descent and distribution.

otherwise provided in a SAR Agreement, notwithstanding any contrary provision in the Plan, in the event of a Change in Control (as defined

in the Plan), all outstanding SARs will become 100% vested and immediately and fully exercisable.

Board at any time, and from time to time, may amend or terminate the Plan.

The Committee at any time, and from time to time, may

amend the terms of any one or more SAR agreements, except that the Committee may not affect any amendment which would otherwise

constitute an impairment of the rights under any SAR unless the participant consents in writing.

of March 24, 2021, there were 127,629 SARs previously issued under the 2020 Plan.

believe that a combination of cash and equity compensation is appropriate to attract and retain the individuals we desire to serve

on our Board of Directors.

Our cash compensation policies are designed to encourage frequent and active interaction between directors

and our executives both during and between formal meetings as well as compensate our directors for their time and effort.

we believe it is important to align the long-term interests of our non-employee directors (i.e., directors who are not

employed by us as officers or employees) with those of the Company and its stockholders, and that awarding equity compensation

to, and thereby increasing ownership of our common stock by, our non-employee directors is an appropriate means to achieve this

Directors who are also employees of our company do not receive compensation for their service on our Board of Directors.

our director compensation program for 2020, each non-employee director received annual compensation of $18,500, 2,500 shares

of restricted common stock, which is fully vested, and an option to purchase 25,000 shares of our common stock, which is also

fully vested.

Such grants were fully vested because the directors agreed to defer the payment of their cash compensation for

the first two quarters of 2020 as a cash saving measure.

In addition, the Chairperson of the Audit Committee received a $2,500

annual retainer in cash.

The Committee at any time, and from time to time, may amend

the terms of any one or more SAR agreements, except that the Committee may not affect any amendment which would otherwise constitute

an impairment of the rights under any SAR unless the participant consents in writing.

of March 23, 2022, there were 412,657 SARs outstanding under the 2020 Plan.

believe that a combination of cash and equity compensation is appropriate to attract and retain the individuals we desire to serve on

our Board of Directors.

Our cash compensation policies are designed to encourage frequent and active interaction between directors and

our executives both during and between formal meetings as well as compensate our directors for their time and effort.

Further, we believe

it is important to align the long-term interests of our non-employee directors (i.e., directors who are not employed by us as officers

or employees) with those of the Company and its stockholders, and that awarding equity compensation to, and thereby increasing ownership

of our common stock by, our non-employee directors is an appropriate means to achieve this alignment.

Directors who are also employees

of our company do not receive compensation for their service on our Board of Directors.

our director compensation program for 2021, each non-employee director received annual compensation of $10,000, and an option to purchase

50,000 shares of our common stock, which is fully vested.

All cash fees are paid quarterly.

Also, each non-employee director may be reimbursed for his reasonable

expenses incurred in the performance of his duties as a director as our Board of Directors determines from time to time.

Our Compensation

Committee periodically evaluates our director compensation program and determines whether any changes should be recommended to

In that regard, under our director compensation program for 2021, each non-employee director will receive a quarterly

cash payment of $2,500, and received a stock option to purchase 50,000 shares of our common stock, which option will vest ratably

each month through December 31, 2021 (26,000 of such shares will only be exercisable upon approval by the Company’s stockholders

at the annual meeting of the Company’s stockholders of an increase in the aggregate number of shares of the Company’s

common stock that may be issued or issuable under the Plan) .

Also, each non-employee director may be reimbursed

for his reasonable expenses incurred in the performance of his duties as a director as our Board of Directors determines from time to

Our Compensation Committee intends to evaluate our director compensation program and determine whether any changes should be

recommended to the Board.

following table sets forth certain information concerning the compensation paid to non-employee directors in 2021 for their services

1 unchanged sentence

The compensation of Mr.

Ruport, who serves as a director and serves as our President and Chief Executive

Ruport, who serves as a director and serves as our Chief Executive

Officer, is described in the Summary Compensation Table of Executive Officers.

Our non-employee directors do not receive fringe

or other benefits.

Our non-employee directors do not receive fringe or other

Battinelli (2)

fees shown were paid to Mr.

Rice for services as a non-employee director from May 1, 2020 through December 31, 2020.

31, 2020, the Company issued 834 shares of the Company’s common stock to Mr.

Rice, pursuant to the Company’s 2013

Equity Incentive Plan, in connection with his service as a director, with such shares immediately vested.

Such shares were

valued at $2,243 or $2.69 per share.

Also on July 31, 2020, the Company granted Mr.

Rice for services as a director.

On January 4, 2021, the Company granted Mr.

Rice an option to purchase

up to 25,000 shares of the Company’s common stock in connection with his service as a director.

The exercise price of

the option is equal to $2.69 per share, is fully vested, and had a grant date fair value of $54,366.

The compensation of Mr.

Rice for the period January 1, 2020 through April 30, 2020, during which time he served as President and Chief Executive officer

in addition to his service as a director, is described in the Summary Compensation Table of Executive Officers.

up to 50,000 shares of the Company’s common stock in connection with his service as a director.

The exercise price of the option

is equal to $3.13 per share, is fully vested, and had a grant date fair value of $134,647.

fees shown were paid to Mr.

Battinelli for services as a director.

On July 31, 2020, the Company issued 2,500 shares of the

Company’s common stock to Mr.

Battinelli, pursuant to the Company’s 2013 Equity Incentive Plan, in connection

with his service as a director, with such shares immediately vested.

Such shares were valued at $6,725 or $2.69

Also on July 31, 2020, the Company granted Mr.

Battinelli an option to purchase up to 25,000 shares of the

Company’s common stock in connection with his service as a director.

The exercise price of the option is equal to $2.69

per share, is fully vested, and had a grant date fair value of $54,366.

fees shown were paid to Mr.

Duitch for services as a director, including $2,500 as a retainer for serving as the Chairman

of the Audit Committee.

On July 31, 2020, the Company issued 2,500 shares of the Company’s common stock to Mr.

pursuant to the Company’s 2013 Equity Incentive Plan, in connection with his service as a director, with such shares

immediately vested.

Such shares were valued at $6,725 or $2.69 per share.

Also on July 31, 2020, the Company

Duitch an option to purchase up to 25,000 shares of the Company’s common stock in connection with his service

as a director.

The exercise price of the option is equal to $2.69 per share, is fully vested, and had a grant date fair value

On January 4, 2021, the Company granted Mr.

Battinelli an option

to purchase up to 50,000 shares of the Company’s common stock in connection with his service as a director.

The exercise price

of the option is equal to $3.13 per share, is fully vested, and had a grant date fair value of $134,647.

fees shown were paid to Mr.

Garofalo for services as a director.

Garofalo resigned from the Board of Directors on February

Duitch for services as a director.

On January 4, 2021, the Company granted Mr.

Duitch an option to purchase

up to 50,000 shares of the Company’s common stock in connection with his service as a director.

The exercise price of the option

is equal to $3.13 per share, is fully vested, and had a grant date fair value of $134,647.

fees shown were paid to Mr.

Summers for services as a director.

On July 31, 2020, the Company issued 2,500 shares of the Company’s

common stock to Mr.

Summers, pursuant to the Company’s 2013 Equity Incentive Plan, in connection with his service as

a director, with such shares immediately vested.

Such shares were valued at $6,725 or $2.69 per share.

On July 31, 2020, the Company granted Mr.

Summers an option to purchase up to 25,000 shares of the Company’s common

stock in connection with his service as a director.

The exercise price of the option is equal to $2.69 per share, is fully

vested, and had a grant date fair value of $54,366.

columns represent the aggregate grant date fair value of stock awards and stock options computed in accordance with FASB ASC

Summers an option to purchase

up to 50,000 shares of the Company’s common stock in connection with his service as a director.

The exercise price of the option

is equal to $3.13 per share, is fully vested, and had a grant date fair value of $134,647.

columns represent the aggregate grant date fair value of stock awards and stock options computed in accordance with FASB ASC Topic

These amounts do not correspond to the actual value that will be recognized by the named directors from these awards.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

following table sets forth certain information regarding beneficial ownership of our common stock as of March 24, 2021

(a) by each person known by us to own beneficially 5% or more of any class of our common stock, (b) by our named executive

officers and each of our directors (and director nominees) and (c) by all executive officers and directors of the Company as a

following table sets forth certain information regarding beneficial ownership of our common stock as of March 23, 2022 (a) by

each person known by us to own beneficially 5% or more of any class of our common stock, (b) by our named executive officers and each

of our directors (and director nominees) and (c) by all executive officers and directors of the Company as a group.

number of shares beneficially owned by each stockholder is determined in accordance with SEC rules.

Under these rules, beneficial

ownership includes any shares as to which a person has sole or shared voting power or investment power.

Percentage ownership is

based on 8,302,098 shares of our common stock outstanding on March 24, 2021.

In computing the number of shares beneficially

owned by a person and the percentage ownership of that person, shares of common stock subject to stock options, warrants or other

rights held by such person that are currently convertible or exercisable or will become convertible or exercisable within 60 days

of March 24, 2021 are considered outstanding, although these shares are not considered outstanding for purposes of computing

the percentage ownership of any other person.

of March 24, 2021, there are no 5% or greater beneficial holders

of our common shares.

We believe, based on information provided to us, that each of the stockholders listed below has sole

voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to

community property laws where applicable.

Under these rules, beneficial ownership

includes any shares as to which a person has sole or shared voting power or investment power.

Percentage ownership is based on 10,498,802

shares of our common stock outstanding on March 23, 2022.

In computing the number of shares beneficially owned by a person and

the percentage ownership of that person, shares of common stock subject to stock options, warrants or other rights held by such person

that are currently convertible or exercisable or will become convertible or exercisable within 60 days of March 23, 2022 are considered

outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person.

We believe, based

on information provided to us, that each of the stockholders listed below has sole voting and investment power with respect to the shares

beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.

of Beneficial Owner

2 unchanged sentences

Executive Officers and Directors:

Orzechowski (3)

Battinelli (5)

executive officers and directors as a group (9 persons) (8)

4,000 shares that may be acquired now or within 60 days of March 24, 2021 upon the exercise of outstanding stock

(a) 13,406 shares that may be acquired now or within 60 days of March 24, 2021 upon the

exercise of outstanding stock options;

(b) 6,166 shares that may be acquired now or within

60 days of March 24, 2021 pursuant to the conversion of the shares of the Company’s

Series E Preferred Stock;

and (c) 4,855 shares that may be acquired now or within 60

days of March 24, 2021 upon exercise of outstanding Class A Warrants.

1,655 shares that may be acquired now or within 60 days of March 24, 2021 upon the exercise of outstanding stock

1,944 shares that may be acquired now or within 60 days of March 24, 2021 upon the exercise of outstanding stock

(a) 4,000 shares that may be acquired now or within 60 days of March 24, 2021 upon the exercise of outstanding stock

options, (b) 3,127 shares that may be acquired now or within 60 days of March 24, 2021 pursuant to the conversion of shares

of the Company’s Series E Preferred Stock, and (c) 2,428 shares that may be acquired now or within 60 days of March

24, 2021 upon exercise of outstanding Class A Warrants.

4,000 shares that may be acquired now or within 60 days of March 24, 2021 upon the exercise

of outstanding stock options.

4,000 shares that may be acquired now or within 60 days of March 24, 2021 upon the exercise of outstanding stock options.

34,463 shares that may be acquired now or within 60 days of March 24, 2021 upon the exercise of outstanding

stock options and 9,293 shares that may be acquired now or within 60 days of March 24, 2021 pursuant to the

conversion of the shares of the Company’s Series E Preferred Stock.

5% Beneficial Holders:

Investment Company, Inc.

Includes 132,548 shares issuable upon the exercise of

stock options.

Includes (a) 204,426 shares issuable upon the exercise of stock

(b) 6,166 shares issuable upon the conversion of the shares of the Company’s Series E Preferred Stock;

Includes 48,306 shares issuable upon the exercise of stock options.

Includes 65,710 shares issuable upon the exercise of stock options.

Includes (a) 75,000 shares issuable upon the exercise of stock

options, (b) 3,082 shares issuable upon the conversion of shares of the Company’s Series E Preferred Stock, and (c)

2,428 shares issuable upon exercise of Class A Warrants.

Includes 75,000 shares issuable upon the exercise of stock options.

Includes (a) 819,733 shares issuable upon the exercise

of stock options, (b) and 9,248 shares issuable upon the conversion of the shares of the Company’s Series E Preferred

Stock, and (c) 7,283 shares issuable upon exercise of Class A Warrants.

AWM Investment Company, Inc.

is the investment advisor to Special Situations

Technology Fund.

(“Tech”) and Special Situations Technology Fund II (“Tech II”) and holds sole voting

and investment power over 105,089 shares and 90,029 warrants to purchase shares held by Tech, and 592,696 shares and 507,757 warrants

to purchase shares held by Tech II.

Such warrants may only be exercised to the extent that the total number of shares then beneficially

owned does not exceed 9.9% of the outstanding shares.

AWM Investment Company, Inc.’s address is c/o Special Situations Funds,

527 Madison Avenue, Suite 2600, New York, NY 10022.

Compensation Plan Information

2 unchanged sentences

Outstanding Options,

of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column

of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))

Equity Incentive Plan (1)

compensation plans not approved by security holders (2)

On March 15, 2013, the Company’s board of directors approved the Company’s 2013 Equity Incentive Plan.

The 2013 Equity

Incentive Plan was approved by holders of at least a majority of the issued and outstanding shares of common stock of the Company

on October 10, 2013.

Pursuant to the 2013 Equity Incentive Plan, the Company is authorized to grant “incentive stock options”

and “non-qualified stock options”, grant or sell common stock subject to restrictions or without restrictions, and

grant stock appreciation rights to employees, officers, directors, consultants and advisers of the Company and its subsidiaries.

Incentive stock options granted under the 2013 Equity Incentive Plan are intended to qualify as “incentive stock options”

within the meaning of Section 422 of the Internal Revenue Code (the “Code”).

Non-qualified stock options granted under

the 2013 Equity Incentive Plan are not intended to qualify as incentive stock options under the Code.

As of December 31, 2020,

the Company issued an aggregate of 74,237 shares of the Company’s common stock, as well as options to purchase up

to 713,010 shares of the Company’s common stock, some of which are subject to vesting restrictions, pursuant to the

Company’s 2013 Equity Incentive Plan.

On June 15, 2020, an amendment to our 2013 Equity Incentive Plan was approved

by holders of at least a majority of the issued and outstanding shares of common stock of the Company, to increase the number

of shares of our common stock subject to the 2013 Equity Incentive Plan to 890,000.

Executive Officer Inducement Options (3)

On March 15, 2013, the Company’s board of directors approved the Company’s 2013 Equity Incentive Plan.

Equity Incentive Plan was approved by our stockholders on October 10, 2013.

On July 15, 2021, an amendment to our 2013 Equity Incentive

Plan was approved by our stockholders to increase the number of shares of our common stock subject to the 2013 Equity Incentive Plan

to 1,765,000.

On June 23, 2020, our Board of Directors adopted the Sigma Labs, Inc.

2020 Stock Appreciation Rights Plan (the “Plan”).

The purposes of the Plan are to:

(i) enable the Company to attract and retain the types of employees, consultants, and directors

who will contribute to the Company’s long-range success;

(ii) provide incentives that align the interests of Service Providers

with those of the shareholders of the Company;

and (iii) promote the success of the Company’s business.

The Plan only provides

for incentive awards that are only made in the form of stock appreciation rights payable in cash (“SARs”).

of common stock were reserved in connection with the adoption of the Plan since no shares will be issued pursuant to the Plan.

As of December 31, 2020, the Company issued an aggregate of 127,679 SARs pursuant to the Plan.

2020 Stock Appreciation Rights Plan (the “Plan”).

purposes of the Plan are to:

(i) enable the Company to attract and retain the types of employees, consultants, and directors who will

contribute to the Company’s long-range success;

(ii) provide incentives that align the interests of Service Providers with those

of the shareholders of the Company;

and (iii) promote the success of the Company’s business.

The Plan only provides for incentive

awards that are only made in the form of stock appreciation rights payable in cash (“SARs”).

No shares of common stock were

reserved in connection with the adoption of the Plan since no shares will be issued pursuant to the Plan.

As of December 31, 2021, the

Company has awarded 370,624 SARs pursuant to the Plan.

On December 3, 2019, in conjunction with the hiring of Mark K.

Ruport, the Company’s Chief Executive Officer, the

Company granted to Mr.

Ruport (i) an option to purchase 10,000 shares of our common stock with an exercise price of $11.20, which fully

vested and became exercisable on January 3,2020;

and (ii) an option to purchase up to 40,000 shares of our common stock, with an exercise

price of $11.20, which will vest and become exercisable in equal monthly installments over three years from the date of grant.

December 31, 2021, a total of 27,025 shares were vested and exercisable.

In accordance with Nasdaq Listing Rule 5635(c)(4),

such options were granted to Mr.

Ruport as an inducement award outside of the 2013 Equity Incentive Plan.

Equity Compensation

have entered into various engagement and placement agent agreements with Dawson James Securities, Inc.

(“Dawson”)

for which compensation has been paid with equity securities that have been previously disclosed in our filings with the SEC, including

warrants issued in April 2018 to purchase up to 14,000 shares of common stock at an exercise price of $14.70 per share and a Unit

Purchase Option issued in June 2018 to acquire up to 19,120 Units, at an exercise price of $12.50 per Unit, consisting of 19,120

shares of common stock and warrants to purchase up to 5,736 shares of common stock at an exercise price of $10.80.

In connection

with our January 27, 2020 private placement of equity securities, we issued Dawson James a warrant to purchase up to 17,004 shares

of common stock at an initial exercise price of $11.30.

During 2020, we issued Dawson James additional warrants to purchase

up to 21,870 shares of common stock at an exercise price of $11.70 per share in connection with the exercise of Series D Preferred

Warrants by certain institutional investors,

January 8, 2021, we entered into an underwriting agreement with H.C.

Wainwright & Co., for which compensation has been paid

with equity securities that have been previously disclosed in our filings with the SEC, including warrants issued in January 2021

to purchase up to 146,943 shares of common stock at an exercise price of $3.75 per share.

August 5, 2019 we entered into an agreement with MHZCI, LLC to provide investor relations services to the Company.

the terms of the agreement, as partial compensation for services to be rendered 5,000 shares of common stock of the Company were

issued to MHZCI, LLC as follows (1) 2,500 shares on or before the 10th day following the Effective Date of the agreement,

and (2) 2,500 shares on or before the 10th day following the six-month anniversary of the agreement, if the agreement is

still then in effect.

Accordingly, on August 15, 2019 the Company issued 2,500 shares of common stock to MHZCI, LLC, and on February

14, 2020 the Company issued an additional 2,500 shares of common stock to MHZCI, LLC.

November 18, 2019, we entered into a six-month consulting agreement with Iron Dome Ventures, LLC to provide certain investor relations

related services to the Company.

Pursuant to the terms of the agreement, as partial compensation for services to be rendered we

agreed to issue to Iron Dome Ventures LLC each month, beginning on the Effective Date, and subsequently on the 18th of each month

during the first three months of the agreement, a warrant to purchase 833 shares of the Company’s common stock at

an exercise price of $0.10.

Effective November 18, 2020, we entered into a new six-month contract with Iron Dome Ventures,

LLC in which we granted 13,500 Stock Appreciation Rights, payable in cash only, with an exercise price of $2.47 per share.

Wainwright & Co., for which compensation has been paid with

equity securities that have been previously disclosed in our filings with the SEC, including warrants issued in January 2021 to purchase

up to 136,943 shares of common stock at an exercise price of $3.75 per share.

On March 22, 2021, we entered into an amendment to the

underwriting agreement with H.C.

Wainwright & Co., for which compensation has been paid with equity securities that have been previously

disclosed in our filings with the SEC, including warrants issued in March 2021 to purchase up to 175,200 shares of common stock at an

exercise price of $5.55625 per share.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

following summarizes transactions by us in which any of our directors, director nominees, executive officers or, to our knowledge,

beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had

or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control

and other arrangements, which are described under “Executive Compensation”

and “Director Compensation”

following summarizes transactions by us since the beginning of the Company’s last fiscal year, and any proposed transactions

in which any of our directors, director nominees, executive officers or, to our knowledge, beneficial owners of more than 5% of our

capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest,

other than equity and other compensation, termination, change in control and other arrangements, which are described under “Executive

Compensation” and “Director Compensation” above.

with Directors and Officers

have entered into an “at will”

employment agreement, effective as of July 1, 2019, with Frank Orzechowski under which

he was engaged to serve as our Chief Financial Officer, Treasurer, Principal Accounting Officer and Corporate Secretary of the

Orzechowski’s employment agreement, he was entitled to receive an annual base salary of $135,000, which

was increased to $155,000 effective March 1, 2020, and which was increased to $180,000 on January 1, 2021.

have entered into an “at will” employment agreement, effective as of September 20, 2021, with Jacob Brunsberg under

which he was engaged to serve as our Senior Vice President of Product Management and Strategic Relationships.

On February 16,

Brunsberg’s employment agreement was amended in connection with his appointment as President and Chief Operating

Officer of the Company to increase his annual base salary from $200,000 to $250,000.

In addition, on February 16,

Brunsberg was granted a stock option to purchase up to 70,000 shares of common stock of the Company, at an exercise price

equal to $2.50 per share under the 2013 Equity Incentive Plan, and 30,000 stock appreciation rights (“SARs”) under the

2020 Stock Appreciation Rights Plan, at an exercise price of $2.50 each.

Both the option and the SARs vest in equal (as closely as

possible) monthly installments over thirty-six months from the grant date, have five year-terms and are on such other terms and

conditions as set forth in the Company’s respective forms of standard agreement.

Pursuant to the employment

agreement, Mr.

Orzechowski was granted (1) a stock option to purchase up to 250 shares of common stock of the Company, at an exercise

price equal to $14.00 per share, which was the closing market price of the Company’s common stock on July 1, 2019 (i.e.,

the Effective Date), and (2) to purchase up to 6,000 shares of common stock of the Company, with an exercise price of $14.00,

and will vest and become exercisable as follows:

387 shares vested and became exercisable on the one-year anniversary of the Effective

Date, 900 shares will vest and become exercisable on the second-year anniversary of the Effective Date, 1,413 shares will vest

and become exercisable on the third-year anniversary of the Effective Date, and 3,300 shares will vest and become exercisable

on the fourth-year anniversary of the Effective Date, provided, in each case, that Mr.

Orzechowski remains an employee of the

Company through such vesting dates.

Orzechowski is eligible to participate in the Company’s 2013 Equity Incentive

Plan, and is eligible to receive medical and dental benefits, life insurance, short and long-term disability coverage, and to

participate in the Company’s Section 125 cafeteria plan, vision plan and 401K plan.

January 27, 2020, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain of its

directors (Mark K.

Ruport, Salvatore Battinelli and Frank Garofalo, a former director) and Carl Schwartz, who was the Company’s

largest shareholder.

Pursuant to the SPA, the Company issued and sold 333.33 shares of the Company’s Series E Convertible

Preferred Stock (the “Series E Preferred Stock”), and Class A Warrants to purchase 48,544 shares of the Company’s

Common Stock (the “Common Warrants”) for a total gross purchase price of $500,000.

The Series E Preferred Stock is

initially convertible into 48,544 shares of Common Stock (61,651 shares of common stock including the “make-whole dividend),

and the Class A Warrants have an initial exercise price of $11.30 per share.

Brunsberg was previously granted a stock option to purchase up to 100,000 shares of common stock of the

Company, at an exercise price equal to $3.18 per share, which was the closing market price of the Company’s common stock on

September 20, 2021 (i.e., the date of grant), under the 2013 Equity Incentive Plan.

Such option is fully vested and exercisable.

option has a five - year term and is on such other terms set forth in the Company’s standard form of non-qualified stock

option agreement, Further, Mr.

Brunsberg is eligible to participate in the Company’s 2013 Equity Incentive Plan and 2020 Stock

Appreciation Rights Plan and is eligible to receive medical and dental benefits, life insurance, short and long-term disability

coverage, and to parti cipate in the Company’s Section 125

cafeteria plan, vision plan and 401K plan.

have entered into an “at will” employment agreement, effective as of August 10, 2015, with Ronald Fisher under which he was

engaged to serve as our Vice President of Business Development.

Fisher is entitled to receive an annual base salary of $180,000.

Pursuant to the employment agreement, Mr.

Fisher also was granted, as a signing bonus, (i) a stock option to purchase up to 2,375 shares

of common stock of the Company, at an exercise price equal to $118.00 per share, which was the closing market price of the Company’s

common stock on August 10, 2015 (i.e., the date of grant), under the 2013 Equity Incentive Plan.

Such option is fully vested and exercisable.

The option has a ten - year term and is on such other terms set forth in the Company’s standard form of non-qualified stock

option agreement, and (ii) 125 shares of common stock of the Company with a value equal to the closing price of our common stock on the

date of grant and is on such other terms and provisions as are contained in Sigma Labs’ standard form of restricted stock letter

agreement under the Plan.

Such shares are fully vested.

Additionally, the Company granted Mr.

Fisher under the 2013 Plan, effective as

of August 11, 2016, a stock option to purchase up to 500 shares of common stock of the Company.

Such option has an exercise price equal

to the closing price of our common stock on the date of grant and is fully vested and exercisable.

Fisher is eligible to

participate in the Company’s 2013 Equity Incentive Plan and Stock Appreciation Rights Plan and is eligible to receive medical and

dental benefits, life insurance, short and long-term disability coverage, and to participate in the Company’s Section 125 cafeteria

plan, vision plan and 401K plan.

September 18, 2017, we and Mr.

Fisher entered into Amendment No.

Fisher’s employment agreement, effective August 10, 2015,

pursuant to which, effective as of February 11, 2017, item 2, entitled “Performance Bonuses,” of Exhibit A of Mr.

employment agreement was deleted in its entirety and replaced with the new item 2 that was set forth in the amendment to employment agreement.

Such amendment provided that Mr.

Fisher would become entitled to receive performance-based stock and cash bonuses if certain milestones

were satisfied by February 11, 2018, so long as Mr.

Fisher remained an employee of the Company as of the date the applicable milestone

was satisfied.

On February 21, 2018, the Company and Mr.

Fisher entered into Amendment No.

Fisher’s employment agreement,

pursuant to which the foregoing February 11, 2018 date was extended to December 31, 2018.

On January 10, 2019, the Company granted Mr.

Fisher an option to purchase up to 1,184 shares of common stock in exchange for the cancellation of his accrued but unpaid vacation balance

at December 31, 2018.

On March 7, 2019, the Company issued 150 shares of common stock under the 2013 Plan to Mr.

Fisher connected with

the satisfaction of a performance milestone.

January 27, 2020, the Company entered into a Securities Purchase Agreement (the “SPA”) with Mark K.

Ruport, Salvatore Battinelli

and Frank Garofalo, a former director, and Carl Schwartz, who was the Company’s largest shareholder.

Pursuant to the SPA, the Company

issued and sold 333.33 shares of the Company’s Series E Convertible Preferred Stock (the “Series E Preferred Stock”),

and 5½ year Class A Warrants to purchase 48,544 shares of the Company’s common stock (the “Class A Warrants”)

for a total gross purchase price of $500,000.

Upon any liquidation, dissolution or winding-up of the Company, the holders of Series E

Preferred Stock will be entitled to receive out of the assets of the Company an amount equal to the stated value of the Series E Preferred

Stock, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon under the Certificate

of Designation, for each share of Series E Preferred Stock before any distribution or payment may be made to the holders of any junior

securities, but after distribution or payment to holders of the Series D Preferred Stock and any other senior securities;

assets of the Company are insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of Series

E Preferred Stock are to be ratably distributed among such holders in accordance with the respective amounts that would be payable on

such shares if all amounts payable thereon were paid in full.

The Series E Preferred Stock is initially convertible into 48,544 shares

of common stock (61,651 shares of common stock including the “make-whole dividend), and the Class A Warrants have an initial exercise

price of $11.30 per share.

Indemnification

have entered into indemnification agreements with each of our directors and executive officers.

These agreements, among other

things, require us to indemnify each director and executive officer to the fullest extent permitted by Nevada law, including indemnification

of expenses such as attorneys’

fees, judgments, fines and settlement amounts incurred by the director or executive officer

in any action or proceeding, including any action or proceeding by or in the right of us, arising out of the person’s services

as a director or executive officer.

These agreements, among other things,

require us to indemnify each director and executive officer to the fullest extent permitted by Nevada law, including indemnification

of expenses such as attorneys’ fees, judgments, fines and settlement amounts incurred by the director or executive officer in any

action or proceeding, including any action or proceeding by or in the right of us, arising out of the person’s services as a director

or executive officer.

and Procedures for Related Person Transactions

Audit Committee is responsible for reviewing and approving, as appropriate, all transactions with related persons (other than

compensation-related matters, which should be reviewed by our Compensation Committee), in accordance with its Charter and the

Nasdaq marketplace rules.

In reviewing and approving any such transactions, our Audit Committee is tasked to consider all relevant

facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be

obtained in an arm’s length transaction and the extent of the related person’s interest in the transaction.

Audit Committee is responsible for reviewing and approving, as appropriate, all transactions with related persons (other than compensation-related

matters, which should be reviewed by our Compensation Committee), in accordance with its Charter and the Nasdaq marketplace rules.

reviewing and approving any such transactions, our Audit Committee is tasked to consider all relevant facts and circumstances, including,

but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm’s length transaction

and the extent of the related person’s interest in the transaction.

PRINCIPAL ACCOUNTING FEES AND SERVICES

following is a summary of the fees billed to the Company by Haynie & Company for professional services rendered

with respect to the years ended December 31, 2020 and 2019:

the above table, in accordance with the SEC’s definitions and rules, “audit fees”

are fees that Sigma Labs,

paid for professional services for the audit of our financial statements included in our Form 10-K and review of the interim

financial statements included in quarterly reports, and for services that are normally provided by the registered public accounting

firm in connection with statutory and regulatory filings or engagements;

“audit-related fees”

are fees for assurance

and related services that are reasonably related to the performance of the audit or review of our financial statements;

and “tax

are fees for tax compliance, tax advice and tax planning.

Board of Directors established an Audit Committee written charter in February 2017.

The Audit Committee’s pre-approval policies

and procedures and other protocols are discussed in its written charter which can be found at www.sigmalabsinc.com under the tab

“Investors.”

our fiscal year ended December 31, 2020, there were no professional services provided, other than those listed above, that would

require our Audit Committee to consider their compatibility with maintaining the independence of Haynie & Company.

following is a summary of the fees billed to the Company by Haynie & Company for professional services rendered with respect to the

years ended December 31, 2021 and 2020:

the above table, in accordance with the SEC’s definitions and rules, “audit fees” are fees that we paid for

professional services for the audit of our financial statements included in our Form 10-K and review of the interim financial statements

included in quarterly reports, and for services that are normally provided by the registered public accounting firm in connection with

statutory and regulatory filings or engagements;

“audit-related fees” are fees for assurance and related services that are

reasonably related to the performance of the audit or review of our financial statements;

and “tax fees” are fees for tax

compliance, tax advice and tax planning.

The Audit Committee’s pre-approval

policies and procedures and other protocols are discussed in its written charter which can be found at www.sigmalabsinc.com under

the tab “Investors.” Before our independent registered public accounting firm is engaged by the Company to render

audit or non-audit services, the Audit Committee must pre-approve the engagement.

Audit Committee pre-approval of audit and

non-audit services are not required if the engagement for the services is entered into pursuant to pre-approval policies and

procedures established by the Audit Committee regarding the Company’s engagement of the independent registered public

accounting firm, provided the policies and procedures are detailed as to the particular service, the Audit Committee is informed of

each service provided and such policies and procedures do not include delegation of the Audit Committee’s responsibilities

under the Exchange Act to the Company’s management.

The Audit Committee may delegate to one or more designated members of the

Audit Committee the authority to grant pre-approvals.

If the Audit Committee elects to establish pre-approval policies and

procedures regarding non-audit services, the Audit Committee must be informed of each non-audit service provided by the independent

registered public accounting firm.

Audit Committee pre-approval of non-audit services (other than review and attestation services)

also will not be required if such services fall within available exceptions established by the SEC.

The Audit Committee may not

engage the independent registered public accounting firm to perform non-audit services prohibited by law or regulation.

basis, our management reports to the Audit Committee all audit services performed during the previous 12 months and all fees billed

by our independent registered public accounting firm for such services.

In our fiscal year ended December

31, 2021, Haynie & Company provided no professional services other than those described above, that would require our

Audit Committee to consider their compatibility with maintaining the independence of Haynie & Company.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

financial statements and related notes thereto are listed and included in this Annual Report beginning on page F-1.

The following

documents are furnished as exhibits to this Form 10-K.

Exhibits marked with an asterisk are filed herewith.

The remainder of the

exhibits previously have been filed with the SEC and are incorporated herein by reference.

Agreement, dated January 8, 2021, by and among Sigma Labs, Inc.

Wainwright & Co., LLC, as the representative

for the underwriters named therein (filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed January

12, 2021, and incorporated herein by reference).

The following documents

are furnished as exhibits to this Form 10-K.

Underwriting Agreement, dated January 8, 2021, by and among Sigma Labs, Inc.

Wainwright & Co., LLC, as the representative for the underwriters named therein (filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed January 12, 2021, and incorporated herein by reference).

Amended and Restated Articles of Incorporation of the Company, as amended.**

of Correction to Amended and Restated Articles of Incorporation, as filed with the Nevada Secretary of State on May 25, 2011

(filed as Exhibit 3.2 to the Company’s Current Report on Form 8-K filed June 1, 2011, and incorporated herein by reference).

of Merger (filed as Exhibit 3.3 to the Company’s Form 10-K, filed on March 16, 2016, for the fiscal year ended December

31, 2015, and incorporated herein by reference).

of Change Pursuant to NRS 78.209 (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed March 21, 2016,

and incorporated herein by reference).

of Change Pursuant to NRS 78.209 (filed as Exhibit 3.2 to the Company’s Current Report on Form 8-K filed February 21,

2017, and incorporated herein by reference).

of Change Pursuant to NRS 78.209.

(filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed February 28,

2020, and incorporated herein by reference).

of Designation of Rights, Preference and Privileges of Series A Convertible Preferred Stock (filed as Exhibit 3.1 to the Company’s

Current Report on Form 8-K filed February 21, 2017, and incorporated herein by reference).

of Designation of Rights, Preference and Privileges of Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the Company’s

Current Report on Form 8-K filed April 6, 2018, and incorporated herein by reference).

of Designation of Rights, Preference and Privileges of Series C Convertible Preferred Stock of Sigma Labs, Inc.

Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 26, 2018, and incorporated herein by reference).

of Designations (Series D Convertible Preferred Stock) (filed as Exhibit 10.2 to the Company’s Current Report on Form

8-K filed on January 30, 2020 and incorporated herein by reference).

of Designations (Series E Convertible Preferred Stock) (filed as Exhibit 10.7 to the Company’s Current Report on Form

8-K filed January 30, 2020 and incorporated herein by reference).

Amended and Restated Bylaws of the Company, as amended .**

of Common Stock Purchase Warrant (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed April 6, 2018,

and incorporated herein by reference).

of Placement Agent Warrants (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed April 6, 2018, and

incorporated herein by reference).

of Common Stock Purchase Warrant.(filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed June 26, 2018,

and incorporated herein by reference).

of Common Stock Purchase Warrant (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed March 14, 2019,

and incorporated herein by reference).

of Unit Purchase Option (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed March 14, 2019, and

incorporated herein by reference).

of Common Stock Purchase Warrant.(filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed May 8, 2019,

and incorporated herein by reference).

of Placement Agent Warrant (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed May 8, 2019, and

incorporated herein by reference).

of Institutional Common Warrant (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed January 30,

2020, and incorporated herein by reference).

Form of Class A Warrant(filed as Exhibit 10.8 to the Company’s Current Report on Form 8-K, filed January 30, 2020, and incorporated herein by reference).

Form of Common Stock Purchase Warrants (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed April 3, 2020, and incorporated herein by reference).

Form of Underwriter Common Stock Purchase Warrant (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed January 12, 2021, and incorporated herein by reference).

Form of Warrant to Purchase Common Stock (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed January 12, 2021, and incorporated herein by reference).

and Restated Bylaws of the Company, as amended.

(previously filed by the Company as Exhibit 3.12 to the Company’s Form

10-K, filed on March 24, 2021, and incorporated herein by reference).

Form of Common Stock Purchase Warrant (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed April 6, 2018, and incorporated herein by reference).

Form of Placement Agent Warrants (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed April 6, 2018, and incorporated herein by reference).

Form of Common Stock Purchase Warrant.(filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed June 26, 2018, and incorporated herein by reference).

Form of Common Stock Purchase Warrant (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed March 14, 2019, and incorporated herein by reference).

Form of Unit Purchase Option (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed March 14, 2019, and incorporated herein by reference).

Form of Common Stock Purchase Warrant.(filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed May 8, 2019, and incorporated herein by reference).

Form of Placement Agent Warrant (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed May 8, 2019, and incorporated herein by reference).

Form of Institutional Common Warrant (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed January 30, 2020, and incorporated herein by reference).

Form of Class A Warrant(filed as Exhibit 10.8 to the Company’s Current Report on Form 8-K, filed January 30, 2020, and incorporated herein by reference).

Form of Common Stock Purchase Warrants (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed April 3, 2020, and incorporated herein by reference).

Form of Underwriter Common Stock Purchase Warrant (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed January 12, 2021, and incorporated herein by reference).

Form of Warrant to Purchase Common Stock (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed January 12, 2021, and incorporated herein by reference).

Form of Warrant to Purchase Common Stock (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed March 30, 2021, and incorporated herein by reference).

Form of Placement Agent Warrant (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed March 30, 2021, and incorporated herein by reference).

Description of Securities.

Purchase Agreement dated April 17, 2010 between B6 Sigma, Inc.

Asset Purchase Agreement dated April 17, 2010 between B6 Sigma, Inc.

and Technology Management Company, Inc.

(filed as Exhibit 10.2

to the Company’s Current Report on Form 8-K/A filed November 12, 2010, and incorporated herein by reference).

of Nonqualified Stock Option Agreement for the Plan (previously filed by the Company as Exhibit 10.4 to the Company’s

Form 10-K, filed on April 1, 2019, and incorporated herein by reference

of Incentive Stock Option Agreement for the 2013 Equity Incentive Plan (filed as Exhibit 4.3 to the Company’s Form S-8

Registration Statement, filed on July 24, 2014, and incorporated herein by reference).*

of Restricted Stock Agreement for the Plan (previously filed by the Company as Exhibit 10.6 to the Company’s Form 10-K,

filed on April 1, 2019, and incorporated herein by reference).

Offer Letter Agreement, effective August 10, 2015, between Sigma Labs, Inc.

and Ronald Fisher (Filed as Exhibit 10.12 to the

Company’s Form 10-K, filed on March 16, 2016, for the fiscal year ended December 31, 2015, and incorporated herein by

of Indemnification Agreement for directors and officers of Sigma Labs, Inc.

(filed as Exhibit 10.12 to the Company’s

Registration Statement on Form S-1, filed on July 28, 2016, and incorporated herein by reference).*

(filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K/A filed November 12, 2010, and incorporated herein by reference).

Form of Nonqualified Stock Option Agreement for the Plan (previously filed by the Company as Exhibit 10.4 to the Company’s Form 10-K, filed on April 1, 2019, and incorporated herein by reference)*

Form of Incentive Stock Option Agreement for the 2013 Equity Incentive Plan (filed as Exhibit 4.3 to the Company’s Form S-8 Registration Statement, filed on July 24, 2014, and incorporated herein by reference).*

Form of Restricted Stock Agreement for the Plan (previously filed by the Company as Exhibit 10.6 to the Company’s Form 10-K, filed on April 1, 2019, and incorporated herein by reference).

Employment Offer Letter Agreement, effective August 10, 2015, between Sigma Labs, Inc.

and Ronald Fisher (Filed as Exhibit 10.12 to the Company’s Form 10-K, filed on March 16, 2016, for the fiscal year ended December 31, 2015, and incorporated herein by reference).*

Form of Indemnification Agreement for directors and officers of Sigma Labs, Inc.

(filed as Exhibit 10.12 to the Company’s Registration Statement on Form S-1, filed on July 28, 2016, and incorporated herein by reference).*

Amendment No.

1, dated September 18, 2017, to Employment Offer Letter Agreement, effective August 10, 2015, between Sigma Labs, Inc.

and Ronald Fisher (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on September 20, 2017 and

incorporated herein by reference).*

2, dated February 21, 2018, to Employment Offer Letter Agreement between the Company and Ronald Fisher (filed as Exhibit

10.1 to the Company’s Current Report on Form 8-K filed on February 27, 2018 and incorporated herein by reference).*

Purchase Agreement, dated as of April 6, 2018, between Sigma Labs, Inc.

and the Purchasers thereunder (filed as Exhibit 10.1

to the Company’s Current Report on Form 8-K filed on April 6, 2018 and incorporated herein by reference).

Agreement, effective as of September 25, 2017, between Darren Beckett and Sigma Labs, Inc.

(filed as Exhibit 10.1 to the Company’s

Form 10-Q, filed on November 14, 2018, for the period ended September 30, 2018, and incorporated herein by reference).*

Purchase Agreement, dated as of May 7, 2019, between the Company and the Purchaser (filed as Exhibit 10.1 to the Company’s

Current Report on Form 8-K filed May 8, 2019, and incorporated herein by reference).

letter agreement, effective as of July 1, 2019, between the Company and Frank D.

(filed as Exhibit 10.2 to the

Company’s Quarterly Report on Form 10-Q filed August 14, 2019, and incorporated herein by reference) *

Sigma Labs, Inc.

2013 Equity Incentive Plan, as Amended (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 19, 2020 and incorporated herein by reference).

Employment letter agreement, effective as of December 3, 2020, between the Company and Mark Ruport (filed by the Company as Exhibit 10.15 to the Company’s Form 10-K, filed on March 24, 2020, and incorporated herein by reference).*

Securities Purchase Agreement (Institutional Investors) (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed January 27, 2020, and incorporated herein by reference).

Rights Agreement (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed January 27, 2020, and incorporated

herein by reference).

Purchase Agreement (Other Investors) (filed as Exhibit 10.6 to the Company’s Current Report on Form 8-K, filed January

27, 2020, and incorporated herein by reference).

Placement Agreement (filed as Exhibit 10.9 to the Company’s Current Report on Form 8-K, filed January 27, 2020, and

incorporated herein by reference).

Securities Purchase Agreement, dated as of April 2, 2020, between the Company and Purchasers (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed April 3, 2020, and incorporated herein by reference).

and Ronald Fisher (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on September 20, 2017 and incorporated herein by reference).*

Amendment No.

2, dated February 21, 2018, to Employment Offer Letter Agreement between the Company and Ronald Fisher (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 27, 2018 and incorporated herein by reference).*

Securities Purchase Agreement, dated as of April 6, 2018, between Sigma Labs, Inc.

and the Purchasers thereunder (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 6, 2018 and incorporated herein by reference).

Employment Agreement, effective as of September 25, 2017, between Darren Beckett and Sigma Labs, Inc.

(filed as Exhibit 10.1 to the Company’s Form 10-Q, filed on November 14, 2018, for the period ended September 30, 2018, and incorporated herein by reference).*

Securities Purchase Agreement, dated as of May 7, 2019, between the Company and the Purchaser (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 8, 2019, and incorporated herein by reference).

Employment letter agreement, effective as of July 1, 2019, between the Company and Frank D.

(filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed August 14, 2019, and incorporated herein by reference) *

Securities Purchase Agreement (Institutional Investors) (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed January 27, 2020, and incorporated herein by reference).

Registration Rights Agreement (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed January 27, 2020, and incorporated herein by reference).

Securities Purchase Agreement (Other Investors) (filed as Exhibit 10.6 to the Company’s Current Report on Form 8-K, filed January 27, 2020, and incorporated herein by reference).

Private Placement Agreement (filed as Exhibit 10.9 to the Company’s Current Report on Form 8-K, filed January 27, 2020, and incorporated herein by reference).

Sigma Labs, Inc.

2020 Stock Appreciation Rights Plan (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 29, 2020 and incorporated herein by reference).*

Form of Stock Appreciation Rights Agreement (Employees;

2020 Stock Appreciation Rights Plan) (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed June 29, 2020 and incorporated herein by reference).*

Form of Stock Appreciation Rights Agreement (Non-employee Directors;

2020 Stock Appreciation Rights Plan) (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed June 29, 2020 and incorporated herein by reference).

Form of Waiver (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed January 12, 2021, and incorporated herein by reference).

of Haynie & Company.**

of principal executive officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley

Act of 2002.**

of principal financial officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley

Act of 2002.**

of principal executive officer and principal financial officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002.***

2020 Stock Appreciation Rights Plan) (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed June 29, 2020 and incorporated herein by reference).

Form of Waiver (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed January 12, 2021, and incorporated herein by reference).

Form of Securities Purchase Agreement (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed March 30, 2021, and incorporated herein by reference).

Amended and Restated Employment Agreement, dated June 10, 2021, between Sigma Labs, Inc.

Ruport (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 15, 2021 and incorporated herein by reference).*

2021 and 2022 Corporate Goals – Cash and Equity Incentive Plan, dated June 10, 2021 (filed as an exhibit to the Company’s Current Report on Form 8-K filed June 15, 2021, and incorporated herein by reference).*

Sigma Labs, Inc.

2013 Equity Incentive Plan, as Amended (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed July 16, 2021 and incorporated herein by reference).*

Sigma Labs, Inc.

2021 Employee Stock Purchase Plan (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed July 16, 2021 and incorporated herein by reference).*

Employment letter agreement, effective as of September 20, 2021, between Sigma Labs, Inc.

and Jacob Brunsberg (filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed October 21, 2021, and incorporated herein by reference).*

Amendment, dated February 16, 2022, to Employment letter agreement, effective as of September 20, 2021, between Sigma Labs, Inc.

and Jacob Brunsberg.* **

Amendment, dated February 16, 2022, to Amended and Restated Employment Agreement, dated June 10, 2021, between Sigma Labs, Inc.

Consent of Haynie & Company.**

Certificate of principal executive officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**

Certificate of principal financial officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**

Certificate of principal executive officer and principal financial officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.***

Instance Document.

4 unchanged sentences

Taxonomy Extension Presentation Linkbase Document.

Cover Page Interactive Data File (formatted as Inline

XBRL and contained in Exhibit 101).

Indicates a management contract or compensatory plan or arrangement.

3 unchanged sentences

may voluntarily include a summary of information required by Form 10-K under this Item 16.

We have elected not to include such

summary information.

to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report

to be signed on its behalf by the undersigned, thereunto duly authorized.

and Chief Executive Officer

We have elected not to include such summary

to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed

on its behalf by the undersigned, thereunto duly authorized.

Executive Officer

Executive Officer)

Frank Orzechowski

1 unchanged sentence

Financial and Accounting Officer)

to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf

of the registrant in the capacities and on the dates indicated.

and Chief Executive Officer

Executive Officer) and Director

to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the

registrant in the capacities and on the dates indicated.

Executive Officer (Principal Executive Officer and Director)

Frank Orzechowski

4 unchanged sentences

to Financial Statements

of Independent Registered Public Accounting Firm

of Operations

of Stockholders’

of Cash Flows

to Financial Statements

of Independent Registered Public Accounting Firm PCAOB ID No.

Balance Sheets

Statements of Operations

Statement of Stockholders’ Equity

Statements of Cash Flows

Notes to Financial Statements

OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

the Board of Directors and

of Sigma Labs, Inc.

Stockholders of Sigma Labs, Inc.

on the Financial Statements

1 unchanged sentence

(the Company) as of December 31, 2021 and 2020, and the related

statements of operations, stockholders’

equity, and cash flows for each of the years in the two-year period ended December

statements of operations, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31,

2021, and the related notes (collectively referred to as the financial statements).

In our opinion, the financial statements

present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results

of its operations and its cash flows for each of the years in the two-year period ended December 31, 2020, in conformity with

accounting principles generally accepted in the United States of America.

financial statements are the responsibility of the Company’s management.

Our responsibility is to express an opinion on

the Company’s financial statements based on our audits.

We are a public accounting firm registered with the Public Company

Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance

with the U.S.

federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the

In our opinion, the financial statements present

fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its

operations and its cash flows for each of the years in the two-year period ended December 31, 2021, in conformity with accounting

principles generally accepted in the United States of America.

financial statements are the responsibility of the Company’s management.

Our responsibility is to express an opinion on the Company’s

financial statements based on our audits.

We are a public accounting firm registered with the Public Company Accounting Oversight Board

(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.

federal securities

laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

conducted our audits in accordance with the standards of the PCAOB.

Those standards require that we plan and perform the audit

to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error

The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial

As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but

not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.

Those standards require that we plan and perform the audit to obtain

reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.

As part of our audits,

we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion

on the effectiveness of the Company’s internal control over financial reporting.

Accordingly, we express no such opinion.

audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to

error or fraud, and performing procedures that respond to those risks.

Such procedures included examining, on a test basis, evidence

regarding the amounts and disclosures in the financial statements.

Our audits also included evaluating the accounting principles

used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that our audits provide a reasonable basis for our opinion.

audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error

or fraud, and performing procedures that respond to those risks.

Such procedures included examining, on a test basis, evidence regarding

the amounts and disclosures in the financial statements.

Our audits also included evaluating the accounting principles used and significant

estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that our audits

provide a reasonable basis for our opinion.

Audit Matters

critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was

communicated or required to be communicated to the audit committee and that:

(1) relates to accounts or disclosures that are material

to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

The communication of

the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not,

by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts

or disclosures to which it relates.

Recognition –

Multiple Deliverables in Revenue Contracts

critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated

or required to be communicated to the audit committee and that:

(1) relate to accounts or disclosures that are material to the financial

statements and (2) involved our especially challenging, subjective, or complex judgments.

The communication of critical audit matters

does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit

matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Recognition – Multiple Deliverables in Revenue Contracts

of the Matter :

discussed in Note 1 to the financial statements, Sigma Labs, Inc.’s revenue is derived primarily from the sale of software,

the related hardware suite, and engineering services.

The Company’s contracts with customers typically include the promise

to transfer multiple goods and/or services to the customer.

Management must assess whether each promised good or service is distinct

for the purpose of identifying the performance obligations within the contract and must then determine and allocate the transaction

price to the performance obligations.

This assessment can be subjective and requires management to make judgments about the individual

promised goods or services and whether such goods or services are separable and distinct from the other aspects of the contractual

relationship.

management’s assessment and recognition of revenue can be complex, involves judgment, and is based on a thorough understanding

of the Company’s offerings.

discussed in Note 1 to the financial statements, Sigma Labs, Inc.’s revenue is derived primarily from the sale of software, the

related hardware suite, and engineering services.

The Company’s contracts with customers typically include the promise to transfer

multiple goods and/or services to the customer.

Management must assess whether each promised good or service is distinct for the purpose

of identifying the performance obligations within the contract and must then determine and allocate the transaction price to the performance

This assessment can be subjective and requires management to make judgments about the individual promised goods or services

and whether such goods or services are separable and distinct from the other aspects of the contractual relationship.

management’s assessment and recognition of revenue can be complex, involves judgment, and is based on a thorough understanding

of the Company’s offerings.

we Addressed the Matter in Our Audit :

obtained a thorough understanding of the controls the Company has in place to perform this assessment including walk-throughs

of the key controls and analysis of whether the controls are designed and operating effectively.

To evaluate Sigma Labs Inc.’s

assessment of performance obligations and allocation of price, our audit procedures included, among others, reading and evaluating

management’s assumptions used to determine the distinct performance obligations and price allocations.

We compared the stand-alone

price for each performance obligation to the allocated prices to ensure the allocation was reasonable.

We also obtained confirmations

from customers verifying the terms of the contracts.

obtained a thorough understanding of the controls the Company has in place to perform this assessment including walk-throughs of the

key controls and analysis of the design and operating effectiveness of these controls.

To evaluate Sigma Labs Inc.’s assessment

of performance obligations and allocation of price, our audit procedures included, among others, reading and evaluating management’s

assumptions used to determine the distinct performance obligations and price allocations.

We compared the stand-alone price for each

performance obligation to the allocated prices to ensure the allocation was reasonable.

We also obtained confirmations from customers

verifying the terms of the contracts.

Haynie & Company

Lake City, Utah

have served as the Company’s auditor since 2018.

Receivable, net

1 unchanged sentence

and Equipment, net

in Joint Venture

Prepaid Asset

AND STOCKHOLDERS’

AND STOCKHOLDERS’ EQUITY

Current Liabilities

2 unchanged sentences

Long-Term Liabilities

Stockholders’

Stock, $ 0.001 par;

10,000,000 shares authorized;

715 and 0 issued and outstanding, respectively

10,000,000 shares

715 shares issued

and outstanding, respectively

Stock, $ 0.001 par;

24,000,000 authorized;

5,995,320 and 1,403,759 issued and outstanding, respectively

10,498,802 and

5,995,320 shares

issued and outstanding, respectively 10,499

Paid-In Capital

Stockholders’

LIABILITIES AND STOCKHOLDERS’

( 40,593,180 )

( 33,105,008 )

Stockholders’ Equity

LIABILITIES AND STOCKHOLDERS’ EQUITY

accompanying notes to financial statements

1 unchanged sentence

PROFIT (LOSS)

& Public Relations

and R&D Costs

Public Relations and Marketing

Organizational

4 unchanged sentences

FROM OPERATIONS

( 8,479,385 )

( 5,698,768 )

INCOME (EXPENSE)

3 unchanged sentences

BEFORE PROVISION FOR INCOME TAXES

( 7,384,605 )

( 5,200,139 )

for Income Taxes

$ ( 7,384,605 )

$ ( 5,200,139 )

Loss applicable to Common Stockholders

$ ( 7,488,172 )

$ ( 7,009,414 )

Loss per Common Share - Basic and Diluted

1 unchanged sentence

accompanying notes to financial statements

of Stockholders’

of Stockholders’ Equity

The Years Ended December 31, 2021 and 2020

4 unchanged sentences

$ ( 26,095,594 )

and Warrants Issued in Public Offering

Issued for Exercise of Warrants

Proceeds in Public Offering

Issued for Cashless Exchange of UPO’s

Sold in Private Placement

Issued to Directors for Services

Issued for Third Party Services

Awarded to Employees

December 31, 2019

$ (26,095,594 )

Shares Sold in Public Offering

on Derivative Liability

Shares Sold in Public Offering

Stock Dividends

( 1,809,275 )

Shares Issued for Conversion of Preferred Shares

1 unchanged sentence

Shares issued for Exercise of Preferred Warrants

Shares Issued for Exercise of Common Warrants

Shares Issued for Exercise of Common Warrants , shares

Issued to Directors for Services

2 unchanged sentences

of Fractional Shares from Reverse Split

( 5,200,139 )

December 31, 2020

$ ( 33,105,008 )

Shares Sold in Public Offerings

on Derivative Liability

( 1,092,441 )

Stock Dividends

Shares Issued for Conversion of Preferred Shares

Shares Issued for Exercise of Common Warrants

Issued to Directors for Services

Issued for Third Party Services

Awarded to Employees

( 1,600,967 )

( 7,384,605 )

December 31, 2021

$ ( 40,593,180 )

accompanying notes to financial statements

1 unchanged sentence

of Cash Flows

$ ( 7,384,605 )

$ ( 5,200,139 )

to reconcile Net Loss to Net Cash used in operating activities:

and Amortization

on Derivative Liability

( 1,092,441 )

Based Compensation - Employees

3 unchanged sentences

portion of Stock Appreciation Rights

Term portion of Deferred

Payroll Taxes under the CARES Act

Term portion of Deferred Payroll Taxes under the CARES Act

CASH USED IN OPERATING ACTIVITIES

( 6,298,959 )

( 4,809,868 )

of Property and Equipment

of Intangible Assets

Received from Notes Receivable

of Joint Venture

2 unchanged sentences

Offering Costs

( 1,600,967 )

of Note Payable

14 unchanged sentences

1 – Summary of Significant Accounting Policies

of Business –Sigma Labs, Inc., formerly named Framewaves, Inc., a Nevada corporation, was founded by a group of scientists,

engineers and businessmen to develop and commercialize novel and unique manufacturing and materials technologies.

Sigma believes

that some of these technologies will fundamentally redefine conventional quality assurance and process control practices by embedding

them into the manufacturing processes in real time, enabling process intervention and ultimately leading to closed loop process

The Company anticipates that its core technologies will allow its clientele to combine advanced manufacturing quality

assurance and process control protocols with novel materials to achieve breakthrough product potential in many industries including

aerospace, defense, oil and gas, bio-medical, and power generation.

The terms the “Company,”

“Sigma,”

“we,”

“us”

and “our”

refer to Sigma Labs, Inc.

Stock Split - Effective February 27, 2020, our Articles of Incorporation were amended to provide for a reverse stock split

of the outstanding shares of our common stock on a 1-for-10 basis (the “Reverse Stock Split”), and a corresponding

decrease in the number of shares of our common stock that we are authorized to issue (the “Share Decrease”).

of the stock split have been retroactively reflected to all periods presented.

of Presentation –

The accompanying financial statements have been prepared by the Company in accordance with Generally

Accepted Accounting Principles (“GAAP”) in the United States of America.

In the opinion of management, all adjustments

(which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and

cash flows at December 31, 2020 and 2019 and for the periods then ended have been made.

Operations –

The Company has sustained losses and had negative cash flows from operating activities since its inception.

Commencing in 2017, the company committed itself to a focused initiative to transition its product and its company culture from

research and development into an enterprise with a commercial industrial product and a business-oriented operation culture.

2020, the Company relied on both public and private offerings to finance the commencement of commercialization by entering

test and evaluation programs with large potential customers, both end-users and OEMs.

In January 2020, we completed two private

placements consisting of shares of our newly created Series D and Series E Preferred Stock, warrants to purchase additional shares

of Series D Preferred Stock and warrants to purchase shares of our Common Stock resulting in net cash proceeds to us of approximately

On March 27, 2020, pursuant to the terms of the Agreement, we forced the exercise of a portion of the warrants to

purchase our Series D Preferred Stock which resulted in net cash proceeds to the Company of $460,000.

On April 6, 2020, the Company

closed an offering of equity securities in which the Company sold and issued to certain institutional investors (a) 493,027 shares

of the Company’s common stock (the “Common Shares”) and pre-funded warrants (the “Pre-funded Warrants”)

to purchase up to 22,438 shares of the Company’s common stock, and (b) Series A Warrants (the “Private Warrants”)

to purchase an aggregate of 515,465 shares of the Company’s common stock pursuant to a private placement resulting in net

proceeds of approximately $1,230,000.

On April 14, 2020 we were granted a loan from BOKF, NA dba Bank of Oklahoma in the aggregate

amount of $361,700, pursuant to the Paycheck Protection Program (the “

) under Division A, Title

I of the Coronavirus Aid, Relief and Economic Security Act (the “

CARES Act ”

), which was enacted March

The Company used the entire loan proceeds to fund payroll expenses, and as such, the loan was forgiven in full on January

During 2020, 6,146 Series D Preferred Warrants were exercised by institutional investors, resulting in net proceeds

to the company of 5,820,998.

In January 2021, the Company closed a public offering of our common stock resulting in net proceeds

of approximately $4,532,444 after deducting underwriting discounts and commissions and other offering expenses payable by the

continuing operations of the Company are no longer solely dependent upon financing the cost of product development in the absence

of revenues, but rather upon our abilities to finance our efforts to successfully ramp up commercialization, thus earning the

product validation of both customer licensing and purchases and creating a dynamic in which public and private offerings facilitate

the growth of revenues.

a result, the Company currently has sufficient cash and working capital to fund operations through the end of 2021 and

is anticipating that contracts may be closed during fiscal 2021 generating additional cash flow in the near-term.

the Company has access to public and private markets from which to derive additional financing to sustain operations beyond that

term, if required;

however, the Company is unable to predict the extent to which the novel coronavirus may affect the financial

markets and the Company’s access to such markets.

There is no assurance that we will be successful in obtaining additional

If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion

of our commercialization efforts and operations.

Per Share –

The computation of loss per share is based on the weighted average number of shares outstanding during the

period in accordance with ASC Topic No.

260, “Earnings Per Share.”

Shares underlying the Company’s outstanding

warrants, options or note conversion features were excluded due to the anti-dilutive effect they would have on the computation.

At December 31, 2020 and 2019, the Company had the following common shares underlying these instruments:

Sigma believes that

some of these technologies will fundamentally redefine conventional quality assurance and process control practices by embedding them

into the manufacturing processes in real time, enabling process intervention and ultimately leading to closed loop process control.

Company anticipates that its core technologies will allow its clientele to combine advanced manufacturing quality assurance and process

control protocols with novel materials to achieve breakthrough product potential in many industries including aerospace, defense, oil

and gas, bio-medical, and power generation.

The terms the “Company,” “Sigma,” “we,” “us”

and “our” refer to Sigma Labs, Inc.

Stock Split - Effective February 27, 2020, our Articles of Incorporation were amended to provide for a reverse stock split of the

outstanding shares of our common stock on a 1-for-10 basis (the “Reverse Stock Split”), and a corresponding decrease in the

number of shares of our common stock that we are authorized to issue (the “Share Decrease”).

The effects of the stock split

have been retroactively reflected to all periods presented.

of Presentation – The accompanying financial statements have been prepared by the Company in accordance with Generally Accepted

Accounting Principles (“GAAP”) in the United States of America.

In the opinion of management, all adjustments (which include

only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at December

31, 2021 and 2020 and for the periods then ended have been made.

Reclassification

- Certain amounts in prior-period financial statements have been reclassified for comparative purposes to conform to presentation

in the current-period financial statements.

These reclassifications have no impact on the previously reported results

Operations – The Company has sustained losses and had negative cash flows from operating activities since its inception.

in 2017, the company committed itself to a focused initiative to transition its product and its company culture from research and development

into an enterprise with a commercial industrial product and a business-oriented operation culture.

2021 and 2020, the Company relied on both public and private offerings to finance its operations.

In January 2021, the Company closed

a public offering of our common stock in which it issued 1,711,783 shares of common stock at $ 3.00 per share, resulting in net proceeds

of approximately $ 4,532,444 after deducting underwriting discounts and commissions and other offering expenses payable by the Company.

In March 2021, the Company closed a public offering of its securities in which it issued 2,190,000 shares of common stock at $ 4.445 per

share, resulting in net proceeds to the Company of approximately $ 8,736,488 after deducting placement agent commissions and other offering

costs payable by the Company.

During the first quarter of 2021, the Company issued 454,404 shares of common stock pursuant to the exercise

of warrants, resulting in net proceeds to the Company of $ 1,136,010 .

January 2020, we completed two private placements consisting of shares of our newly created Series D and Series E Preferred Stock, warrants

to purchase additional shares of Series D Preferred Stock and warrants to purchase shares of our Common Stock resulting in net cash proceeds

to us of approximately $ 1,711,124 .

On March 27, 2020, pursuant to the terms of the Agreement, we forced the exercise of a portion of the warrants to purchase our Series

D Preferred Stock which resulted in net cash proceeds to the Company of $ 460,000 .

On April 6, 2020, the Company closed an offering of equity securities in which the Company sold and issued to certain institutional investors

(a) 493,027 shares

of the Company’s common stock (the “Common Shares”) and pre-funded warrants (the “Pre-funded Warrants”)

to purchase up to 22,438

shares of the Company’s common stock, and (b) Series

A Warrants (the “Private Warrants”) to purchase an aggregate of 515,465

shares of the Company’s common stock pursuant

to a private placement resulting in net proceeds of approximately $ 1,230,000 .

On April 14, 2020 we were granted a loan from BOKF, NA dba Bank of Oklahoma in the aggregate amount of $ 361,700 , pursuant to the Paycheck

Protection Program (the “ PPP ” ) under Division A, Title I of the Coronavirus Aid, Relief and Economic Security

Act (the “ CARES Act ” ), which was enacted March 27, 2020.

The Company used the entire loan proceeds to fund

payroll expenses, and as such, the loan was forgiven in full on January 13, 2021.

continuing operations of the Company are no longer solely dependent upon financing the cost of product development in the absence of

revenues, but rather upon our abilities to finance our efforts to successfully ramp up commercialization, thus earning the product validation

of both customer licensing and purchases and creating a dynamic in which public and private offerings facilitate the growth of revenues.

a result, the Company currently has sufficient cash and working capital to fund operations through the end of 2022 and is anticipating

that contracts may be closed during fiscal 2022 generating additional cash flow in the near-term.

In addition, the Company has access

to public and private markets from which to derive additional financing to sustain operations beyond that term, if required;

the Company is unable to predict the extent to which the novel coronavirus or global economic and geopolitical developments may

affect the financial markets and the Company’s access to such markets.

There is no assurance that we will be successful in obtaining

additional funding.

If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a

portion of our commercialization efforts and operations.

Per Share – The computation of loss per share is based on the weighted average number of shares outstanding during the period

in accordance with ASC Topic No.

260, “Earnings Per Share.” Shares underlying the Company’s outstanding warrants, options

or note conversion features were excluded due to the anti-dilutive effect they would have on the computation.

At December 31, 2021 and

2020, the Company had the following common shares underlying these instruments:

of Antidilutive Securities Excluded from Computation of Earnings Per Share

Ended December 31,

1 unchanged sentence

Underlying Common Shares

and Equipment –

Property and equipment are stated at cost.

Expenditures for major renewals and betterments that extend

the useful lives of property and equipment are capitalized upon being placed in service.

Expenditures for maintenance and repairs

are charged to expense as incurred.

Depreciation is computed using the straight-line method over the estimated useful lives of

The estimated life has been determined to be five years unless a unique circumstance exists, which is then fully documented

as an exception to the policy.

and Equipment – Property and equipment are stated at cost.

Expenditures for major renewals and betterments that extend the

useful lives of property and equipment are capitalized upon being placed in service.

Expenditures for maintenance and repairs are charged

to expense as incurred.

Depreciation is computed using the straight-line method over the estimated useful lives of the assets.

The estimated

life has been determined to be five years unless a unique circumstance exists, which is then fully documented as an exception to the

accordance with its policy, the Company reviews the estimated useful lives of its fixed assets on an ongoing basis.

Taxes –

The Company accounts for income taxes in accordance with ASC Topic No.

740, “Accounting for Income Taxes.”

Company has no tax positions at December 31, 2020 and 2019 for which the ultimate deductibility is highly uncertain but for which

there is uncertainty about the timing of such deductibility.

Taxes – The Company accounts for income taxes in accordance with ASC Topic No.

740, “Accounting for Income Taxes.”

Company has no tax positions at December 31, 2021 and 2020 for which the ultimate deductibility is highly uncertain but for which there

is uncertainty about the timing of such deductibility.

Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.

During the years ended December 31, 2020 and 2019, the Company recognized no interest and penalties.

All tax years starting with

2017 are open for examination.

Receivable and Allowance for Doubtful Accounts - Trade accounts receivable are carried at original invoice amount less an

estimate made for doubtful accounts.

We determine the allowance for doubtful accounts by identifying potential troubled accounts

and by using historical experience and future expectations applied to an aging of accounts.

Trade accounts receivable are written

off when deemed uncollectible.

the years ended December 31, 2021 and 2020, the Company recognized no

interest and penalties.

All tax years starting

with 2018 are open for examination.

Receivable and Allowance for Doubtful Accounts - Trade accounts receivable are carried at original invoice amount less an estimate

made for doubtful accounts.

We determine the allowance for doubtful accounts by identifying potential troubled accounts and by using

historical experience and future expectations applied to an aging of accounts.

Trade accounts receivable are written off when deemed

uncollectible.

Recoveries of trade accounts receivable previously written off are recorded as income when received.

There was no allowance for doubtful accounts at December 31, 2020 or 2019.

and Intangible Assets –

Long-lived assets and certain identifiable definite life intangibles to be held and used by

the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset

may not be recoverable.

The Company continuously evaluates the recoverability of its long-lived assets based on estimated future

cash flows and the estimated liquidation value of such long-lived assets and provides for impairment if such undiscounted

cash flows are insufficient to recover the carrying amount of the long-lived assets.

If impairment exists, an adjustment is made

to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.

Fair values are determined based on quoted market values, discounted cash flows or internal and external appraisals, as applicable.

Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value.

No patents were written

off in 2020, and $23,909 of patents related to PrintRite3D ®

Contour were written off in December of 2019.

Equivalents - The Company considers all highly liquid investments with an original maturity of three months or less at date

of purchase to be cash equivalents.

There was no allowance

for doubtful accounts at December 31, 2021 or 2020.

and Intangible Assets – Long-lived assets and certain identifiable definite life intangibles to be held and used by the Company

are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows and the estimated

liquidation value of such long-lived assets and provides for impairment if such undiscounted cash flows are insufficient to recover the

carrying amount of the long-lived assets.

If impairment exists, an adjustment is made to write the asset down to its fair value, and

a loss is recorded as the difference between the carrying value and fair value.

Fair values are determined based on quoted market values,

discounted cash flows or internal and external appraisals, as applicable.

Assets to be disposed of are carried at the lower of carrying

value or estimated net realizable value.

Three patents were written off totaling $ 10,510 in December of 2021, and no patents were written

Equivalents - The Company considers all highly liquid investments with an original maturity of three months or less at date of purchase

to be cash equivalents.

Value of Financial Instruments - The Company applies ASC 820, “Fair Value Measurements .

” This guidance defines

fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements

for fair value measures.

The three levels are defined as follows:

1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that

are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

3 - inputs to valuation methodology are unobservable and significant to the fair measurement.

carrying amounts reported in the balance sheets for the cash and cash equivalents, receivables, accounts payable, and accrued liabilities

each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination

of such instruments and their expected realization and their current market rate of interest.

Company does not use derivative instruments for hedging of market risk or for trading or speculative purposes.

On March 26, 2021, the

Company closed an offering in which it issued warrants to purchase an aggregate of 2,190,000 shares of common stock in a private placement

concurrently with a registered direct offering (“Registered Offering”) of our common stock The warrants became exercisable

on May 24, 2021 , the date the Company obtained stockholder approval to increase its authorized common shares from 12,000,000 to 24,000,000

(“the Initial Exercise Date”) and will expire two years after the Initial Exercise Date.

to ASC 815-40-25-10, because the Company did not have sufficient authorized and unissued shares of common stock available to settle the

warrants at the issue date, such warrants were accounted for as a derivative liability.

On May 24, 2021, upon receiving shareholder approval

to increase its authorized common shares, the Company reclassified the warrant liability to equity pursuant to ASC 815.40.35.8.

fair value of the warrant liability measured on a recurring basis is as follows:

of Warrant Liability Measured on Recurring Basis

of Issuance March 26, 2021

Liability - Warrants

following table presents a reconciliation of the derivative liability measured at fair value on a recurring basis using significant unobservable

input (Level 3):

of Derivative Liability Measured on a Recurring Basis Using Significant Unobservable Input (Level 3)

Value on Issuance Date

in Fair Value

( 1,092,441 )

Fair Value on May

Extinguishment

of Derivative Liability

( 4,615,771 )

Value on December 31, 2021

Concentration

of Credit Risk - The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits.

The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash

and cash equivalents.

Based Compensation –

The Company recognizes compensation costs to employees under ASC Topic No.

718, “Compensation

Stock Compensation.”

Under ASC Topic No.

718, companies are required to measure the compensation costs of share-based

compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period

during which employees are required to provide services.

Share based compensation arrangements may include stock options, grants

of shares of common stock with and without restrictions, performance-based awards, share appreciation rights and employee share

purchase plans.

As such, compensation cost is measured on the date of grant at its fair value.

Such compensation amounts, if any,

are amortized over the respective vesting periods of the option or stock grants.

Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash

Based Compensation – The Company recognizes compensation costs to employees under ASC Topic No.

718, “Compensation –

Stock Compensation.” Under ASC Topic No.

718, companies are required to measure the compensation costs of share-based compensation

arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees

are required to provide services.

Share based compensation arrangements may include stock options, grants of shares of common stock with

and without restrictions, performance-based awards, share appreciation rights and employee share purchase plans.

As such, compensation

cost is measured on the date of grant at its fair value.

Such compensation amounts, if any, are amortized over the respective vesting

periods of the option or stock grants.

instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC Topic No.

505, “Equity Based Payments to Non-Employees.”

In general, the measurement date is either (a) when a performance commitment,

as defined, is reached or (b) the earlier of the date that (i) the non-employee performance requirement is complete or (ii) the

instruments are vested.

The measured value related to the instruments is recognized over a period based on the facts and circumstances

of each particular grant as defined in the FASB Accounting Standards Codification.

“Equity Based Payments to Non-Employees.” In general, the measurement date is either (a) when a performance commitment, as

defined, is reached or (b) the earlier of the date that (i) the non-employee performance requirement is complete or (ii) the instruments

The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular

grant as defined in the FASB Accounting Standards Codification.

- Utility patents are amortized over a 17 -year period.

Patents which are pending are not amortized.

Estimates - The preparation of financial statements in conformity with generally accepted accounting principles in the United

States requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the

disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues

and expenses during the reporting period.

Estimates - The preparation of financial statements in conformity with generally accepted accounting principles in the United States

requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the disclosures

of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during

the reporting period.

Actual results could differ from those estimated by management.

Significant accounting

estimates that may materially change in the near future are impairment of long-lived assets, values of stock compensation awards

and stock equivalents granted as offering costs, and allowance for bad debts and inventory obsolescence.

Recognition –

The Company’s revenue is derived primarily from sales of our software and related hardware suite

and from providing engineering services under contracts.

Significant accounting estimates that may materially

change in the near future are impairment of long-lived assets, values of stock compensation awards and stock equivalents granted as offering

costs, and allowance for bad debts and inventory obsolescence.

Recognition – The Company’s revenue is derived primarily from sales of our software and related hardware suite and from

providing engineering services under contracts.

The Company recognizes revenue in accordance with ASC Topic No.

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.

2014-09, Revenue

from Contracts with Customers .

ASU 2014-09 is a comprehensive revenue recognition standard that superseded nearly all existing

revenue recognition guidance under prior U.S.

In May 2014, the

Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.

2014-09, Revenue from Contracts with Customers .

ASU 2014-09 is a comprehensive revenue recognition standard that superseded nearly all existing revenue recognition guidance under prior

GAAP and replace it with a principles-based approach for determining revenue recognition.

The core principle of the standard is the recognition of revenue upon the transfer of promised goods or services to customers

in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.

The core principle of the standard is

the recognition of revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration

to which the company expects to be entitled in exchange for those goods or services.

general, we determine revenue recognition by:

(1) identifying the contract, or contracts, with our customer;

(2) identifying the

performance obligations in the contract;

(3) determining the transaction price;

(4) allocating the transaction price to performance

(2) identifying the performance

obligations in the contract;

and (5) recognizing revenue when, or as, we satisfy performance obligations by transferring the promised

goods or services.

Stock Offering Costs –

Costs related to stock offerings (if any) are deferred and will be offset against the proceeds

of the offering in additional paid-in capital.

In the event a stock offering is unsuccessful, the costs relating to the offering

will be written-off directly to expense.

Inventories consist of raw materials used in the production of customized parts, work-in-process and finished goods

components which will be sold to customers.

Inventories are valued at the lower of cost or net realizable value, using the first-in,

first-out (FIFO) method.

and Development –

Research and development costs are expensed as they are incurred.

Research and development costs for

the years ended December 31, 2020 and 2019 were $351,404 and $647,994, respectively.

(3) determining the transaction price;

(4) allocating the transaction price to performance obligations in

the contract;

and (5) recognizing revenue when, or as, we satisfy performance obligations by transferring the promised goods or services.

Stock Offering Costs – Costs related to stock offerings (if any) are deferred and will be offset against the proceeds of the

offering in additional paid-in capital.

In the event a stock offering is unsuccessful, the costs relating to the offering will be written-off

directly to expense.

– Inventories consist of raw materials used in the production of customized parts, work-in-process and finished goods components

which will be sold to customers.

Inventories are valued at the lower of cost or net realizable value, using the first-in, first-out (FIFO)

and Development – Research and development costs are expensed as they are incurred.

Research and development costs for the

years ended December 31, 2021 and 2020 were $ 417,744 and $ 126,292 , respectively.

2 - Inventory

December 31, 2020 and December 31, 2019, the Company’s inventory was comprised of:

December 31, 2021 and December 31, 2020, the Company’s inventory was comprised of:

3 – Property and Equipment

following is a summary of property and equipment, less accumulated depreciation, as of December 31, 2021 and 2020:

of Property and Equipment

Ended December 31,

1 unchanged sentence

Accumulated Depreciation

( 1,146,690 )

( 1,057,824 )

Property and Equipment

1 unchanged sentence

4 – Intangible Assets

Company’s intangible assets consist of Patents and Patent Pending Applications.

patent applications are not amortized until a patent has been granted.

Once a patent is granted, the Company will amortize the

related costs over the estimated useful life of the patent.

If a patent application is denied, then the costs will be expensed

at that time.

2020, $70,175 of costs related to patents issued to us during 2020 were reclassified from provisional patent application

to patent status and began to be amortized as of the date of issue.

Once a patent is granted, the Company will amortize the related

costs over the estimated useful life of the patent.

If a patent application is denied, then the costs will be expensed at that time.

2021, $ 91,260 of costs related to patents issued to us during 2021 were reclassified from provisional patent application to patent status

and began to be amortized as of the date of issue.

following is a summary of definite-life intangible assets less accumulated amortization as of December 31, 2021 and 2020, respectively:

of Definite-life Intangible Assets and Accumulated Amortization

Ended December 31,

4 unchanged sentences

estimated aggregate amortization expense for each of the succeeding years ending December 31 is as follows:

5 - Notes Payable

January 31, 2020, the Company paid off its Secured Convertible Promissory Note in full in the amount of $56,458, including accrued

interest of $1,458 and a late fee penalty of $5,000.

of Aggregate Amortization Expense

asset and amortization expense

5 – Paycheck Protection Plan Loan

April 14, 2020, the Company was granted a loan from BOKF, NA dba Bank of Oklahoma in the aggregate amount of $361,700, pursuant

to the Paycheck Protection Program (the “

) under Division A, Title I of the Coronavirus Aid, Relief

and Economic Security Act (the “

CARES Act ”

), which was enacted March 27, 2020.

Under the terms of the

PPP, PPP loans and accrued interest are forgivable after twenty-four weeks as long as the borrower uses the loan proceeds for

eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels.

The amount of loan forgiveness

will be reduced if the borrower terminates employees or reduces salaries during the forgiveness period.

of December 31, 2020, the Company has used the entire loan proceeds to fund its payroll expenses.

As a result, the Company believes

that it has met the PPP eligibility criteria for forgiveness and has concluded that the loan represents, in substance, a government

grant that is expected to be forgiven.

As such, the Company has recognized the entire loan amount as Other Income at December

April 14, 2020, the Company was granted a loan from BOKF, NA dba Bank of Oklahoma in the aggregate amount of $ 361,700 , pursuant to the

Paycheck Protection Program (the “ PPP ” ) under Division A, Title I of the Coronavirus Aid, Relief and Economic

Security Act (the “ CARES Act ” ), which was enacted March 27, 2020.

Under the terms of the PPP, PPP loans and

accrued interest are forgivable after twenty-four weeks as long as the borrower uses the loan proceeds for eligible purposes, including

payroll, benefits, rent and utilities, and maintains its payroll levels.

The amount of loan forgiveness will be reduced if the borrower

terminates employees or reduces salaries during the forgiveness period.

of December 31, 2020, the Company had used the entire loan proceeds to fund its payroll expenses.

As a result, the Company concluded

that it met the PPP eligibility criteria for forgiveness and recognized the entire loan amount as Other Income.

January 2021, the Company received notice from the lender that the entire amount of the loan had been forgiven.

6 – Deferral of Social Security Tax Payments

to sections 2302(a)(1) and (a)(2) of the CARES Act, the Company has elected to defer payments of its share of Social Security

tax due during the “payroll tax deferral period”.

The payroll tax deferral period began on March 27, 2020 and ended on

December 31, 2020.

At December 31, 2020 the total amount of such deferral was $75,455.

Per the terms of the deferral program,

50% of the deferred amount is due on December 31, 2021, and the remaining 50% is due on December 31, 2022 at 0% interest.

Stockholders’

February 27, 2020, our Articles of Incorporation were amended to provide for a reverse stock split of the outstanding shares of

our common stock on a 1-for-10 basis (the “Reverse Stock Split”), and a corresponding decrease in the number of shares

of our common stock that we are authorized to issue (the “Share Decrease”).

The effects of the stock split have been

retroactively reflected to all periods presented.

March 27, 2020, at a special shareholders’

meeting, our authorized shares of common stock were increased from 2,250,000

to sections 2302(a)(1) and (a)(2) of the CARES Act, the Company has elected to defer payments of its share of Social Security tax due

during the “payroll tax deferral period”.

The payroll tax deferral period began on March 27, 2020 and ended on December 31,

At December 31, 2021 the total remaining amount of the deferral was $ 37,728 .

Per the terms of the deferral program, such amount

is due on December 31, 2022 at 0 % interest.

7 - Derivative Liability

March 26, 2021 (the “Issuance Date”), the Company issued warrants to purchase an aggregate of 2,190,000 shares of common

stock to holders in a private placement concurrently with a registered direct offering of 2,190,000 shares of its common stock.

entitle the holders to purchase one share of our common stock at an exercise price equal to $ 4.32 per share commencing on May 24, 2021

and will expire two years from such date.

The Company has determined that these warrants are free standing financial instruments that

are legally detachable and separately exercisable from the common stock included in the registered direct offering.

Management also determined

that on the Issuance Date, the Company did not have sufficient authorized and unissued shares to settle the warrants, and as such required

classification as a liability pursuant to ASC 815 “Derivative Instruments and Hedging” .

In accordance with the accounting

guidance, the outstanding warrants were recognized as a warrant liability on the balance sheet and were measured at their inception date

fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income in the statement

of operations.

a Special Stockholders Meeting held on May 24, 2021, the Company received approval to increase its authorized common shares from 12,000,000

to 24,000,000 .

At our annual shareholders’

meeting held on June 15, 2020, our authorized shares of common stock were increased

from 8,000,000 to 12,000,000.

April 6, 2020, the Company closed a public offering of equity securities in which it issued 493,027 shares of common stock and

pre-funded warrants to purchase up to 22,438 shares of the Company’s common stock.

The Company also issued Series A Warrants

to purchase an aggregate of 515,465 shares of the Company’s common stock pursuant to a private placement.

In connection

with this offering, the Company issued Dawson James Securities, Inc., its Placement Agent, a warrant to purchase an aggregate

of 41,237 shares of the Company’s Common Stock (which amount is based on the number of Common Shares and shares underlying

the Pre-Funded Warrants) at an exercise price of $3.64 per share.

Net proceeds to the Company after deducting offering expenses

were approximately $1,230,000.

On December 4, 2020, the Company issued 22,438 shares of common stock for the exercise of the pre-funded

the twelve months ended December 31, 2020, the Company issued 3,272,048 shares of common stock in exchange for the conversion

of 7,404 shares of Series D Convertible Preferred stock, and 774,940 shares of common stock as in-kind payment of preferred stock

Pursuant to ASC 815-40-35-8, the Company reclassified the warrant liability to equity as of such date.

fair value of the derivative liability presented below was measured using the Black Scholes valuation model.

Significant inputs into

the model for the year ended December 31, 2021 are as follows:

of Fair Value of Derivative Liability Using Black Scholes Valuation Model

interest rate

life (in years)

warrants outstanding and fair values at each of the respective valuation dates are summarized below:

of Fair Value of Warrant Liability

Value Per Share

Value at initial measurement date of March 26, 2021

on change in Fair Value of Warrant Liability

( 1,092,441 )

Fair Value as of

Extinguishment

of Derivative Liability

( 2,190,000 )

( 4,615,771 )

Value as of December 31, 2021

Company has presented the fair value measurement as a Level 3 measurement, relying on unobservable inputs reflecting management’s

Level 3 measurements, which are not based on quoted prices in active markets, introduce a higher degree of subjectivity

and may be more sensitive to fluctuations in stock prices, volatility rates and U.S.

Treasury Bond rates and could have a material impact

on future fair value measurements.

Company uses the Black Scholes model, based on the adjusted historical volatility rates for fair value measurements through the date

of stockholder approval (i.e., May 24, 2021).

Management has determined the Black Scholes model to be the most reliable and least volatile

determinate of the current fair value of the warrants.

It is the Company’s expectation to maximize on all observable market inputs

for the warrants and calibrate the model to incorporate relevant observable market data into the fair value measurement at each future

measurement date, if applicable.

the twelve months ended December 31, 2021, the Company recognized a gain of $ 1,092,441 on the change in fair value of the warrants.

8 – Stockholders’ Equity

February 27, 2020, our Articles of Incorporation were amended to provide for a reverse stock split of the outstanding shares of our common

stock on a 1-for-10 basis (the “Reverse Stock Split”), and a corresponding decrease in the number of shares of our common

stock that we are authorized to issue (the “Share Decrease”).

The effects of the stock split have been retroactively reflected

to all periods presented.

May 24, 2021, at a special shareholders’ meeting, our authorized shares of common stock were increased from 12,000,000 to 24,000,000 .

At our annual shareholders’ meeting held on June 15, 2020, our authorized shares of common stock were increased from 8,000,000

to 12,000,000 .

On March 27, 2020, at a special shareholders’ meeting, our authorized shares of common stock were increased from

2,250,000 to 8,000,000 .

January 2021, the Company closed a public offering of its securities in which it issued 1,711,783 shares of common stock at $ 3.00 per

share, resulting in net proceeds of approximately $ 4,532,445 after deducting underwriting commissions and other offering expenses payable

by the Company.

Pursuant to the Underwriting Agreement, the Company also issued to the Underwriter or its designee warrants to purchase

136,943 shares of common stock.

Such warrants have a term of five years and an exercise price of $ 3.75 per share.

February 2021, the Company issued 263,200 shares of common stock pursuant to the exercise of warrants issued in our January 2020 private

March 2021, the Company issued 119,000 shares of common stock in exchange for the conversion of 250 shares of Series D Convertible Preferred

Stock, including 19,000 shares of common stock as in-kind payment of preferred stock dividends.

Also in March 2021, the Company issued

191,204 shares of common stock pursuant to the exercise of warrants issued in our April 2020 offering, and 21,591 shares of common stock

issued pursuant to the cashless exercise of placement agent warrants.

March 2021, the Company closed a public offering of its securities in which it issued 2,190,000 shares of common stock at $ 4.445 per

share, resulting in net proceeds to the Company of approximately $ 8,736,488 after deducting placement agent commissions and other offering

costs payable by the Company.

In a concurrent private placement under the Purchase Agreement, the Company issued to the purchasers warrants

to purchase an aggregate of 2,190,000 shares of Common Stock at an exercise price of $ 4.32 per share.

Each Warrant became exercisable

on May 24, 2021 , the date the Company obtained stockholder approval of an increase in the authorized shares of the Company’s Common

Stock and will expire two years from such date.

The Company also issued to designees of the Placement Agent warrants to purchase up to

175,200 shares of Common Stock (the “Placement Agent Warrants”) constituting 8 % of the aggregate number of shares of Common

Stock sold in the Registered Offering.

The Placement Agent Warrants have substantially the same terms as the Warrants, except that the

Placement Agent Warrants have an exercise price equal to 125 % of the offering price per share (or $ 5.55625 per share).

Upon any exercise

of the Warrants for cash, we have also agreed to pay the Placement Agent warrants to purchase 8.0 % of the number of shares of our Common

Stock issued upon the cash exercise of the Warrants.

March 2021, Company issued 1,500 shares of common stock valued at $ 4.99 per share to an investor relations firm as partial compensation for services previously rendered.

September 2021, the Company granted 5,204 shares of common stock to non-executive employees pursuant to the 2013 Equity Incentive Plan.

April 6, 2020, the Company closed a public offering of equity securities in which it issued 493,027 shares of common stock and pre-funded

warrants to purchase up to 22,438 shares of the Company’s common stock.

The Company also issued Series A Warrants to purchase an

aggregate of 515,465 shares of the Company’s common stock pursuant to a private placement.

In connection with this offering, the

Company issued Dawson James Securities, Inc., its Placement Agent, a warrant to purchase an aggregate of 41,237 shares of the Company’s

Common Stock (which amount is based on the number of Common Shares and shares underlying the Pre-Funded Warrants) at an exercise price

of $ 3.64 per share.

Net proceeds to the Company after deducting offering expenses were approximately $ 1,230,000 .

On December 4, 2020,

the Company issued 22,438 shares of common stock for the exercise of the pre-funded warrants.

the twelve months ended December 31, 2020, the Company issued 3,272,048 shares of common stock in exchange for the conversion of 7,404

shares of Series D Convertible Preferred stock, and 774,940 shares of common stock as in-kind payment of preferred stock dividends.

the twelve months ended December 31, 2020, the Company issued 25,851 shares of common stock for services.

January 2019, the Company issued 20,000 shares of common stock to directors valued at $15.00 per share, or $300,000, with such

shares vesting ratably over four quarterly installments.

in January 2019, the Company issued 8,843 shares of common stock upon the cashless exercise of Unit Purchase Options issued in

our June 2018 public offering.

January and February 2019, the Company issued a total of 7,023 shares of common stock upon the exercise of 7,023 warrants having

an exercise price of $10.80 resulting in gross cash proceeds of $75,848.

March 2019, the Company issued 150 shares of common stock valued at $20.00 per share to the Company’s Vice President of

Business Development in connection with his achievement of performance milestones, with such shares vesting immediately.

in March 2019, the Company closed a public offering of equity securities in which it issued 140,080 shares of common stock and

warrants to purchase a total of 42,024 shares of common stock resulting in net proceeds of approximately $1,679,230, after deducting

placement agent commissions and other offering expenses payable by the Company.

May 2019, the Company closed a private placement of equity securities in which it issued 40,000 shares of common stock and warrants

to purchase a total of 22,000 shares of common stock resulting in net proceeds of approximately $515,000, after deducting placement

agent commissions and other offering expenses payable by the Company.

August 2, 2019, the Company closed a public offering of equity securities in which it issued 287,500 shares of common stock resulting

in net proceeds of approximately $1,971,000, after deducting commissions and other offering expenses payable by the Company.

August 15, 2019, the Company issued 2,500 shares of common stock valued at $6.84 per share to MHZCI, LLC, an investor relations

firm engaged by the Company, as partial compensation for services to be rendered.

September 13, 2019, Aegis Capital Corp.

partially exercised its over-allotment option granted by the Company in the foregoing

August 2019 public offering by purchasing an additional 20,000 shares of common stock, resulting in net proceeds of $148,800 after

deducting commissions.

2020 and 2019, the Company issued to various employees, directors, and contractors shares of the Company’s common

stock, subject to restrictions, pursuant to the 2013 Equity Incentive Plan (the “2013 Plan”).

Such shares were valued

at the fair value at the date of issue.

The fair value was expensed as compensation over the vesting period and recorded as a

reduction of stockholders’

During 2020 and 2019, $77,187 and $303,000, respectively, of the unvested compensation

cost related to these issues was recognized.

2021 and 2020, the Company issued to various employees, directors, and contractors shares of the Company’s common stock, subject

to restrictions, pursuant to the 2013 Equity Incentive Plan (the “2013 Plan”).

Such shares were valued at the fair value

at the date of issue.

The fair value was expensed as compensation over the vesting period and recorded as a reduction of stockholders’

During 2021 and 2020, $ 19,255 and $ 77,187 , respectively, of the unvested compensation cost related to these issues was recognized.

Company is authorized to issue 10,000,000 shares of preferred stock, $ 0.001 par value.

715 and 0 shares of

preferred stock were issued and outstanding at December 31, 2020 and 2019, respectively.

January 2020, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional investors

(the “Institutional Private Placement”).

Pursuant to the SPA, the Company issued and sold 1,640 shares of the Company’s

newly created Series D Convertible Preferred Stock (the “Series D Preferred Stock”).

465 and 715 shares of preferred stock were issued

and outstanding at December 31, 2021 and 2020, respectively.

January 2020, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional investors (the

“Institutional Private Placement”).

Pursuant to the SPA, the Company issued and sold 1,640 shares of the Company’s

newly created Series D Convertible Preferred Stock (the “Series D Preferred Stock”).

Under the Certificate of Designations

for the Series D Preferred Stock, the Series D Preferred Stock has an initial stated value of $1,000 per share (the “Stated

Value”).

Dividends accrue at a dividend rate of 9% per annum (subject to increase upon the occurrence (and during the continuance)

of certain triggering events described therein) and, on a monthly basis, shall be payable in kind by the increase of the Stated

Value of the Series D Preferred Shares by said amount.

The holders of the Series D Preferred Shares will have the right at any

time to convert all or a portion of the Series D Preferred Shares (including, without limitation, accrued and unpaid dividends

and make-whole dividends through the third anniversary of the closing date) into shares of the Company’s Common Stock at

the conversion price then in effect, which is $2.50 (subject to adjustment for stock splits, dividends, recapitalizations and

similar events and full ratchet price protection).

In addition, a holder may at any time, alternatively, convert all, or any part,

of its Series D Preferred Shares at an alternative conversion price, which equals the lower of the applicable conversion price

then in effect, and the greater of (x) $1.80 and (y) 85% of the average volume weighted average price (“VWAP”) of

the Common Stock for a five (5) trading day period prior to such conversion.

Upon the occurrence of certain triggering events,

described in the Certificate of Designations, including, but not limited to payment defaults, breaches of transaction documents,

failure to maintain listing on the Nasdaq Capital Market, and other defaults set forth therein, the Series D Preferred Shares

would become subject to redemption, at the option of a holder, at a 125% premium to the underlying value of the Series D Preferred

Shares being redeemed.

for the Series D Preferred Stock, the Series D Preferred Stock has an initial stated value of $ 1,000 per share (the “Stated Value”).

Dividends accrue at a dividend rate of 9 % per annum (subject to increase upon the occurrence (and during the continuance) of certain

triggering events described therein) and, on a monthly basis, shall be payable in kind by the increase of the Stated Value of the Series

D Preferred Shares by said amount.

The holders of the Series D Preferred Shares will have the right at any time to convert all or a portion

of the Series D Preferred Shares (including, without limitation, accrued and unpaid dividends and make-whole dividends through the third

anniversary of the closing date) into shares of the Company’s Common Stock at the conversion price then in effect, which is $ 2.50

(subject to adjustment for stock splits, dividends, recapitalizations and similar events and full ratchet price protection).

a holder may at any time, alternatively, convert all, or any part, of its Series D Preferred Shares at an alternative conversion price,

which equals the lower of the applicable conversion price then in effect, and the greater of (x) $1.80 and (y) 85% of the average volume

weighted average price (“VWAP”) of the Common Stock for a five (5) trading day period prior to such conversion.

occurrence of certain triggering events, described in the Certificate of Designations, including, but not limited to payment defaults,

breaches of transaction documents, failure to maintain listing on the Nasdaq Capital Market, and other defaults set forth therein, the

Series D Preferred Shares would become subject to redemption, at the option of a holder, at a 125% premium to the underlying value of

the Series D Preferred Shares being redeemed.

December 31, 2021 there were 132 shares of Series D Convertible Preferred stock outstanding, which if converted as of December 31, 2021,

including the make-whole dividends, would have resulted in the issuance of 87,267 shares of common stock.

with the Institutional Private Placement, the Company entered into a Securities Purchase Agreement (the “SPA”) with

certain of its directors and the Company’s largest shareholder (the “Other Private Placement”).

the SPA, the Company issued and sold 333 shares of the Company’s newly created Series E Convertible Preferred Stock (the

“Series E Preferred Stock”).

Dividends accrue at a dividend rate of 9% per annum and, on a monthly basis, shall be

payable in kind by the increase of the Stated Value of the Series E Preferred Shares by said amount.

The Series E Preferred Stock

is initially convertible into 48,544 shares of Common Stock.

with the Institutional Private Placement, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain

of its directors and the Company’s formerly largest shareholder (the “Other Private Placement”).

Pursuant to the SPA, the Company issued and sold 333

shares of the Company’s newly created Series

E Convertible Preferred Stock (the “Series E Preferred Stock”).

Dividends accrue at a dividend rate of 9 %

per annum and, on a monthly basis, shall be payable in kind by the increase of the Stated Value of the Series E Preferred Shares by said

The Series E Preferred Stock is initially convertible into 48,544

shares of Common Stock.

December 31, 2021, all of the issued Series E Convertible Preferred Stock were outstanding, which if converted as of December 31, 2021,

including the make-whole dividends, would have resulted in the issuance of 61,651 shares of common stock.

June 15, 2020, at the Annual Meeting of Stockholders of the Company, the Company’s stockholders approved an amendment to

the 2013 Plan to increase the number of shares of the Company’s common stock reserved for issuance under the 2013 Plan by

650,000 shares of our common stock to a total of 890,000 shares.

As of December 31, 2020, there were 152,753 shares available

for issuance under the 2013 Plan.

2020, the Company granted a total of 579,998 options to 19 employees, 4 directors, and 5 consultants with

vesting periods ranging from immediately upon issue to three years beginning May 1, 2020.

In 2020, 294,373

options vested and $854,217 of compensation cost was recognized during the year.

As of December 31, 2020, there were

options to purchase 663,010 shares issued and outstanding under the 2013 Plan.

Of this amount, there are vested options

exercisable for 349,642 shares of common stock.

No options were exercised during the year ended December 31, 2020.

2019, the Company granted a total of 100,326 options to 22 employees and 2 consultants with vesting periods ranging from immediately

upon issue to 4 years beginning January 1, 2019.

July 15, 2021, at the Annual Meeting of Stockholders of the Company, the Company’s stockholders approved an amendment to the 2013

Plan to increase the number of shares of the Company’s common stock reserved for issuance under the 2013 Plan by 875,000 shares

of our common stock to a total of 1,765,000 shares.

As of December 31, 2021, there were 339,677 shares available for issuance under the

2021, the Company granted a total of 698,831 options to 35 employees, 4 directors, and 4 consultants with vesting periods ranging from

immediately upon issue to three years beginning January 4, 2021 .

In 2021, 598,789 options vested and $ 1,741,366 of compensation cost

was recognized during the year.

As of December 31, 2021, there were options to purchase 1,395,882 , shares issued and outstanding, 1,345,882

of which have been issued under the 2013 Plan.

At December 31, 2021, there are vested options exercisable for 941,934 shares of common

Options to purchase 5,204 shares of common stock were exercised during the year ended December 31, 2021.

2020, the Company granted a total of 579,998 options to 19 employees, 4 directors, and 5 consultants with vesting periods ranging from

immediately upon issue to three years beginning May 1, 2020 .

In 2020, 294,373 options vested and $ 854,217 of compensation cost was recognized

during the year.

As of December 31, 2019, there were options to purchase 180,903 shares issued and outstanding under the 2013

Of this amount, there are vested options exercisable for 88,163 shares of common stock.

No options were exercised during

the year ended December 31, 2019.

Company generally grants stock options to employees and directors at exercise prices equal to the fair market value of the Company’s

stock on the dates of grant.

Stock options are typically granted throughout the year and generally vest over four years of service

and expire ten years from the date of the award, unless otherwise specified.

The Company recognizes compensation expense for the

fair value of the stock options over the requisite service period for each stock option award.

share-based compensation expense included in the statements of operations for the years ended December 31, 2020 and 2019 is $596,842,

of which $573,232 is related to stock options, and $497,240, of which $ 494,740 is related to stock options,

respectively.

There was no capitalized share-based compensation cost as of December 31, 2020 and 2019, and there were no recognized

tax benefits during the years ended December 31, 2020 and 2019.

As of December 31, 2020, there were options to purchase 713,010 shares issued and outstanding, 663,010 of which have

been issued under the 2013 Plan.

At December 31, 2020, there were vested options exercisable for 349,642 shares of common stock.

were exercised during the year ended December 31, 2020.

Company generally grants stock options to employees, consultants and directors at exercise prices equal to the fair market value of the

Company’s stock on the dates of grant.

Stock options are typically granted throughout the year and generally vest over three years

of service and expire five years from the date of the award, unless otherwise specified.

The Company recognizes compensation expense

for the fair value of the stock options over the requisite service period for each stock option award.

employee share-based compensation expense included in the statements of operations for the year ended December 31, 2021 is $ 1,066,455

of which $ 1,047,200 is related to stock options.

Total employee share-based compensation for 2020 totaled $ 596,842 , of which $ 573,232

is related to stock options.

There was no capitalized share-based compensation cost as of December 31, 2021 and 2020, and there were

no recognized tax benefits during the years ended December 31, 2021 and 2020.

estimate the value of an award, the Company uses the Black-Scholes option-pricing model.

2 unchanged sentences

The forfeiture rate also impacts the amount of aggregate compensation.

These inputs are subjective and generally require significant analysis and judgment to develop.

While estimates of expected life,

volatility and forfeiture rate are derived primarily from the Company’s historical data, the risk-free rate is based on

the yield available on U.S.

Treasury constant maturity rates with similar terms to the expected term of the stock option awards.

The fair value of share-based awards was estimated using the Black-Scholes model with the following weighted-average assumptions

for the years ended December 31, 2020 and 2019:

are subjective and generally require significant analysis and judgment to develop.

While estimates of expected life, volatility and forfeiture

rate are derived primarily from the Company’s historical data, the risk-free rate is based on the yield available on U.S.

constant maturity rates with similar terms to the expected term of the stock option awards.

The fair value of share-based awards was

estimated using the Black-Scholes model with the following weighted-average assumptions for the years ended December 31, 2021 and 2020:

of Share Based Payment Award Stock Option Valuations Assumptions

interest rate

0.19 - 0.67 %

0.19 - 0.50 %

life (in years)

activity for the year ended December 31, 2021 and 2020 was as follows:

of Share Based Compensation Stock Option Activity

outstanding at December 31, 2019

outstanding at December 31, 2020

expected to vest in the future as of December 31, 2020

exercisable at December 31, 2020

vested, exercisable, and options expected to vest at December 31, 2020

Options outstanding

at December 31, 2020

outstanding at December 31, 2021

2 unchanged sentences

vested, exercisable, and options expected to vest at December 31, 2021

aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price

of our common stock for those awards that have an exercise price currently below the $3.38 closing price of our Common

Stock on December 31, 2020.

All of the 2020 option grants have an exercise price currently below $3.38.

December 31, 2020, there was $1,029,056 of unrecognized share-based compensation expense related to unvested share options

with a weighted average remaining recognition period of 2.90 years.

aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of

our common stock for those awards that have an exercise price currently below the $ 1.84 closing price of our Common Stock on December

All of the 2021 option grants have an exercise price currently above $ 1.84 .

December 31, 2021, there was $ 1,164,723 of unrecognized share-based compensation expense related to unvested share options with a weighted

average remaining recognition period of 2.10 years.

Appreciation Rights

June 23, 2020, the board of directors (the “Board”) of the Company adopted the Sigma Labs, Inc.

2020 Stock Appreciation

Rights Plan (the “Plan”).

June 23, 2020, the board of directors (the “Board”) of the Company adopted the Sigma Labs, Inc.

2020 Stock Appreciation Rights

Plan (the “Plan”).

The purposes of the Plan are to:

(i) enable the Company to attract and retain the types

of employees, consultants, and directors (collectively, “Service Providers”) who will contribute to the Company’s

long-range success;

(ii) provide incentives that align the interests of Service Providers with those of the shareholders of the

and (iii) promote the success of the Company’s business.

The Plan provides for incentive awards that are only made

in the form of stock appreciation rights payable in cash (“SARs”).

No shares of common stock were reserved in connection

with the adoption of the Plan since no shares will be issued pursuant to the Plan.

(i) enable the Company to attract and retain the types of employees,

consultants, and directors (collectively, “Service Providers”) who will contribute to the Company’s long-range success;

(ii) provide incentives that align the interests of Service Providers with those of the shareholders of the Company;

and (iii) promote

the success of the Company’s business.

The Plan provides for incentive awards that are only made in the form of stock appreciation

rights payable in cash (“SARs”).

No shares of common stock were reserved in connection with the adoption of the Plan since

no shares will be issued pursuant to the Plan.

may be granted to any Service Provider.

A SAR is the right to receive an amount equal to the Spread with respect to a share of

the Company’s common stock (“Share”) upon the exercise of the SAR.

The “Spread”

is the difference

between the exercise price per share specified in a SAR agreement on the date of grant and the fair market value per share on

the date of exercise of the SAR.

The exercise price per share will not be less than 100% of the fair market value of a Share on

the date of grant of the SAR.

The administrator of the Plan will have the authority to, among other things, prescribe the terms

and conditions of each SAR, including, without limitation, the exercise price and medium of payment and vesting provisions, and

to specify the provisions of the SAR Agreement relating to such grant.

June 23, 2020, the Company granted, pursuant to the Plan, (i) 60,094 SARs to its President and Chief Executive Officer, (ii) 12,019

SARs to its Vice President of Business Development, (iii) 24,038 SARs to its Chief Technology Officer, and (iv) 18,028 SARs to

its Chief Financial Officer.

The exercise price of each such SAR is $2.63, which was the closing price of the Company’s

common stock on the date of grant.

Such SARs expire on the fifth anniversary of the grant date and may be settled only in cash.

Additionally, each such SAR will vest and become exercisable in three equal (as closely as possible) installments on each of the

first, second and third anniversaries of the grant date, subject, in each case, to the applicable SAR holder being in the continuous

employ of the Company on the applicable vesting date, and, in the event of a Change in Control (as defined in the Plan), will

become immediately vested and exercisable as long as the applicable holder is in the Company’s employ immediately prior

to the Change in Control, and will otherwise be on such other terms set forth in the form of Stock Appreciation Rights Agreement.

On November 19, 2020, we granted 13,500 SARs to a consultant as partial compensation for services pursuant to the consulting agreement.

Company recognizes compensation expense and a corresponding liability for the fair value of the SARs over the requisite service

period for each SAR award.

The SAR’s are revalued at each reporting date in accordance with ASC 718 “Compensation-Stock

Compensation”, and any changes in fair value are reflected in income as of the applicable reporting date.

fair value of SAR awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the twelve

months ended December 31, 2020:

A SAR is the right to receive an amount equal to the Spread with respect to a share of the Company’s

common stock (“Share”) upon the exercise of the SAR.

The “Spread” is the difference between the exercise price

per share specified in a SAR agreement on the date of grant and the fair market value per share on the date of exercise of the SAR.

exercise price per share will not be less than 100% of the fair market value of a Share on the date of grant of the SAR.

The administrator

of the Plan will have the authority to, among other things, prescribe the terms and conditions of each SAR, including, without limitation,

the exercise price and medium of payment and vesting provisions, and to specify the provisions of the SAR Agreement relating to such

August 11, 2021, the Company granted, pursuant to the Plan, (i) 77,748 SARs to its Chief Executive Officer, (ii) 30,313 SARs to its Vice

President of Business Development, (iii) 76,304 SARs to its Chief Technology Officer, and (iv) 48,580 SARs to its Chief Financial Officer.

The exercise price of each such SAR is $ 3.42 , which was the closing price of the Company’s common stock on the date of grant.

June 23, 2020, the Company granted, pursuant to the Plan, (i) 60,094 SARs to its Chief Executive Officer, (ii) 12,019 SARs to its Vice

President of Business Development, (iii) 24,038 SARs to its Chief Technology Officer, and (iv) 18,028 SARs to its Chief Financial Officer.

The exercise price of each such SAR is $ 2.63 , which was the closing price of the Company’s common stock on the date of grant.

SARs expire on the fifth anniversary of the grant date and may be settled only in cash.

Additionally, each such SAR will vest and become

exercisable in three equal (as closely as possible) installments on each of the first, second and third anniversaries of the grant date,

subject, in each case, to the applicable SAR holder being in the continuous employ of the Company on the applicable vesting date, and,

in the event of a Change in Control (as defined in the Plan), will become immediately vested and exercisable as long as the applicable

holder is in the Company’s employ immediately prior to the Change in Control, and will otherwise be on such other terms set forth

in the form of Stock Appreciation Rights Agreement.

July 29, 2021, we granted 10,000 SARs to a consultant as partial compensation for services pursuant to his consulting agreement, and

on November 19, 2020, we granted 13,500 SARs to such consultant as partial compensation for services pursuant to his consulting agreement.

As of December 31, 2021, all such SARs were full vested and exercisable.

Company recognizes compensation expense and a corresponding liability for the fair value of the SARs over the requisite service period

for each SAR award.

The SAR’s are revalued at each reporting date in accordance with ASC 718 “Compensation-Stock Compensation”,

and any changes in fair value are reflected in income as of the applicable reporting date.

fair value of SAR awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the twelve months

ended December 31, 2021:

of Share Based Payments Award Stock Options Valuation Assumptions

interest rate

0.39 - 0.40 %

0.19 - 0.22 %

life (in years)

activity for the twelve months ended December 31, 2021 was as follows:

of Stock Option Activity

SARs outstanding

at December 31, 2019

outstanding at December 31, 2020

3 unchanged sentences

vested, exercisable, and options expected to vest at December 31, 2021

aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price

of our common stock for those awards that have an exercise price currently below the $3.38 closing price of our common stock on

December 31, 2020.

All of the 2020 SARs grants have an exercise price currently below $3.38.

December 31, 2020, there was $216,149 of unrecognized share-based compensation expense related to unvested SARs with a weighted

average remaining recognition period of 2.48 years.

December 31, 2020, the Company had outstanding warrants to purchase a total of 1,881,429 shares of common stock.

warrants have exercise prices that range from $0.10 to $40.00, which if not exercised, will expire between February 21, 2022 and

December 9, 2025.

aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of

our common stock for those awards that have an exercise price currently below the $ 1.84 closing price of our common stock on December

All of the SARs grants have an exercise price currently above $ 1.84 .

December 31, 2021, there was $ 685,503 of unrecognized share-based compensation expense related to unvested SARs with a weighted average

remaining recognition period of 2.37 years.

December 31, 2021, the Company had outstanding warrants to purchase a total of 3,987,931

shares of common stock.

The warrants have exercise

prices that range from $ 0.10

which if not exercised, will expire

between February 22, 2022 and January 6, 2026 .

activity for the year ended December 31, 2021 and 2020 was as follows:

of Warranty Activity

outstanding at December 31, 2019

1 unchanged sentence

outstanding at December 31, 2021

connection with its January 2020 private placement, the Company issued 6,156 warrants to purchase its Series D Preferred Stock

(the Preferred Warrants”).

As of December 31, 2020, there were 10 Preferred Warrants outstanding, which if exercised would

result in the issuance of 10 shares of Series D Convertible Preferred Stock.

The Series D Convertible Preferred stock, including

make-whole dividends, was convertible into 4,748 shares of common stock on December 31, 2020.

9 – Income Taxes

Company accounts for income taxes in accordance with ASC Topic No.

This standard requires the Company to provide a net deferred

tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and

tax accounting methods and any available operating loss or tax credit carryforwards.

Income tax returns open for examination by

the Internal Revenue Service consist of tax years ended December 31, 2017 through 2019.

Company has available at December 31, 2020, unused operating loss carryforwards of approximately $19,925,769 which may

be applied against future taxable income and which expire in various years through 2040.

However, if certain substantial

changes in the Company’s ownership should occur, there could be an annual limitation on the amount of net operating loss

carryforward which can be utilized.

The amount of and ultimate realization of the benefits from the operating loss carryforwards

for income tax purposes is dependent, in part, upon the tax laws in effect, the future earnings of the Company and other future

events, the effects of which cannot be determined.

tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting

methods and any available operating loss or tax credit carryforwards.

Income tax returns open for examination by the Internal Revenue

Service consist of tax years ended December 31, 2018 through 2020.

Company has available at December 31, 2021, unused operating loss carryforwards of approximately $ 26,342,855

which may be applied against future taxable income

and which expire in various years through 2040 .

However, if certain substantial changes in the Company’s ownership should occur, there could be an annual limitation on the amount

of net operating loss carryforward which can be utilized.

The amount of and ultimate realization of the benefits from the operating loss

carryforwards for income tax purposes is dependent, in part, upon the tax laws in effect, the future earnings of the Company and other

future events, the effects of which cannot be determined.

Because of the uncertainty surrounding the realization of the loss carryforwards,

the Company has established a valuation allowance equal to the tax effect of the loss carryforwards and other temporary differences

of approximately $4,170,100 and $3,037,800 at December 31, 2020 and 2019, respectively, and, therefore, no deferred tax

asset has been recognized for the loss carryforwards.

the Company has established a valuation allowance equal to the tax effect of the loss carryforwards and other temporary differences of

approximately $ 6,771,000

and $ 4,170,100

at December 31, 2021 and 2020, respectively,

and, therefore, no deferred tax asset has been recognized for the loss carryforwards.

tax assets are comprised of the following:

Schedule of Deferred Tax Assets

( 6,771,000 )

( 4,170,100 )

deferred tax asset

reconciliation of the provision for income taxes computed at the U.S.

federal statutory tax rate (21%) to the Company’s

effective tax rate for the years ended December 31, 2020 and 2019 is as follows:

federal statutory tax rate ( 21 %) to the Company’s effective

tax rate for the years ended December 31, 2021 and 2020 is as follows:

Schedule of Reconciliation of the Provision for Income Taxes

$ ( 1,572,500 )

4 unchanged sentences

10 – Loss Per Share

following data show the amounts used in computing loss per share and the effect on income and the weighted average number of shares

of dilutive potential common stock for the periods ended December 31, 2020 and 2019:

following data show the amounts used in computing loss per share and the effect on income and the weighted average number of shares of

dilutive potential common stock for the periods ended December 31, 2021 and 2020:

Schedule of Earnings Per Share, Basic and Diluted

Ended December 31

3 unchanged sentences

average number of common shares Outstanding used in loss per share during the Period (denominator)

loss per share was not presented as the Company’s outstanding common and preferred warrants, stock options and preferred

stock common equivalent shares for the periods presented would have had an anti-dilutive effect.

At December 31, 2020, the

Company had outstanding 1,881,429 common warrants which could be converted to 1,881,429 shares of common stock,

and 713,010 stock options exercisable for 713,010 shares of common stock, 10 Series D Preferred Warrants exercisable

for 10 shares of Series D Preferred Stock, which in turn, are convertible into 4,748 shares of common stock, and 715 shares of

preferred stock, which could be converted into 243,024 shares of common stock, resulting in a potential total additional 2,842,211

common stock shares outstanding in the future.

At December 31, 2019, the Company had outstanding 363,728 warrants which

could be converted to 363,728 shares of common stock, a $50,000 note payable convertible into 2,500 shares of common stock,

and 180,903 stock options exercisable for 180,903 shares of common stock resulting in a potential total additional 547,131

common stock shares outstanding in the future.

loss per share was not presented as the Company’s outstanding common and preferred warrants, stock options and preferred stock

common equivalent shares for the periods presented would have had an anti-dilutive effect.

At December 31, 2021, the Company had outstanding

3,987,931 common warrants which could be converted to 3,987,931 shares of common stock, and 1,395,882 stock options exercisable for 1,395,882

shares of common stock, 132 shares of Series D Preferred Stock, which is convertible into 87,267 shares of common stock, and 333 shares

of Series E Preferred Stock, which could be converted into 61,651 shares of common stock, resulting in a potential total additional 5,532,731

shares of common stock outstanding in the future.

At December 31, 2020, the Company had outstanding 1,881,429 common warrants which could

be converted to 1,881,429 shares of common stock, and 713,010 stock options exercisable for 713,010 shares of common stock, 10 Series

D Preferred Warrants exercisable for 10 shares of Series D Preferred Stock, which in turn, are convertible into 4,748 shares of common

stock, and 715 shares of preferred stock, which could be converted into 243,024 shares of common stock, resulting in a potential total

additional 2,842,211 common stock shares outstanding in the future.

11 – Commitments and Contingencies

Leases –

The Company leases office and laboratory space under operating leases.

Expense relating to these operating

leases was $76,394 and $73,255 for the years ended December 31, 2020 and 2019, respectively.

The future minimum lease payments

required under non-cancellable operating leases at December 31, 2020 were $6,115.

The future minimum lease payments are

due during the year 2021.

Leases – The Company leases office and laboratory space under operating leases.

Expense relating to these operating leases

was $ 101,004 and $ 103,242 for the years ended December 31, 2021 and 2020, respectively.

The future minimum lease payments required under

non-cancellable operating leases at December 31, 2021 were $7,230.

The future minimum lease payments are due during the year 2022 , with

$ 1,115 due in January 2023.

12 – Concentrations

During the years ended December 31, 2020 and 2019, the Company had the following significant customers who accounted

for more than 10% each of the Company’s revenue in at least one of the periods presented.

The change in the composition

of customers between the two years resulted primarily from the change of focus from sales to R&D customers to Proof-of-Concept

sales to customers preparing to initiate commercial production.

Receivable –

The Company had the following significant customers who accounted for more than 10% each of the Company’s

– During the years ended December 31, 2021 and 2020, the Company had the following significant customers who accounted for

more than 10 % each of the Company’s revenue in at least one of the periods presented.

The change in the composition of customers

between the two years resulted primarily from the change of focus from sales to R&D customers to customers preparing to initiate

commercial production.

Schedule of Concentration of Risks

Receivable – The Company had the following significant customers who accounted for more than 10 % each of the Company’s

accounts receivable balance at December 31, 2021 and 2020, respectively.

13 - Joint Venture

July 2015, we entered into a joint venture agreement with Arete Innovative Solutions LLC (“Arete”).

The Joint Venture

was not consolidated, but rather was accounted for on the equity method of recording investments.

The Company and Arete terminated

the Joint Venture in 2020 and distributed the remaining cash to the former partners.

July 2015, we entered into a joint venture agreement with Arete Innovative Solutions LLC (“Arete”).

The Joint Venture was

not consolidated, but rather was accounted for on the equity method of recording investments.

The Company and Arete terminated the Joint

Venture in 2020 and distributed the remaining cash to the former partners.

14 - Defined Contribution Plan

2014, the Company adopted a qualified 401(K) plan (“the Plan”), in which all employees over the age of 21 may participate.

The Company makes a Safe Harbor contribution match of 100% of each participant’s contribution up to 3% of

salary, and 50% of the next 2% of salary contributed.

The costs of matching contributions were $55,321 in 2020 and $45,080

2014, the Company adopted a qualified 401(K) plan (“the Plan”), in which all employees over the age of 21 may participate.

The Company makes a Safe Harbor contribution match of 100% of each participant’s contribution up to 3% of salary, and 50% of the

next 2% of salary contributed .

The costs of matching contributions were $ 86,554 in 2021 and $ 55,321 in 2020.

15 – Related Party Transactions

1 unchanged sentence

16 – Subsequent Events

February and March of 2021, the Company issued 454,404 shares of common stock upon the exercise of warrants with an exercise price

of $2.50 per share, resulting in net cash proceeds to the Company of $1,136,010.

March of 2021, the Company issued 119,000 shares of common stock pursuant to the conversion of 250 Series D Preferred shares.

January 13, 2021, we were notified by our bank, BOKF, NA dba Bank of Oklahoma, that the SBA had forgiven 100% of our PPP loan

January 8, 2021, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with H.C.

(the “Underwriter”), which provided for the issuance and sale by the Company in an underwritten public offering

and the purchase by the Underwriter of 1,488,507 shares of the Company’s common stock, $0.001 par value per share.

closed on January 12, 2021.

to the terms and conditions contained in the Underwriting Agreement, the shares were sold to the Underwriter at a public offering

price of $3.00 per share, less underwriting discounts and commissions.

The Company also granted the Underwriters a 30-day option

to purchase up to 223,276 additional shares of the Company’s common stock on the same terms and conditions.

The Underwriter

fully exercised such option to purchase up to 223,276 additional shares of the Company’s common stock, for an aggregate

of 1,711,783 shares of Common Stock.

Pursuant to the Underwriting Agreement, we have also issued to the Underwriter or its designee

warrants to purchase a number of shares equal to 8% of the aggregate number of shares of common stock sold in the Offering, including

shares issued upon exercise of the option to purchase additional shares (the “Underwriter Warrants”).

The Underwriter

Warrants have a term of five years from the commencement of sales in the Offering and an exercise price of $3.75 per share.

net offering proceeds to the Company from the Offering are approximately $3,919,552 (or approximately $4,532,444 taking into account

the Underwriter’s exercise of its option to purchase additional shares in full), after deducting underwriting discounts

and commissions and other estimated offering expenses.

January 8, 2021, the Company obtained a waiver (“Waiver”) from certain investors (“Investors”) with respect

to certain anti-dilution adjustment provisions of a January 2020 warrant and an April 2020 warrant issued to the Investors.

consideration for the Waiver, the Company issued an additional warrant (“Warrant”) to the Investors to purchase an

aggregate of 100,000 shares of common stock, each exercisable after six months for a five-year period with an exercise price equal

to 115% of the closing price of the Company’s stock on the date of the waiver.

16, 2022, Jacob Brunsberg was appointed as President and Chief Operating Officer.

In connection with this appointment, Mr.

Brunsberg’s employment agreement was amended to increase his salary to $ 250,000

from $ 200,000

In addition, Mr.

Brunsberg was granted a stock option to purchase up to 70,000

shares of our common stock under our 2013 Equity Incentive Plan at an exercise price of $ 2.50 ,

stock appreciation rights (“SARs”) under our 2020 Stock Appreciation Rights Plan at an exercise price of $ 2.50

Both the option and the SARs have a five-year

term and are on such other terms and conditions as contained in the Company’s forms of standard agreement.

Concurrently, Mark

Ruport resigned as President but remains as Chief Executive Officer and continues to serve as a director on the Board of

Ruport’s employment agreement was amended to decrease his salary from $ 250,000

to $ 200,000 per

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 9A. Controls and Procedures